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Summary
Haematopoietic stem cells (HSCs) possess self-renewal capacity and give rise to the entire 
blood and immune systems. Notch is an evolutionarily conserved signalling pathway activated 
by cell-to-cell interactions with roles in stem cell maintenance, survival and differentiation. 
While studies in the murine haematopoietic system have proposed different roles for Notch 
signalling under stress and steady-state conditions, whether Notch is involved in the regulation 
of human haematopoietic stem/progenitor cells (HSPCs) has been scarcely explored. Here, 
we showed HSPCs express mainly Notch1 and Notch2 receptors and possess an active Notch
pathway. We employed pharmacological inhibition by using the γ-secretase inhibitor DAPT 
and shRNA-mediated silencing of Notch pathway members (NCSTN and RBPJ) in human 
HSPCs. Notch inhibition led to reduced colony forming capacity in vitro and reduced frequency 
of immunophenotypic HSCs. Additionally, Notch inhibition caused decreased myelo-lymphoid 
engraftment in vivo along with deregulation of most stem/progenitor cell compartments, of 
which the HSC fraction was the most affected. Silencing RBPJ additionally impaired B cell 
development both in vitro and in vivo. These data contrast with the studies on the mouse 
haematopoietic system and suggest an essential role for Notch in the regulation of human 
HSCs. Malignant transformation of HSPCs lead to the development of haematological 
malignancies such as leukaemias. Here, we characterised Notch signalling in Acute Myeloid 
Leukaemia (AML) and showed that this pathway appears to be mostly silenced in this context. 
Reactivation of the pathway via membrane-bound Notch ligand and via a soluble Jag1 based 
peptide decreased proliferation and induced apoptosis in various AML cell lines. Furthermore, 
small molecule agonists of Notch were tested for their potential therapeutic value. All in all, 
our data further support the notion that Notch reactivation may exhibit therapeutic significance 
in some instances of AML. 
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Chapter 1 – Introduction
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21
This thesis is focused on human haematopoiesis and all aspects discussed here concern the 
human system, except when the murine haematopoietic system is referred to at times for 
comparison purposes.
1.1. Normal haematopoiesis
1.1.1. Brief history of Haematopoietic stem cell (HSC) discovery
HSCs are the founders of the entire blood and immune system. These are multipotent cells 
with the ability to self-renew and to generate both a pool of stem cells and more committed 
progenitors. The latter differentiate into different mature blood and immune cells. The story of 
haematopoietic stem cell discovery came about with the advent of atomic warfare at the later 
stages of the second world war. The seminal works of Jacobson and colleagues, who at the 
time were studying the effects of ionizing radiation in mice, first showed that the animals could 
be protected from the lethal effects of ionizing radiation by shielding their spleens with lead 
(Jacobson et al., 1951). Later, Lorenz and colleagues showed that this type of protection could 
also be conferred by intravenous infusion of bone marrow (BM) cells (Lorenz et al., 1951). 
Soon after, scientists understood that this protection was conferred by transplanted stem cells, 
which launched the platform for the use of these cells in the treatment of several diseases. 
The understanding that the damage caused by myeloablation could be overcome, led to 
discovery of transplantable bone marrow cells capable of regenerating the haematopoietic 
system. This was originated from the attempt to quantify the minimal number of cells that 
would protect a lethally irradiated recipient. In these pivotal experiments, a key observation 
was made: the appearance of nodules at the surface of the spleens from the recipient animals; 
more importantly, the fact that the number of nodules was linearly correlated to the number of 
cells transplanted suggested that there must be a subpopulation within the transplanted cells 
with the capacity to generate splenic nodules (Till and McCulloch, 1961). From these early 
experiments, crucial observations led to several important conclusions: within the bone 
marrow of these mice lie haematopoietic cells of mixed myeloid origin, but also with some 
lymphoid differentiation potential, that could generate splenic nodules in secondary recipients 
(Wu et al., 1967). In this way, the concept of a multilineage repopulating cell with apparent 
self-renewal capacity was born, and in fact with it, so did the concept of a stem cell.
22
1.2. Hierarchy of the human haematopoietic system, a brief note
1.2.1. Haematopoietic stem cells
In the classical view, the haematopoietic system is believed to be organised in a hierarchical 
manner. It is commonly viewed that the most primitive cells sitting at the top of the hierarchy 
successively give rise to more committed progenitors which differentiate into the mature blood 
and immune cells, and supposedly progress from multipotent to oligopotent to unipotent cells. 
As they differentiate, cells gradually lose self-renewal capacity. The earliest bifurcation in cell 
fate decision is thought to be between the myeloid (granulocytes (G), monocytes (M), 
erythrocytes (Er) and megakaryocytes (Mk)) and the lymphoid (B, T, Natural Killer (NK) cells) 
lineages. A multipotent progenitor (MPP), which retains multilineage potential, gives rise to 
either a common myeloid progenitor (CMP) responsible for generating all the myeloid cell 
types, or to a common lymphoid progenitor (CLP) that gives rise to lymphocytes and NK cells.
There are three main sources of human post-natal HSCs: umbilical cord blood (UCB), 
peripheral blood (PB) and BM (Sirinoglu Demiriz et al., 2012). However, for instance it is 
estimated that only 1 in 106 cells in the BM is a transplantable HSC (Wang et al., 1997). To 
study such rare cells, HSCs must be isolated from the bulk of mononuclear cells (MNCs). This 
was made possible by technological advances in the field of fluorescence-activated cell sorting 
(FACS) by which the isolation of HSCs can be achieved with specific cell surface markers. 
The CD34 antigen was the first used to isolate a compartment of immature haematopoietic 
cells (Civin et al., 1984). Only about 1-4% of the total BM MNCs express CD34 (Civin et al., 
1984). The CD90 (Thy-1) surface antigen was later found to further refine this primitive 
population (Baum et al., 1992). However, this is still a heterogeneous population containing 
many progenitors, which can be further enriched by the lack of CD38 (cyclic ADP ribose 
hydrolase) (Bhatia et al., 1997) and CD45RA (an isoform of protein tyrosine phosphatase, 
receptor type C) expressions (Lansdorp et al., 1990). For a while, the CD34+CD38-CD45RA-
CD90+ was considered the population where HSCs could be confidently identified and indeed, 
transplantation of these cells into immunocompromised mice led to successful engraftment in
most mice using as few as 100 cells  (Majeti et al., 2007). In the same report, the authors 
suggested that the CD34+CD38-CD45RA-CD90- compartment contained candidate progenitor 
cells, since these cells were also shown to have multilineage reconstitution but with a higher 
transplanted cell number (Majeti et al., 2007). However, more than 30% of the cells in the 
CD34+CD38-CD45RA-CD90- compartment are also able to reconstitute secondary recipients, 
which raises the question of whether CD90 is in fact a reliable marker capable of segregating 
true HSCs from MPPs. To address this, Notta and colleagues used CD49f (integrin α6) antigen 
as an additional surface antigen for further purifying human HSCs. CD49f+ cells were shown 
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to yield an almost 7-fold higher human chimerism in transplantation assays as compared to 
CD49f- cells and as little as ten CD34+CD38-CD45RA-CD90+CD49f+ cells resulted in 
successful multilineage engraftment. This study has redefined the HSC immunophenotype 
and certified CD34+CD38-CD45RA-CD90-CD49f- into bona fide MPPs instead (Notta et al., 
2011) (Figure 1.1).  
Figure 1.1 – Models of adult Mouse and Human Haematopoietic Hierarchies. The different 
populations discovered by functional assays are showed for both systems, with the immunophenotypes 
associated with each. In both models, gradual lineage restriction progresses from the left starting at the 
HSCs, through intermediate progenitors until mature cells on the right. (Lin: cocktail containing cell 
surface markers for all terminally differentiated populations (B cell; T cell; NK; dendritic cell, monocyte, 
granulocyte, megakaryocyte, and erythrocyte). (Reprinted from “Hematopoiesis: A Human 
Perspective”, volume 10, Issue 2. Doulatov et al., P120-136, February 03, 2012 Copyright (2012), with 
permission from Elsevier).  
24
So far, this immunophenotype has remained the gold standard for isolating highly purified 
human HSCs, although undoubtedly new markers will be discovered that will allow the 
isolation of populations progressively more enriched for true HSCs. On the other hand, a highly 
quiescent type of HSC can also be found in the CD34- compartment and can be placed at the 
top of the human hierarchy. Over 20 years ago, Bhatia and colleagues found a new CD34-
population capable of repopulating non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice which the authors termed CD34- SCID-repopulating cells (Bhatia et al., 
1998). These cells were found at a proportion of one repopulating cell per 125,000 Lin-CD34-
cells and were shown to have a very different behaviour under culture conditions as compared 
to CD34+ cells. For example, human umbilical vein endothelial cell (HUVEC)-conditioned 
media co-culture increased the number of CD34--SRCs, while these conditions led to 
differentiation of CD34+ cells (Bhatia et al., 1998). In addition to this, mice transplanted with 
UCB-derived Lin-CD34-CD38- showed human myelo-lymphoid engraftment at 24 weeks (Ishii 
et al., 2011). Later on,  CD34- cells with engraftment potential were shown to be confined in 
the CD93+ (C1qRp) fraction (Danet et al., 2002). Recent evidences suggest that they comprise 
highly quiescent cells, regulated in part by Notch and TGFβ signalling, which not only are able 
to give rise to but also possess higher repopulating potential than CD34+ HSCs (Anjos-Afonso 
et al., 2013). All this suggests that CD34- HSCs are a rarer form of stem cells that can be 
placed at the top of human haematopoietic tree, are functionally very distinct and present 
different repopulation kinetics from CD34+ HSCs. It is believed they represent a reservoir of 
very primitive cells that only contribute to haematopoiesis under stress conditions.  
1.2.2. Haematopoietic progenitor cells
1.2.2.1. Multipotent progenitors (MPPs)
Downstream of HSCs lie the MPPs. These cells retain multilineage differentiation potential but 
are only capable of short-term engraftment. Early studies showed that CB CD34+CD38lo cells 
were able to generate transient myelo-lymphoid engraftment in NOD/SCID mice at 2 weeks 
post-transplantation (Mazurier et al., 2003). This very lose definition of MPP population was 
later refined as being contained in the Lin-CD34+CD38-CD45RA-CD90- population as 
mentioned above (Majeti et al., 2007) and later,  specifically demarcated as being CD49f-
(Notta et al., 2011). These cells are capable of short-term multipotential engraftment in 
NOD/SCID/γcnull (NOD/SCID gamma chain null; NSG) mice at 4 weeks but disappear by week 
12 (Majeti et al., 2007), (Notta et al., 2011). These data reinforce the idea that multilineage 
capacity is retained in MPPs, but self-renewal is limited when compared to HSCs, which are 
able to generate multilineage repopulation by week 12 and later. In a similar fashion to the 
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murine MPP population, these cells appear to display early lineage bias whereby MPPs can 
be further fractionated based on the expression of CD71 (transferrin receptor) and BAH-1 
(also known as CD110 or thrombopoietin receptor), of which the F1 fraction (CD71- BAH-1-) 
retains multilineage potential, while F2 (CD71+ BAH-1-) and F3 (CD71+ BAH-1+) predominantly 
give rise to Mk and Er lineages (Notta et al., 2016). 
 
1.2.2.2. Lineage-restricted progenitors
Under the classical view of haematopoiesis, it is believed that a bifurcation occurs following 
the MPP stage, after the loss of lymphoid clonogenic potential, that segregates these cells by 
myeloid potential (via CMP) or lymphoid potential (via CLP). Efforts to isolate human CMPs 
have shown these cells to be the direct progenitors of GMP and MEPs. While CMPs can 
initiate a mix of colonies containing all the GM, M, G, Mk and Megakaryocyte/Erythrocyte 
(MkE) lineages in colony assays, GMPs can only give rise to GM colonies, while MEPs mostly
originate colonies of the Er, Mk and MkE lineages (Manz et al., 2002). Transplanting human 
CMPs or MEPs into sub-lethally irradiated NOD/SCID/β2m mice led to 30% or 3% of human 
CD45+ and/or CD71+ cells, respectively. CMPs have been shown to differentiate into CD15+
(3-fucosyl-N-acetyl-lactosamine) myelomonocytic cells and glycophorin-A+ erythroid cells in 
vivo, whereas MEPs have been demonstrated to only generate glycophorin-A+ erythroid cells 
at 3 weeks, reinforcing the concept of a gradual progression towards lineage commitment 
(Manz et al., 2002). These immunophenotypes were further refined by Doulatov and 
colleagues that argued the GMP population is confined in the CD34+CD38+CD10- (Neprilysin)
CD45RA+CD135+ (Fms-related tyrosine kinase 3) compartment (Doulatov et al., 2010). Later, 
the previously described CMP fraction was revealed to still be heterogeneous. It was then 
demonstrated to contain an almost unbiased CD71-CD105-(endoglin) fraction that generated 
a CD71+CD105- Mk/Er-biased population or GMPs (Mori et al., 2015). Using these markers, 
MEPs were further fractionated into a CD71+CD105- subpopulation of erythrocyte-biased 
MEPs still capable of Mk production, and a true erythroid progenitor (EP) defined as 
CD71int/+CD105+ responsible for the generation of red blood cells (Mori et al., 2015). Yet, 
according to Notta and colleagues, the CD71 and BAH-1 markers are able to further partition 
the CMPs present in the CD34+CD38+CD10-Flt3+CD45RA- fraction, revealing three distinct 
populations: F1 (CD71-BAH-1-), F2 (CD71+BAH-1-), and F3 (CD71+BAH-1+). As assayed by 
co-culturing on MS5 stroma in the presence of cytokines SCF (stem cell factor), TPO 
(thrombopoietin), interleukin-7 (IL-7), interleukin-2 (IL-2), G-CSF (granulocyte-colony 
stimulating factor) and GM-CSF (granulocyte/macrophage-colony stimulating factor), CMPs 
found in CB or BM were shown to generate mostly myeloid colonies, showing no lymphoid 
potential. The F1 fraction was determined to be myeloid-biased while both F2 and F3 were 
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shown to preferentially generate erythrocytic progeny, suggesting that these newly uncovered 
fractions are functionally diverse from one another (Notta et al., 2016). 
Over twenty years ago, a Lin-CD34hiCD45RA+CD10+ primitive lymphoid progenitor present in 
the BM was described (Galy et al., 1995). This population was described to have B, T, NK and 
DC differentiation potential, but lack any myeloid, Er, and Mk lineage capacity. On the other 
hand, Hao and colleagues reported an early human lymphoid progenitor contained in the 
CD34+CD38-CD7+ (T-cell antigen CD7) compartment instead. However, this population was 
reported to give rise to B and NK but not myeloid or erythroid cells (Hao et al., 2001). More 
recently, a CD34+CD10+CD24- (small cell lung carcinoma cluster 4 antigen) human post-natal 
lymphoid progenitor was shown to be present in both CB and BM, with T, B and NK cells 
lineage capacity (Six et al., 2007). At around the same time, Hoebeke and colleagues argued 
that human CLPs could be found in the CD34+CD38-CD7+ fraction (Hoebeke et al., 2007)
instead. The identification of true human CLPs has been particularly problematic rendering 
very divergent opinions which can be due to the historical absence of reliable assays.
More recently, a population of multi-lymphoid progenitors (MLPs) emerging from MPPs has 
been described. MLPs are considered to have B, T and NK lineage potential while retaining
some myeloid potential. In fact, MLPs are not lymphoid restricted and may, under the right 
conditions, give rise to dendritic cells (DCs) and macrophages (Doulatov et al., 2010). In this 
work, the authors have defined a CD34+CD38-CD10+ population possessing B and NK cell 
potential with a bias towards NK cells but no myeloid potential, excluding these cells from the 
MLP compartment. On the other hand, two other populations defined as CD34+CD38-CD90-
/loCD45RA+CD10+CD7- or CD7+ were demarcated. The former cell fraction was defined as 
MLPs by the authors, and was described to produce B and NK cells, as well as CD33+ (sialic 
acid-binding Ig-like Lectin 3) CD11b+(integrin, alpha M (complement component 3 receptor 3 
subunit or Mac-1) myeloid cells. Additionally, this population was reported to give rise to T-
cells on OP9-Delta1 stroma. Importantly, these MLPs appear to only have B, T, NK and 
DC/macrophage potential but no G or Er potential.  In vivo transplantation assays confirmed 
that MLPs showed a bipotent lymphoid/monocytic potential but not a granulocytic one 
(Doulatov et al., 2010). 
The perception of the human haematopoietic system has been challenged in more recent 
years. We now hold that the first bifurcation in the human tree is not a clear separation of 
myeloid and lymphoid cells as previously thought. In the murine haematopoietic system, cells 
with lymphoid potential that can still generate granulocytes and macrophages, but no Mk or 
Er have been described. These have been termed lymphoid-primed multipotent progenitors 
(LMPPs) (Adolfsson et al., 2005). Conversely, a human LMPP-like population was uncovered 
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in acute myeloid laeukemia (AML) (Goardon et al., 2011). It can be defined as CD34+CD38-
CD45RA+CD10+ and produces granulocytes, unlike the MLPs described in Doulatov et al.
(Doulatov et al., 2010). In agreement with these findings, Gӧrgens and colleagues 
hypothesised that CD133 (Prominin-1) could further demarcate functionally different subsets 
of progenitors (Gorgens et al., 2013).  Cells with long-term in vitro and in vivo potentials are 
specifically defined as CD34+CD133+. Within this population, CB-derived CD45RA+CD10-
LMPP-like cells were demonstrated to originate MLPs (CD45RA+CD10+) or GMPs 
(CD45RA+CD7-CD10-) (Gorgens et al., 2013). However, no phenotypically defined 
CD34+CD38-CD45RA+CD10+ MLP population is detected in human BM. Instead, another BM-
derived population similar to CB MLPs, devoid of clonogenic myelo-erythroid potential, was 
isolated from the CD34+CD38+CD45RA+CD10- fraction, based on high expression of L-
selectin (CD62L) (Kohn et al., 2012). In summary, this implies that the earliest bifurcation in 
the human system does not entirely segregate myeloid and lymphoid potential. Rather, all 
lymphoid and some myeloid cells are still generated in a lympho-myeloid arm, while the 
remaining myeloid cells originate in the myelo-erythroid restricted branch. 
1.2.3. Brief notes on the evolving view of a dynamic hierarchy
The depiction of the human hierarchical system has shifted over the recent years from the 
view of a somewhat rigid structure with very well-defined stages of differentiation, towards a 
more gradual and plastic process. Current work from John Dick’s lab exposed a different 
interpretation on the roadmap for lineage commitment in human haematopoiesis (Notta et al., 
2016). A key observation was that this hierarchy changes its shape when moving from foetal 
to adult haematopoiesis. The former is dominated by the presence of oligopotent progenitors 
with My-Er-Mk and Er-Mk potential (Notta et al., 2016). On the other hand, the authors suggest 
that adult haematopoiesis is organised as a two-tier system, with the top tier comprising 
multipotent cells such as HSCs and MPPs and the bottom tier containing mainly unipotent 
progenitors. They also suggest that Mk and Er commitment occurs very early and arises 
directly from stem cells, dismissing the likelihood of existing intermediate oligopotent 
progenitors, although claiming that if such cells exist, they are probably very short lived and 
could not be detected with the experimental setup used (Notta et al., 2016). In agreement with 
this view, human haematopoiesis is now proposed to be a continuum process where a 
“continuum of low primed undifferentiated cells (CLOUD)-HSPCs” contains phenotypic MPPs 
and MLPs (Velten et al., 2017). Such progenitors do not constitute stable and discrete cell 
types but rather transitory states where CLOUD-HSPCs acquire transcriptional programmes 
driving them into a specific direction. The authors suggest that transcriptomic priming is linked 
to the restriction of differentiation potential at an early stage both in vitro and in vivo. 
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Interestingly, early transcriptional priming events that drive differentiation into the lympho-
myeloid, or into the Mk-Er direction are present in the most primitive HSCs, suggesting lineage 
bias very early on (Velten et al., 2017). A study from the Camargo’s lab used transposon 
tagging to perform lineage tracing and appreciated the fates of stem and progenitor cells in 
steady state murine haematopoiesis. Under homeostatic conditions, part of the Mk population 
was described to arise independently from other lineages whereby a subset of long-term HSCs 
(LT-HSCs) contributed actively to Mk output directly, without seemingly going through any 
intermediate MPP stage, which means the roadmap concept is more flexible than previously 
realised (Rodriguez-Fraticelli et al., 2018). 
 
1.2.4. Molecular regulation of HSCs - a brief summary
To maintain a balanced daily production of blood, HSCs must decide whether to divide or 
maintain their usual quiescence, and if division is undertaken, do they self-renew or 
differentiate into more mature progenitors. This is regulated by a complex system of intrinsic
(e.g. cell cycle, chromatin modifiers, etc.) and extrinsic (e.g. integrins, cytokines, etc.) 
regulators. When this balance is skewed, diseases such as leukaemia may develop. 
HSCs reside in the haematopoietic niche – a very rich microenvironment encompassing 
numerous molecular cues. The BM is the primary site of haematopoiesis, but other niches 
such as the spleen and the liver are also the home for haematopoietic cells. The BM is 
particularly rich, comprising of many cell types (Crane et al., 2017) Of those, the most 
abundant are the osteoblasts – a bone-lining endosteal cell type. Additionally, CXC-
chemokine ligand 12 (Cxcl12)-abundant (CAR) cells, leptin receptor-expressing (Lepr+) 
stromal cells, immune cells such as macrophages, monocytes and megakaryocytes, paired-
related homeobox 1 (Prrx1+) stromal cells and to a lesser extent, nervous system components 
such as neurons and Schwann cells have all been shown to contribute to the regulation of 
HSCs in mice (Crane et al., 2017). Thus, it is easy to appreciate the complexity of such a rich 
microenvironment where many different types of cell-to-cell interactions regulate HSCs via 
specific surface molecules, as well as indirectly through the secretion of molecules into the 
BM.
Among the myriad of signalling molecules present in this niche, SCF, CXCL12 and TPO 
appear to be particularly relevant. Scf from haematopoietic cells, osteoblasts and Nestin-
expressing stromal cells were shown not to be required for HSC maintenance (Ding et al., 
2012). But deletion of Scf directly in endothelial cells (ECs) and Lepr+ perivascular cells were 
demonstrated to lead to depletion of HSCs and ultimately overall loss of myeloid and lymphoid 
cells (Ding et al., 2012). CXCL12, through its receptor CXCR4 found on HSCs, is an important 
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factor in HSCs retention in the BM niche. Loss of either Cxcl12 or Cxcr4 was described to 
deplete HSCs from the BM (Sugiyama et al., 2006), (Tzeng et al., 2011). Mice lacking either 
Tpo – a well-known regulator of platelet production, or its receptor c-Mpl are deficient in 
multiple haematopoietic lineages including the stem cell compartment (Kimura et al., 1998), 
which is due, at least in part, to a decrease in cell cycle regulators p57kip2 (p57) and p19ink4d
and Hox transcription factors (Qian et al., 2007). TPO is also required both in the initial 
expansion of HSCs following transplantation as well as in the maintenance of adult quiescent 
HSCs (Qian et al., 2007), through its close interaction with TPO-producing osteoblasts 
(Yoshihara et al., 2007). 
Many of the major signalling pathways including FGF1/2, BMPs, WNT, TGF-β and Notch have 
also been implicated in HSPCs regulation (Crane et al., 2017). Conditional deletion of Smad1 
and Smad5 in BM cells was shown to contribute normally to the re-establishment of the 
haematopoietic system (Singbrant et al., 2010). Instead, wild type (WT) HSCs were verified to 
have reduced activity in a BMP4-deficient background (Goldman et al., 2009).  Loss of β or γ-
catenin has been revealed to have little impact in the murine haematopoietic system. However, 
the WNT signalling pathway regulates foetal haematopoiesis, as well as both murine and 
human adult HSCs, whereby stimulation of these cells by WNT ligands increases self-renewal 
capacity (Van Den Berg et al., 1998). Additionally, non-canonical WNT signalling appears to 
play a role in the maintenance of quiescent HSCs (Sugimura et al., 2012). Quiescence is one 
of the cellular hallmarks of stem cells. Such a dormant state is imposed, at least in part, by 
TGF-β signalling. TGF-β can upregulate potent cell cycle inhibitors such as p21Waf1 (p21) and 
p57 and block the expression of cytokine receptors such as KIT, FLT3, c-MPL and IL-6R 
(Fortunel et al., 2003). FGF1 produced by megakaryocytes aids in haematopoietic system 
recovery following injury. Indeed, FGFR1-specific inactivation was shown to prevent 
CXCL12/CXCR4-induced HSPC mobilisation following BM damage (Zhao et al., 2012). FGF2 
on the other hand, appears not to be required in steady state conditions, but it seems to be 
essential in recovery under stress conditions. In fact, FGF2 induction was shown to trigger the 
expansion of Nestin+ MSCs that induced Scf expression in the niche (Itkin et al., 2012). 
Interestingly, human CD34+ HSPCs are also in close contact with CD271+ (nerve growth factor 
receptor) MSCs and a balance in CXCL12 exposure of HSPCs in that microenvironment is 
important to maintain a healthy bone marrow (Flores-Figueroa et al., 2012). Finally, Notch 
signalling, being the focus of this thesis will be described in greater detail later. 
Due to evident difficulties in studying the human haematopoietic system, most of what is 
understood about the BM niche comes from studies on the murine system. However, despite 
the many differences between the two systems, some similarities can be appreciated. For 
example, when comparing human BM biopsies and mouse BM xenografts, Guezguez and 
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colleagues showed that human HSPCs were preferentially detected in the endosteal region 
either in the native human BM or in the mouse BM following transplantation (87% and 85%, 
respectively) rather than the vascular region (13% and 15%, respectively) (Guezguez et al., 
2013). Moreover, HSCs were described to be enriched in the trabecular bone area (TBA) and 
with higher SRC activity than HSCs localised in the long bone area (LBA) as addressed by 
secondary transplantation. Interestingly, TBA-HSCs were reported to have increased Notch 
activity which appeared to be mediated by the close interactions with TBA-residing Notch 
ligand- expressing osteoblasts (Guezguez et al., 2013).Nevertheless, the cell fate decision 
ultimately made by HSPCs are not fully imposed by external cues. Microarray data (Laurenti 
et al., 2013) and RNA-sequencing technology have allowed for a deeper look into the 
transcriptional programmes of human haematopoietic cells revealing new or reinforcing the 
roles of known intrinsic regulators of human haematopoiesis. As a result of the increasing 
applicability of this new technology, a great deal of research has focused on HSCs 
transcriptional programmes to show these are very dynamic throughout the differentiation 
journey, and possess a specific signature that is different from lineage-restricted progenitors 
(Novershtern et al., 2011), (Buenrostro et al., 2018), (Karamitros et al., 2018). 
Despite different studies having established different specific gene expression modules for 
each haematopoietic population, the general view is that different populations share many of 
these modules at diverse stages of differentiation, suggesting that changes in the 
transcriptional states are a gradual process (Novershtern et al., 2011), (Buenrostro et al., 
2018), (Karamitros et al., 2018). Of these, HSCs have a prevalent module containing surface 
markers including CD34, and transcription factors such as GATA2, HOXA9, HOXA10, MEIS1 
and N-MYC (Novershtern et al., 2011). This module, although particularly prevalent in HSCs, 
persists through many steps of differentiation. Of note, GATA2, HOXA9 and HOXA10 have 
been described as Notch targets (Robert-Moreno et al., 2005), (Weerkamp et al., 2006). Other 
studies have also reinforced the idea of “lineage priming” as imposed by key transcription 
factors that direct lineage specification early on (Novershtern et al., 2011). Nevertheless, 
HSCs and MLPs share many transcriptional programmes, especially regarding the expression 
of transcription factors (Laurenti et al., 2013). As briefly mentioned, a study undertaking single 
cell RNA-seq analysis of different HSPCs cells revealed that, apart from particular sets of 
transcription factors, the most primitive HSCs were described to possess prevalent modules 
associated with typical features of primitive stem cells such as quiescence, low gene 
expression machinery, low RNA content, low cellular respiration, low CD38 and high CD90 
expression (Velten et al., 2017). Thus, not only transcriptional landscapes associated with 
HSCs persist for a few stages of differentiation, but HSCs also express sets of genes 
associated with myeloid/lymphoid (FLT3/SATB1) and megakaryocyte/erythrocyte 
31
(GATA2/NFE2) lineage commitment. This has been interpreted as the occurrence of lineage 
priming at the very early stages of HSC development (Velten et al., 2017). Even though 
changes in transcriptional profiles are also imposed by external cues, the extent to which these 
landscapes are part of intrinsic properties of certain cells is unknown. 
Molecular regulation of stem and progenitor cells goes beyond the expression of hallmark TFs 
and is indeed very complex. Chen and colleagues believe that different cell types utilise the 
expression of transcripts and their respective isoforms as well as a myriad of splice junction 
alterations differentially (Chen et al., 2014). Additionally, it is now recognised that other layers 
of regulation that control cells including epigenetics and non-coding RNAs have emerged as 
players in the regulation of HSCs as well. As an example, G9a/GLP promotes H3K9me2 
patterning in HSPCs generating a specific chromatic structure landscape that prevents the 
activation of lineage-affiliated genes (Chen et al., 2012). Non-coding RNAs such as miR-22 
increases self-renewal in HSCs (Song et al., 2013), and interestingly miR-126 seems to play 
a differential a role in HSCs and leukaemia initiating cells (LICs) opening potential therapeutic 
avenues (Lechman et al., 2016). 
 
1.2.5. In vitro assays
1.2.5.1. Colony-forming unit (CFU) assay 
The CFU assay focuses on the detection of haematopoietic progenitor cells, with limited self-
renewal capacity. It is carried out by seeding test cells onto semi-solid media, such as 
methylcellulose, collagen, agar or fibrin clots supplemented with nutrients and growth factors. 
Methylcellulose – a commonly used medium consists of a gelling agent that is chemically inert 
and which properties do not change with pH (Miller and Lai, 2005). Progenitors present in the 
initial cell suspension give rise to recognisable colonies of different lineages, such as the 
colony-forming-unit erythroid (CFU-E), burst-forming unit-erythroid (BFU-E), CFU-
granulocyte/macrophage (CFU-GM) and mixed lineage CFU-granulocyte, erythroid, 
megakaryocyte, macrophage (CFU-GEMM). For instance, the generation of more colonies of 
the mixed CFU-GEMM lineage indicates the presence of more primitive cells with multilineage 
capacity. Under an optimal plating condition, the number of colonies formed is derived from 
single progenitors, hence the assay gives an idea not only of the type but also the frequency 
of progenitors present in the initial mix (Miller and Lai, 2005). 
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1.2.5.2. Long-term culture-initiating cell (LTC-IC) assay
The most relevant in vitro assay for HSCs is the LTC-IC assay. During the 1970s, when 
building on the colony-forming unit spleen (CFU-S) assay for murine HSCs, it was discovered 
that certain human haematopoietic cells can be maintained in in vitro cultures for several 
weeks given the adequate conditions (Dexter et al., 1977), (Gartner and Kaplan, 1980), 
(Sutherland et al., 1990). Minimally manipulated cells containing prospective HSCs are co-
cultured in the presence of an irradiated stromal feeder layer, frequently the MS5 cell line, 
which supports human HSCs and allows differentiation of progenitors (Issaad et al., 1993). 
After irradiation, a test population of haematopoietic cells can be deposited on top of the 
stromal layer and cultured for many weeks. More mature progenitors differentiate and 
eventually disappear from the culture. The more primitive cells remain in culture, proliferate 
and originate more mature progenitors. By the fifth week of culture, progenitors present in the 
mix have differentiated and died off and the remaining cells capable of generating colonies 
are the most primitive ones and these are designated the long-term culture-initiating cells 
(LTC-IC). In addition, these cells migrate underneath the stromal layer and form cobblestone-
like areas - the number of which correlates to the number of primitive cells present. Usually, 
at the end of the five-week period, the cells are harvested and seeded in a semi-solid medium 
such as methylcellulose, containing cytokines that support the growth and differentiation of 
the progenitors present similarly to a CFU assay. The in vitro culture system has remained the
surrogate assay for multipotent cells for a long time. However, the real difference between 
these LTC-ICs and bona fide HSCs could not be discovered without in vivo experiments, which 
in humans is understandably not possible. This has been overcome by the development of 
xenogeneic transplantation models, where strains of successively more immunodeficient mice 
have been used as hosts for testing human cells such as HSCs.
1.2.6. In vivo assays
1.2.6.1. Xenotransplantation mouse models
The first attempt to xenograft human cells was focused on transplantation of acute myeloid 
leukaemia (AML) cells into immunocompromised mice (Palu et al., 1979) and athymic nude 
mice (Flanagan, 1966). These nude mice are homozygous for the nude (nu) gene (Foxn1nu) 
and allowed for the first transplantation studies of human cells in immunocompromised mice 
(Segre et al., 1995). However, the outcomes were frequently inconsistent and unreliable, and 
worked preferentially using cell lines. Further improvements in 1983, led to the development 
of SCID mice (Bosma et al., 1983). These mice have a disrupted protein kinase DNA-activated 
catalytic polypeptide (Prkdc) gene, which results in the lack of expression of rearranged 
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antigen receptors, and therefore these mice lack functional B and T cells (Bosma et al., 1983). 
However, residual NK cells and macrophages impair human engraftment in these mice. The 
generation of the NOD/SCID mice by crossing SCID mice with NOD mice, led to more defects 
in adaptive and innate immunological cells, lacking functional B and T cells and decreased 
macrophage activity as a consequence of poor secretion of interleukin-1 (IL-1) (Shultz et al., 
2005). These mice allow a higher human engraftment compared to SCID mice. However, even 
with this already severe compromised mouse model, only 70% of AML samples can engraft 
(Ailles et al., 1999). In addition, a major drawback is that these animals have a short lifespan 
of 8.5 months as a result of frequent development of thymic lymphomas, which limits the 
observation of human engraftment (Shultz et al., 2005), and the presence of NK cells also limit 
long term studies (Prochazka et al., 1992). To overcome these limitations, the IL-2 receptor 
common gamma chain (IL2Rγc) which interferes with IL-15 signalling that is necessary for NK 
cell development was deleted (Ito et al., 2002). The NOD/SCIDγcnull (NSG) mouse strain was 
then generated, which is devoid of B, T, and NK cells. These mice do not develop thymic 
lymphomas and are overall better recipients for human cells, making it a popular model for 
xenotransplantation studies. More recently, cutting edge models have been developed. In 
2010 the generation of the NSGS mouse model, by crossing NGS with NSS mice (NOD/SCID 
SCF, GM-CSF, interleukin-3 (IL-3)), which lacks the IL2Rγc and produces human SCF, GM-
CSF and IL-3, that allows a better homing of leukemic cells as compared to the NGS and NSS 
models (Wunderlich et al., 2010). In 2014, the MISTRG (standing for M-CSF, IL-3/GM-CSF 
and TPO in a Rag2−/−Il2rg−/−background) mouse model was developed and this strain 
supports the development of human innate immune cells such as monocytes, macrophages 
and NK cells through the expression human cytokines (M-CSF; IL-3, GM-CSF and TPO) 
(Rongvaux et al., 2014). We can expect in the future newer strains of immunocompromised 
mice that better mimic the human haematopoietic niche that will allow a better understanding 
of normal and leukaemic human haematopoiesis.
1.3. Acute Myeloid Leukaemia (AML)
1.3.1. Brief description of AML
Acute myeloid leukaemia (AML) is an aggressive type of blood cancer characterised by the 
block in myeloid differentiation from HSPCs into mature myeloid cells and uncontrolled growth 
of abnormal myeloid cells. It is the second most common type of adult leukaemias. It can arise 
following an underlying haematological malignancy but most of the times it appears as a de 
novo disease in healthy individuals. In the UK, around 3100 people were diagnosed in 2015 
(www.cancerresearchuk.org). Even though the tremendous research effort in the field has 
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significantly increased the survival and quality of life of the patients, the overall survival (OS) 
at 5-years is still very low, especially in older patients. While the OS at 5-years is more than 
65% in children aged 14 or younger and around 60% in patients aged between 15 and 24, this 
number drops to 40% in patients aged between 25 and 64 and to a staggering 5% in people 
aged 65 or older (https://www.cancerresearchuk.org/about-cancer/acute-myeloid-leukaemia-
aml/survival). The diagnosis is usually done by morphological detection of blasts, which must 
represent at least 20% of cells in blood smears (Dohner et al., 2017). In addition, cytogenetics
and immunophenotyping are employed by using specific markers such as CD34 precursors, 
CD65 granulocytic, CD14 monocytic or CD41 megakaryocytic markers (additional information 
on the markers can be found in Dohner et al., 2017 (Dohner et al., 2017)). AML is 
characterised by genomic changes such as translocations and emergence of complex 
karyotypes discussed later in the text. Standard metaphase chromosomal profiling is still 
routinely used to detect such alterations (Grimwade et al., 1998). Fluorescence in situ
hybridisation (FISH) represents another method for detecting these large-scale genomic 
alterations. Fluorescent DNA probes designed to target specific loci allow for the visualisation 
and quantification of specific translocations (Wertheim, 2015). Still, a low number of cells are 
analysed when using FISH or cytogenetics. Real-time polymerase chain reaction (RT-PCR) 
using primer pairs covering the two loci involved in the translocation is a common alternative 
diagnostic tool (Bacher et al., 2009). More recently, the development of next generation 
sequencing (NGS) strategies has helped uncover novel genetic alterations in AML by 
detecting specific translocations and mutations in AML-related genes. Whole genome 
sequencing (WGS), based on NGS allows for the identification of complete genomic 
alterations encompassing point mutations, indels, copy number changes, translocations, 
cryptic rearrangements, inversions and complex rearrangements in the whole genome (Ilyas 
et al., 2015). The first whole cancer genome sequencing to be performed was in an AML 
patient in 2008 by Ley and colleagues (Ley et al., 2008). This led to the detection of recurrent 
somatic mutations in FLT3 and NPM1 and the finding of other eight novel somatic mutations. 
The same group soon after found that DNMT3A mutation is a recurrent event in patients with 
de novo AML of intermediate risk category (Ley et al., 2010). Interestingly, Welch et al. have 
employed WGS strategies to detect acute promyelocytic leukaemia (APL) fusion genes which 
could not be detected using FISH, which resulted in the patient being successfully treated for 
APL (Welch et al., 2011). The development of “bench-top” NGS instruments means this 
technology will be available to an increasing number of researchers and clinicians for the 
diagnosis of AML.
Occasionally, stem and progenitor cells with mutations arise which upon expansion generate 
a sub-clone of cells with a different genetic background in a process called clonal 
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haematopoiesis. Some argue that this process might contribute to disease initiation although 
this is debatable. Clonal haematopoiesis-harbouring mutations in AML-associated genes was 
found in 95% of 50-70-year-olds with clonal haematopoiesis (Young et al., 2016), which is 
higher than previously thought. However, these clonal mutations appear to confer higher self-
renewal capacity without increasing proliferation (Young et al., 2016). Furthermore, it is not 
known whether clonal haematopoiesis occurs due to certain clones being selected for or if on 
the other hand, random fluctuations in HSC states such as cell cycle and contributions from 
different HSCs is at the root of this condition (Mupo et al., 2013). 
1.3.2. Characterisation of AML
AML arises due to abnormal proliferation and differentiation of primitive myeloid cells that 
sustain genetic abnormalities. The current model of leukemogenesis proposes that three 
different classes of mutations must occur (De Kouchkovsky and Abdul-Hay, 2016),(Gruszka 
et al., 2017). An early model hypothesis had been proposed as a mechanism for the 
emergence and progression of AML (Kelly and Gilliland, 2002). Within this view, two types of 
mutations must occur for the disease to develop. Class I type of mutations give a subset of 
cells a proliferative advantage. These frequently arise from mutations in the FLT3 gene, 
yielding a FLT3-internal tandem duplication mutation (commonly known as FLT3-ITD). This 
results in constitutive activation of the FLT3 receptor, leading to activation of downstream
targets STAT5 and mitogen-activated protein (MAP) kinase (Hayakawa et al., 2000). Other 
genes commonly involved are KIT, N/KRAS and TP53. Class II mutations on the other hand 
block the natural differentiation process. These occur in genes such as NPM1 and CEBPA.
More recently, a third type of mutations in DNA modifiers such as DNMT3A, TET2 and IDH1/2
have been identified (De Kouchkovsky and Abdul-Hay, 2016). Beyond point mutations, other 
genetic lesions such as aneuploidies, fusion genes and complex karyotypes arise in the 
context of AML. In one study analysing some of the largest patient cohorts so far has 
consolidated the landscape of driver mutations in AML (Papaemmanuil et al., 2016). These 
genetic alterations are summarised in Figure 1.2. 
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Figure 1.2 – Landscape of driver mutations in AML. Each bar is a driver lesion which may include 
mutations, chromosomal aneuploidies, fusion genes and complex karyotypes. The Y axis shows the 
number of unique patients containing the driver mutation. A total of 1540 patient samples were 
analysed. The colours indicate the risk stratification according to the European LeukemiaNet (ELN) 
classification. As in (Pappamanuil et al., 2016). (Reproduced with permission from Papaemmanuil, Elli 
et al. “Genomic Classification and Prognosis in Acute Myeloid Leukemia.” The New England journal of 
medicine vol. 374,23 (2016): 2209-2221, Copyright Massachusetts Medical Society).
First established in 1976, the French-American-British (FAB) classification system divided 
leukaemias into one of eight (M0-M7) subtypes based on the cytological and chemical 
properties of the blasts (Bennett et al., 1976). These are summarised in Table 1.1:
Table 1.1 – French-American-British (FAB) classification of AML (Bennett et al., 1976). 
FAB subtype Name
M0 Undifferentiated acute myeloblastic leukaemia
M1 Acute myeloblastic leukaemia with minimal maturation
M2 Acute myeloblastic leukaemia with maturation
M3 Acute promyelocytic leukaemia (APL)
M4 Acute myelomonocytic leukaemia
M4eos Acute myelomonocytic leukaemia with eosinophilia
M5 Acute monocytic leukaemia
M6 Acute erythroid leukaemia
M7 Acute megakaryoblastic leukaemia
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Technological advances led to the creation of another classification system by the World 
Health Organization (WHO) that goes beyond morphological classification and includes 
information on genomic alterations. The latest update from the WHO classification of AMLs is 
depicted on Table 1.2 (Arber et al., 2016). 
Table 1.2 – World Health Organisation (WHO) classification of acute leukaemias and myeloid 
neoplasms (Arber et al., 2016). 
WHO classification of AML
AML with recurrent genetic abnormalities
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 APL
APL with PML-RARA
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
AML with t(6;9)(p23;q34.1);DEK-NUP214
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
Provisional entity: AML with BCR-ABL1
AML with mutated NPM1
AML with biallelic mutations of CEBPA
Provisional entity: AML with mutated RUNX1
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML, not otherwise specified (NOS)
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic laeukemia
Acute monoblastic/monocytic laeukemia
Pure erythroid laeukemia
Acute megakaryoblastic laeukemia
Acute basophilic laeukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down syndrome
Transient abnormal myelopoiesis (TAM)
Myeloid laeukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute laeukemias of ambiguous lineage
Acute undifferentiated laeukemia
Mixed phenotype acute laeukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
MPAL with t(v;11q23.3); KMT2A rearranged
MPAL, B/myeloid, NOS
MPAL, T/myeloid, NOS
Patients can be stratified according to their risk of treatment resistance or treatment-related 
mortality (TRM). In general, age and performance status help predicting the risk of TRM and 
these factors are taken into consideration when deciding on a treatment plan. But the 
cytogenetic profile is the most important prognostic factor for complete remission (CR) and 
overall survival (OS) in AML. In a simplified manner, AML patients can be stratified into 
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favourable, intermediate or adverse risk groups (Dohner et al., 2017), (De Kouchkovsky and 
Abdul-Hay, 2016) (Table 1.3). 
Table 1.3 – Current Stratification of Molecular Genetic and Cytogenetic Alterations – according 
to ELN Recommendations. Adapted from (Dohner et al., 2017). 
Risk profile Subsets
Favourable
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-
MYH11 Mutated NPM1 without FLT3-ITD (normal 
karyotype) Biallelic mutated CEBPA (normal 
karyotype)
Intermediate-I 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal 
karyotype) Wild-type NPM1 without FLT3-ITD
(normal karyotype)
Intermediate-II
t(9;11)(p22;q23); MLLT3-KMT2A
Cytogenetic abnormalities not classified as 
favourable or adverse (insufficient data)
Adverse
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2–
MECOM (EVI1)
t(6;9)(p23;q34); DEK-NUP214 t(v;11)(v;q23); 
KMT2A rearranged −5 or del(5q); −7; abnl(17p); 
complex karyotype
The chromosomal translocations t(8,21), t(15,17) and inv(16) all fall into the favourable group. 
Patients with normal cytogenetics usually fall in the intermediate group, while adverse 
cytogenetics comprise abnormalities such as monosomy 5 or 7, t(6,9) and inv(3) and complex 
karyotype which is defined as three or more chromosomal abnormalities. A summary on the 
stratification of patients based on cytogenetics and molecular profile can be found in (De 
Kouchkovsky and Abdul-Hay, 2016). 
In the initial step of leukemogenesis, the driver mutation occurs in a normal stem or progenitor 
cell that may possesses other mutations that do not necessarily play a role in the disease. The 
driver mutation confers advantage to the affected cell, and with the expansion of this clone, all 
the other passenger mutations are retained. When a new driver mutation further confers 
advantage to the founding clone, it acquires more passenger mutations during the disease 
progression. At the time of diagnosis, the founding clone contains few drivers, but many 
passenger mutations. Indeed, it is known that AML progression is driven by relatively few 
driver mutations when compared to other types of cancers. Hence, understanding which driver 
and passenger mutations are important is imperative. As an example, FLT3-ITD is one of the 
most common of these genetic abnormalities (Welch et al., 2012). We now know that the 
tandem duplication of this gene alone does not initiate overt leukaemia, but additional driver 
mutations that are acquired leads to propagation of the disease (Kelly and Gilliland, 2002), (Li 
et al., 2008), (Sallmyr et al., 2008). Using exome-sequencing for leukaemia-specific mutations,
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a model for FLT3-mutated AML progression was proposed in which a series of mutations or 
epigenetic events occur in self renewing HSCs, acquiring new mutations throughout the 
disease progression (Jan et al., 2012). 
The authors found pre-leukemic mutations in residual non-leukaemic HSCs in all the cases of 
normal karyotype AML analysed. For example, in 2 out of 5 cases TET2 mutations were found 
in residual HSCs whereas FLT3 mutation was not found in any of the cases (Jan et al., 2012). 
Therefore, it is currently viewed that FLT3 mutations are secondary events. It has also been 
highlighted that mutations in epigenetic modifiers such as DNMT3A, ASXL1, IDH1/2 and TET2
genes are often acquired earliest (Papaemmanuil et al., 2016). These are usually present in 
the founding clone and are very rarely found alone in leukaemic cells suggesting the clone 
requires additional mutations to cause overt leukaemia. Another example relates to NPM1 
mutation which is usually considered a primary event (Falini et al., 2011), although in some 
cases DNMT3A mutations can precede NPM1 mutations (Shlush et al., 2014), (Kronke et al., 
2013). Altogether, this suggests that AML is not the sum of random genetic abnormalities but 
rather follows a defined multi-step leukaemogenic trajectory (Papaemmanuil et al., 2016). 
1.3.3. The Leukaemic Initiating Cell (LIC) 
A major problem in cancer biology is identifying the cell of origin capable of replicating the 
tumour – the cancer initiating cell (CIC). This concept - now widely accepted in a variety of 
cancer types was first introduced in the context of AML via two seminal works from John Dick’s 
group (Lapidot et al., 1994), (Bonnet and Dick, 1997). In Lapidot et al., the authors showed 
that cells from all the AML subtypes tested engrafted in SCID mice (Lapidot et al., 1994). 
Importantly, cells from the M4 and M5 FAB subtypes proliferated more aggressively and 
disseminated to extramedullary sites more readily than M1 and M2 cells, showing that the 
SCID-leukaemia model was able to accurately reflect the aggressiveness of the various AML 
subtypes. Importantly, only CD34+CD38- cells were demonstrated to be capable of extensive 
leukaemic engraftment and the authors concluded that AML developed in these mice due to 
extensive proliferation and differentiation of these LICs or Leukaemic Stem Cells (LSCs) in 
vivo. Later, Bonnet and colleagues suggested that AML is organised in a hierarchical manner 
(Bonnet and Dick, 1997). In this view, a leukaemogenic event targeting HSCs (CD34++CD38-
) generates LICs that produce committed leukaemic progenitors that ultimately lead to the 
detection of the several subtypes of AML. Importantly, the authors demonstrated that LICs 
were exclusively present in the CD34++CD38- compartment irrespective of subtype or lineage 
markers expressed on the blasts. We now know this consisted of a simplified version of a 
much more complex picture. A third of AML cases are in fact CD34- AMLs (defined as the 
presence of <10% CD34+ cells) in which the bulk of LICs are found in the CD34- fraction, 
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although LICs can be at times detected in a minor fraction of CD34+ cells (Quek et al., 2016). 
Contrary to LICs arising from the CD34+ compartment, these are not believed to represent 
hierarchically related cells but are rather the consequence of plastic expression of the CD34 
antigen, which in AML is not a cell immaturity marker (Quek et al., 2016). It was shown in a 
study that within the CD34+ fraction, two subpopulations of LICs could be found: LMPP-like 
CD34+CD38- and GMP-like CD34+CD38+ cells, whose names derived from the similarity to 
their healthy counterparts (Goardon et al., 2011). Remarkably, LMPP-like LICs were reported 
to give rise to GMP-like cells, but not the contrary, reinforcing the notion of a hierarchical 
organisation (Goardon et al., 2011). These authors further suggested that these LICs were 
found to be more closely related to normal haematopoietic progenitors that gained self-
renewal capacity, rather than stem cells, which was validated by gene expression profile 
analysis (Goardon et al., 2011). Interestingly, a study showed that the experimental setup 
used may influence the outcome of the experiments. Anti-CD38 antibodies, routinely used in 
the isolation of putative LICs, may lead to the clearing of LICs by innate immune cells in 
transplantation models (Taussig et al., 2008). The authors showed that LICs could be mostly 
found in the CD34+CD38+ compartment in all the AML samples tested but can also be found 
in the CD34+CD38- compartment. 
Disease relapse following complete remission is the major hurdle in AML management. Shlush 
and colleagues combined genetic and functional approaches and performed whole-genome 
sequencing (WGS) of AML samples harvested at diagnosis and relapse (Shlush et al., 2017). 
The authors showed that in some patients, the cellular origin of relapse lies in a rare population 
of cells with a primitive phenotype resembling HSPCs. In others, relapse originates from cells 
with a more committed immunophenotype (Shlush et al., 2017). Regardless, relapse in both 
patient groups seems to be closely linked to stem cell properties whereby in the first case, 
primitive LICs are responsible for relapse, while stemness transcriptional programmes that are 
retained in the bulk of the leukaemia population are the culprit when more committed 
progenitors are at the origin of relapse (Shlush et al., 2017). It was further suggested that 
chemotherapy does not induce mutations leading to emergence of new clones, but it rather 
selects for pre-existing subclones that were already resistant to therapy due to their 
quiescence (Shlush et al., 2017). In agreement with this, a stemness transcriptional signature 
has been demonstrated to predict therapy success (Ng et al., 2016). Gene expression analysis 
of LSC+ versus LSC- fractions of AML samples revealed a 17-gene list comprising a 
transcriptional signature that is predictive of overall performance (Ng et al., 2016). A high 
LSC17 score was associated with poor overall survival and event-free survival. High LSC17 
score patients were also found to present higher percentage of bone marrow blasts at 
diagnosis, higher rates of relapse and lower response rates to standard induction 
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chemotherapy. Interestingly, in one AML cohort, the LSC17 signature proved to be the 
strongest predictive factor of resistance to therapy, ahead of variables such as age, de novo
vs secondary AML, total white blood cell count and cytogenetics (Ng et al., 2016). 
It seems increasingly clear that in order to eradicate the disease, both bulk blasts and LICs 
need to be effectively targeted. Even though LICs can resemble their normal HSPCs 
counterparts in many aspects of their biology, they possess some unique features that may 
be the focus of therapeutic intervention. Some LICs, just as normal HSCs, appear to be 
quiescent. In fact, in a study from the 1960s, patients were injected with tritiated thymidine (a 
radioactive nucleoside – 3H-thymidine, used to measure the extent of cell division) revealed 
the presence of cells with different kinetic properties within the disease (Clarkson et al., 1967). 
It was hypothesised that slowly cycling cells could perhaps show increased resistance to anti-
proliferative therapies. More recently, AML cells from 6 out of 7 samples tested were shown 
to capture leukaemic progenitors that engrafted in NOD/SCID mice and were resistant to killing 
by tritiated thymidine (Guan et al., 2003). Isolated quiescent AML cells were shown to exit G0 
after 24-72 hours of serum-free culture without cytokines, which did not happen in normal 
lineage-negative BM cells (Guan et al., 2003). The notion that their quiescence may help 
escaping chemotherapy has remained a popular concept for a long time. However, this is not 
always the case. A subset of CD93-expressing LICs found in the CD34+CD38- fraction was 
reported to be actively cycling in MLL-rearranged AMLs (Iwasaki et al., 2015). These cells, 
which were found in the G1 phase of the cell cycle, were demonstrated to have serial 
transplantation capacity while the G0 phase CD34+CD38-CD93- cells were inefficient in 
engrafting in primary recipients (Iwasaki et al., 2015). 
Whether LICs’ metabolism compares to that of normal HSPCs is also debatable. LICs were 
shown to possess lower levels of reactive oxygen species (ROS) and oxygen consumption -
typical of a low oxidative phosphorylation profile (Lagadinou et al., 2013). Additionally, these 
cells were described to be more reliant on oxidative phosphorylation and were determined to 
have an upregulated BCL2 expression pattern when compared to high oxidative 
phosphorylation LICs and normal haematopoietic cells (Lagadinou et al., 2013). In the same 
study, the authors used BCL-2 inhibitors and demonstrated a selective eradication of LICs 
while normal HSCs were mostly spared and this was due, at least in part, to the higher 
glycolytic reserve capacity of HSCs (Lagadinou et al., 2013). More recently however, 
challenging this idea, Farge and colleagues described that chemotherapy-resistant AML cells 
have a high oxidative phosphorylation (OXPHOS) status (Farge et al., 2017). They proposed 
that chemoresistance might be more strongly driven by cellular metabolism rather than 
quiescence or maturity of the cells. These high OXPHOS cells, in contrast to low OXPHOS 
cells were found to be chemo-resistant in vivo. Targeting mitochondrial protein synthesis, 
42
electron transfer or fatty acid oxidation was able to shift the cells towards low OXPHOS, 
enhancing their susceptibility to the anti-leukemic effects of cytarabine. All in all, this 
demonstrates metabolic heterogeneity in the LIC compartment.
Altered epigenetics is another important hallmark of LICs. Pre-leukemic HSCs very frequently 
contain mutations in epigenetic regulator genes such as TET2, DNMT3A and IDH1/2, that 
ultimately alter their metabolism and confer self-renewal capacity to haematopoietic progenitor 
cells (Wouters and Delwel, 2016). The natural process of DNA methylation influences gene 
expression. Aberrant DNA methylation patterns have been recognised as contributors to 
leukemogenesis. DNMT3A mutated proteins are believed to act as a dominant negative over 
wild-type DNMT3A and lead to abnormal methylation patterns (Russler-Germain et al., 2014). 
Ten-Eleven-Translocation (TET)-enzymes catalyse the oxidation of 5-methylcytosine into 5-
hydroxymethlycytosine (5hmC). TET2 mutations results in decreased levels of 5hmC. 
Although the biological relevance of this metabolite is not fully understood, TET2 mutations 
ultimately confer poor prognosis in intermediate-risk AML (Metzeler et al., 2011). Isocitrate 
dehydrogenase (IDH) enzymes catalyse the conversion of isocitrate to α-ketoglutarate. 
Mutations in IDH1 and IDH2 result in the production of the aberrant metabolite 2-
hydroxyglutarate which competes with α-ketoglutarate, ultimately inhibiting TET2 (Wouters 
and Delwel, 2016). 
In addition to the cellular features mentioned, several surface markers that are upregulated in 
CD34+CD38- AML LICs compared to normal HSPCs could be the target for therapeutic 
intervention. These include CD123, CD44, CD47, TIM3, CD96, CD99, CLL-1, CD32, CD25, 
IL1RAP, GRP56 and CD93 (Thomas and Majeti, 2017). Some of these have been the target 
of a more specific therapeutic approach briefly described in the following section. 
1.3.4. Treatment and management of AML, a brief note
The standard induction therapy employed to treat AML comprises administration of cytarabine 
(Ara-C) in combination with an anthracycline. Cytarabine is a nucleoside analog that is 
incorporated into cells during the S phase of the cell cycle and inhibits DNA synthesis. 
Anthracyclines intercalate between adjacent DNA base pairs and are believed to inhibit the 
nuclear enzyme topoisomerase II. Standard induction therapy leads to a complete response 
in 60-85% of the patients younger than 60 years old. For patients older than 60, complete 
response is 40-60% (Dohner et al., 2017). This has remained the standard therapy for nearly 
fifty years. Figure 1.3 summarises the major approvals for AML treatment, including newly 
identified drugs. Noticeably, few agents have been introduced for AML management in nearly 
25 years following the introduction of the 7+3 regimen (7 days standard dose cytarabine and 
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3 days anthracycline). However, the last three years have seen a very promising boost in the 
number of approvals towards AML treatment (Figure 1.3). 
Figure 1.3 – Timeline of major approvals for the treatment of AML. R/R – relapsed/refractory; 
MRC – myelodysplasia-related changes; y.o. – years old.
Newer agents aimed at improving on this have been tested as potential alternative therapies 
targeting various aspects of cellular features. Among these are drugs targeting epigenetic 
modifiers, such as IDH1/2 mutant enzyme inhibitors. AG-120 is an IDH-1 mutant inhibitor that 
yielded haematological responses in half of IDH-1 positive patients including four CR (DiNardo 
et al., 2015). For IDH-2 mutants, AG-221 demonstrated benefits in survival of an IDH-2 mutant 
AML xenograft model (Stein et al., 2015). Recent approvals for this subclass of AML include 
enasidenib and ivosidenib. Enasidenib has emerged as a treatment option for 
relapsed/refractory (R/R) IDH2-mutated AML. This drug led to complete remission and
complete remission with partial hematologic recovery rate of 23% and median remission 
duration of 8.2 months (Stein et al., 2019). Ivosidenib is a small molecule inhibitor of mutated 
IDH1 enzyme, which showed a complete remission rate of 21.6% and median duration of 8.2 
months (DiNardo et al., 2018). In 2019, this drug was approved for treatment of newly 
diagnosed AML patients 75 years old and older or with comorbidities (Lai et al., 2019). 
Tyrosine kinase inhibitors, such as FLT3 and KIT inhibitors are also of relevance. Well-known 
first generation FLT3-ITD inhibitors include sorafenib and midostaurin, and second-generation 
agents include quizartinib and crenolanib, some of which have shown improvements on OS 
and event-free survival (EFS) (De Kouchkovsky and Abdul-Hay, 2016),(Dohner et al., 2017). 
Midostaurin is a multi-targeted kinase inhibitor, which has shown activity in FLT3-mutated cell 
lines and mouse models (Weisberg et al., 2002). A phase III clinical trial studied the efficiency 
of midostaurin combined with standard chemotherapy. Compared to placebo, this drug was 
associated with longer OS and EFS (Stone et al., 2017). In 2018, gilteritinib was approved in 
44
the United States and Japan for the treatment of R/R FLT3-mutated AML, which has shown 
to prolong OS compared to the control arm of the study (Perl, 2019). Venetoclax - a potent 
BCL-2 inhibitor, was approved for the treatment of patients 75 years and older. It showed 
promising results regarding the rate and duration of CR and its combination with 
hypomethylating agents or low-dose cytarabine is now an option for this group of patients (Lai 
et al., 2019),(Estey et al., 2020). Also noteworthy is CPX-351 – a liposomal formulation 
containing a fixed 1:5 M ratio of daunorubicin and cytarabine, capable of bypassing drug efflux 
pumps, entering the cells as liposomes. This drug was approved by the FDA in 2017 and the 
European Medicines Agency (EMA) in 2018 for the treatment of therapy-related AML (t-AML)
and AML with myelodysplasia-related changes (AML-MRC) (Lai et al., 2019). CPX-351 
displayed improved CR and OS when compared to standard 7+3 therapy (Lancet et al., 2018). 
Other approaches include cell cycle and signalling inhibitors and nuclear export inhibitors 
(Wouters and Delwel, 2016). Additionally, antibody-based therapies have resurfaced as 
potential candidates. These include antibody-drug conjugates such as Gemtuzumab 
ozogamicin (GO, trade name Mylotarg) – an anti-CD33 and calicheamicin conjugate. Even 
though FDA approval was rescinded prematurely for this drug, a later analysis showed a 
decrease in relapse and improved survival in patients treated with Mylotargwhen combined 
with standard chemotherapy (Hills et al., 2014). The more recent approval for Mylotarg is for 
a lower recommended dose and schedule than its previous approval and is aimed at a different 
patient population. Immunotherapy strategies employing bi- and trispecific antibodies such as 
anti-CD33 and anti-CD3 bispecific T-cell engagers (BiTE) conjugates aim to engage T-cells 
into attacking leukemic cells (Jitschin et al., 2018). Additionally, engineered chimeric antigen 
receptor (CAR) have been explored. CARs are genetically engineered membrane receptors 
capable of activating T cells by linking an extracellular tumour antigen-recognising fragment 
to an intracellular signalling component comprising the T-cell receptor (TCR) primary domain 
and additional co-stimulatory endodomains (Shang and Zhou, 2019). CAR T cells targeting 
CD33 and CD123 are being investigated in early clinical trials (Dohner et al., 2017). Yet, the 
most effective therapy to prevent relapse is allogeneic HSC transplantation (aHSCT) 
(Cornelissen et al., 2012). T-cells present in the donor graft have a strong anti-leukaemic effect 
due to the graft-versus-leukaemia effect. However, these can also attack healthy tissue in the 
recipient leading to graft-versus-host disease which is associated with high level of transplant-
related mortality. 
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1.4. The Notch signalling pathway
1.4.1. The Notch pathway members and mechanism
Over 100 years ago, John S. Dexter observed aberrant fly wing phenotypes (Dexter, 1914)
that were later on shown to be the result of mutant alleles. Only around 70 years later, Spyros 
Artavanis-Tsakonas and Michael Young identified that the wing phenotype was due to Notch 
gene haploinsufficiency (Kidd et al., 1986), (Wharton et al., 1985). In mammals, there are four 
Notch receptors (Notch-1, 2, 3, and 4) and five structurally related, single-pass membrane 
Notch ligands (Delta-1, 3 and 4 and Jagged-1 and 2, simply termed Jag-1 and Jag-2 from now 
on) (D'Souza et al., 2010). Canonical Notch signalling is activated when a canonical 
transmembrane ligand interacts with a canonical transmembrane receptor on contacting cells, 
instigating the first cleavage of the Notch receptor, which is mediated by metalloproteases like 
the tumor necrosis factor alpha converting enzyme (TACE). This licenses a second cleavage 
mediated by the γ-secretase complex (comprising of Nicastrin, Presenilin 1/2, PEN2 
(presenilin enhancer 2) and APH1 (anterior pharynx-defective 1)). Upon this second cleavage 
it generates the intracellular Notch receptor domain (NICD), which subsequently translocates 
into the nucleus and cooperates with the DNA-binding protein RBPJκ (Recombination signal 
binding protein for immunoglobulin kappa J region; also known as CSL (standing for CBF1, 
Su(H), Lag-1)). Subsequently, this allows the conversion of the transcriptional repressor 
complex into an activator complex together with its co-activator Mastermind-like 1 (MAML1), 
and other specific co-activators (Bray, 2006), (Andersson et al., 2011). MAML1 also recruits 
the histone acetylase p300, which promotes assembly of initiation and elongation complexes 
(Bray, 2006). Another member that interacts with NICD is SKIP (ski-interacting protein) that 
gets recruited to spliceosomes (Bray, 2006). In the absence of Notch activity, CSL proteins 
recruit histone deacetylases instead, such as SMRT, SHARP, which in turn recruit CtBP
(Borggrefe and Oswald, 2009). The activation of Notch signalling triggers the expression of 
various target genes, such as members of the HES and HES-related (HESR/HEY) family of 
basic helix-loop-helix transcription factors (Iso et al., 2003) and subsequently regulates the 
expression of other genes (Figure 1.4). Notch signalling can also be orchestrated in a non-
canonical manner via HES- or RBPJk/HES-independent axis or by other means (Andersen et 
al., 2012). 
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Figure 1.4 – A simplified illustration of the Notch signalling pathway. Binding of a Notch ligand on 
one cell to the Notch receptor on another cell results in two proteolytic cleavages of the receptor.
Metalloproteases catalyse the S2 cleavage, generating a substrate for S3 cleavage by the γ-secretase 
complex. This releases the Notch intracellular domain (NICD), which upon binding with the CSL domain, 
the Mastermind (Maml1) and others, relieves repression on target genes. The γ-secretase inhibitor 
DAPT and shRNA targeting NCSTN used in this project block Notch receptor processing, therefore 
acting as pan-Notch inhibitors. shRNAs targeting RBPJ, inhibit canonical Notch signalling.
1.4.2. Notch ligands and receptors
The Notch genes encode for ~300 kDa type 1 transmembrane proteins. These contain around 
36 tandem EGF-like repeats (Wharton et al., 1985). EGF-like repeats 11 and 12 in particular, 
are thought to be necessary for binding to ligands in Drosophila (Rebay et al., 1991). 
Additionally, they have three Lin12/Notch repeats (LNR) which are cysteine rich regions; a 
heterodimerisation domain (HD); a negative regulatory region (NRR) responsible for 
preventing activation of the pathway in the absence of ligands (Gordon et al., 2007); a 
transmembrane subunit (TMN) that is anchored to the plasma membrane; a RAM domain that 
binds to CSL and seven ankyrin repeats responsible for binding to downstream effector 
proteins (Andersson et al., 2011). A proline-glutamine-serine-threonine rich domain (PEST) is 
required for Notch degradation (in fact its frequent mutations in Notch-1 leads to T-ALL (Weng 
et al., 2004). A C-terminal transcriptional activation domain (TAD) modulates epigenetic 
regulation of gene expression (Kurooka and Honjo, 2000). The latter is only present in Notch-
1 and Notch-2 receptors (Figure 1.5). 
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Figure 1.5 - Notch receptors and ligands. Notch receptors are type I transmembrane proteins. They 
contain multiple EGF-like repeats. A negative regulatory region (NRR) is composed of three cysteine-
rich Lin repeats (LNR) and a heterodimerization domain (HD). They also contain a transmembrane 
domain (TM), a RAM domain, a nuclear localization sequence (NLS), seven ankyrin repeats (ANK) and 
a transactivation domain (PEST). The canonical DSL ligands contain DOS and EGF-like repeats.
The canonical DSL (for Delta, Serrate and Lag2) ligands are type I cell-surface proteins. Just 
as the receptors, the ligands contain multiple EGF-like repeats; an N-terminal (NT) domain, 
followed by the DSL domain. The latter is necessary but not sufficient for interaction with Notch 
(Shimizu et al., 1999). Also, a Delta and OSM-11-like proteins (DOS) domain located within 
the first two EGF-like repeats cooperates with the DSL domain (Komatsu et al., 2008) in 
certain ligands (Delta-4 and Delta-3 do not possess this domain). Jag-1 and Jag-2 ligands 
have additional cysteine-rich (CR) regions not present in Delta-like ligands.  Many of the 
intracellular regions of DSL ligands contain multiple lysine residues and a C-terminal PDZ 
ligand motif. They are required for signalling activity and interactions with cytoskeleton 
48
respectively (D'Souza et al., 2010) (Figure 1.5). Although these ligands are structurally very 
similar, they are not functionally equivalent. Interestingly, Delta-3 ligand does not activate 
Notch signalling in trans, and seems to function exclusively as an antagonist (Ladi et al., 2005). 
 
1.4.3. The role of the Notch pathway
The Notch pathway has been implicated in several systems described in more detail in the 
review by Sarah Bray (Bray, 2006). For instance, it plays a role in the effect of lateral inhibition. 
This arises from the concept that equivalent populations of cells have roughly the same 
amount of Notch receptors and ligands at the cell surface. However, small differences where 
a certain cell expresses slightly more Notch receptors than its neighbours, will turn into a 
Notch-receiving cell, reinforcing this pathway and inhibiting the expression of ligands. This is 
on the other hand, turns the surrounding cells into Notch-sending cells that mainly express 
Notch ligands as opposed to receptors. Such differences regulate cell fate determination by 
creating boundaries of cells based at least in part, on Notch receptor and ligand expressions 
(Bray, 2006). Therefore, another role for this pathway can be found in lineage determination 
and asymmetric division. This arises from the principle that the asymmetrical inheritance of 
Notch regulators on a certain bi-potent cell, such as a sensory organ precursor (SOP) cell 
from the Drosophila peripheral nervous system (PNS), will determine the Notch activity in each 
daughter cell (Guo et al., 1996). If one such cell receives a higher concentration of the negative 
Notch regulator Numb, this will lead to a higher turnover and degradation of the receptors thus,
making this cell have less Notch activity than a surrounding neighbour that inherited less Numb 
(Guo et al., 1996). Notch signalling also has a role in self-renewal versus differentiation 
decisions. In radial glial cells from the central nervous system (CNS), the polarity of partitioning 
defective protein 3 (PAR3) segregates Mindbomb (Mib-1) to the apical daughter cell, therefore 
restricting Notch signalling to the basal daughter cell, hence promoting self-renewal, while the 
apical daughter cell with low Notch signals differentiates (Dong et al., 2012). Not only different 
Notch receptor/ligand pairings have shown to determine diverse outcomes (Ramasamy and 
Lenka, 2010), but also the strength of such interactions is important in certain contexts. 
Specification of HSCs in the mouse haemangiogenic endothelium requires low-strength Jag1
ligand mediated signalling, while specification of endothelial arterial cells requires high-
strength Delta4 mediated signalling (Gama-Norton et al., 2015). Remarkably, a recent study 
documented different outcomes of Notch1 receptor mediated signalling depending on the 
ligand engaged (Nandagopal et al., 2018). While Delta1/Notch1 interactions were shown to 
lead to pulsatile activation of Notch1 receptor with preferential Hes1 upregulation, the outcome 
on Delta4/Notch1 interactions were demonstrated to sustain activation of the pathway through 
Hey/L upregulation in CHO-K1 cells (Nandagopal et al., 2018). An additional way by which a 
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seemingly simple pathway can become complex is by CSL interaction with factors from other 
signalling pathways. For example, in the mouse forkhead box p3 (Foxp3) gene, an overlapping 
CSL-NFκB binding site in the promoter helps the cooperative regulation by Notch3 receptor 
and NF-κB signalling (Barbarulo et al., 2011). Furthermore, Notch has been shown to interact 
with many other pathways such as Wnt, Hedgehog, TGF-β/BMP, Hippo/Yap as well as stress 
and hypoxia-related pathways (Bigas and Espinosa, 2016). 
1.4.4. Notch target genes
Among the many Notch target genes, the best characterised is HES1 - a member of the Hes-
related family (Iso et al., 2003). Other members such as HES5, HES7, HEY1, HEY2 and HEYL
are also upregulated by Notch (Iso et al., 2003). HES and HEY proteins function mainly as 
transcriptional repressors. There are two possible mechanisms by which HES1 promotes 
transcriptional repression: HES1 can form non-DNA binding complexes with other bHLH 
factors through its bHLH domain, thereby preventing these factors from carrying out their 
functions. A second mechanism is active repression: HES1 can bind to N-boxes by forming 
complexes with co-repressors (Iso et al., 2003). The recruitment of histone deacetylases 
(HDACs) promotes transcriptional inhibition (Liu et al., 2015). HES1 has many known targets, 
such as PTEN (phosphatase and tensin homolog). By binding to its promoter, HES1 strongly 
silences PTEN expression (Palomero et al., 2007). In the mouse embryo, HES1 protein 
represses Gata2 – a necessary process for emerging HSCs (Guiu et al., 2013). However, 
HES1 has been shown to be more than a repressor. As an example, HES1 amplifies Runx2
expression by cooperating with pRb (Lee et al., 2006), as well as binding to CDKN1A promoter 
thus, inducing p21 expression and consequently HSPCs’ growth arrest (Yu et al., 2006).  Other 
identified Notch targets comprise CD25, GATA3, NRARP and DTX1, the latter of which is a 
Notch pathway regulator (Borggrefe and Oswald, 2009). In the context of cancer, MYC has 
been found to be a target of Notch-1 in T-ALL (Weng et al., 2006). Still in the cancer context, 
other implicated genes in the Notch signalling have been CCND1 (Ronchini and Capobianco, 
2001) and CDKN1A (Rangarajan et al., 2001) linking Notch to cell cycle regulation.
1.4.5. The roles of Notch in haematopoiesis
Notch signalling has been shown to be active in very primitive human CD34- (Anjos-Afonso et 
al., 2013) and in CD34+ HSCs (Kojika and Griffin, 2001), (Ohishi et al., 2002), being gradually 
downregulated as the cells progress towards more committed cell fates therefore, suggesting 
a role in the maintenance of an undifferentiated state. The Notch pathway is known to be 
essential in the developing haematopoietic system (Kumano et al., 2003) and in T-cell 
differentiation (Radtke et al., 1999).  However, whether it is necessary for the maintenance of 
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adult HSCs is still a matter of controversy. A review from our group has discussed this topic 
in a greater detail (Lampreia et al., 2017). Gain-of-function approaches have shown that 
inducing Notch signalling leads to an increase in the self-renewal capacity of stem cells which 
is accompanied by a decrease in differentiation (Table 1.4). 
Table 1.4 – Notch signalling gain-of-function studies.
Study Species Outcome
Exposure of KSL cells to membrane bound 
or immobilised Jag1 (Varnum-Finney et al.,
1998)
Mouse
Increased self-
renewal of HSPCs / 
Decreased 
differentiation
Constitutively active Notch1 allele (Carlesso
et al., 1999) Human
Exposure of progenitors to Notch ligands in 
vitro (Karanu et al., 2001) Human
Exposure of human CD34+CD38- cells to 
immobilised Delta1 (Ohishi et al., 2002) Human
Overexpression of Notch downstream target 
Hes1 in mouse KSL (Kunisato et al., 2003) Mouse
Activation of Jag-1 expression through 
osteoblast stimulation (Calvi et al., 2003) Mouse
Exposure of KSL cells to immobilised Delta-1 
(Varnum-Finney et al., 2003) Mouse
Exposure of human CD34+CD38low cells on 
membrane bound Delta4 (Lauret et al., 2004) Human
KSL, c-Kit+Sca-1+Lin- cells (containing mouse HSCs).
This has been demonstrated through the direct exposure of stem/progenitors to ligands in vitro
(Varnum-Finney et al., 1998), (Karanu et al., 2001), (Ohishi et al., 2002), (Varnum-Finney et 
al., 2003), (Lauret et al., 2004) or by the overexpression of the constitutively active form of 
Notch1-intracellular domain (N1-ICD) (Carlesso et al., 1999) or the Notch target HES1
(Kunisato et al., 2003). Exposure of UCB CD34+CD38- cells to immobilised Delta1 in the 
presence of SCF, FLT3L, TPO, interleukin-6 (IL-6) and IL-3 was shown to inhibit differentiation 
while expanding CD34+ cells as compared to cultures without the ligand (Ohishi et al., 2002). 
As stated before, quiescence is a hallmark of HSCs and Notch appears to play a role in cell 
cycle regulation. As an example, enforced expression of HES1 was demonstrated to induce 
cell cycle arrest in vitro and to block expansion in vivo, partially through upregulation of p21, 
a potent cell cycle inhibitor (Yu et al., 2006). Yet in another report, JunB was shown to control 
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the responsiveness of HSCs to Notch and TGFβ signalling whereby, limiting the expansion 
and myeloid differentiation of HSPCs (Santaguida et al., 2009). Importantly, it was observed 
that JunB-deficient HSPCs failed to respond to Notch and TGFβ, leading to a reduction in 
Hes1, p57 and Smad7 thus, triggering the overproduction of myeloid progenitors in vivo and 
consequently contributing to myeloproliferative disease (MPD) development (Santaguida et 
al., 2009). In the context of AML, HES1 expression induced by Notch activation was shown to 
downregulate BCL-2 and upregulate p53 and p21 resulting in leukaemic cell growth arrest 
(Kannan et al., 2013). On the other hand, loss-of-function approaches on the role for Notch 
signalling in the maintenance of murine adult HSCs have led to conflicting results (Table 1.5). 
Table 1.5 - Evidences of Notch signalling in HSPC regulation.
Study Species Outcome
Notch1 loss of function (Mx1-Cre) 
(Radtke et al., 1999) Mouse
Blockage in T cell development
Notch1-deficient cells contribute normally 
to other lineages
RBPJk loss of function (Mx1-Cre) (Han
et al., 2002) Mouse
Blockage in T cell development
Notch1-deficient cells contribute normally 
to other lineages
Notch inhibition (dnRBPJk-transduced 
LSK cells) (Duncan et al., 2005)
Mouse Depletion of LT-HSCs
Notch1 and Jag-1 loss of function (Mx1-
Cre) (Mancini et al., 2005)
Mouse
No effect on self-renewal
Normal repopulation on Notch1/Jag1 
deficient animals after 5FU
RBPJk deletion (Mx1-Cre) (Maillard et 
al., 2008) Mouse No effect on HSC maintenance
Notch1/2 loss of function (Mx1-Cre) 
(Varnum-Finney et al., 2011)
Mouse
Notch2 mediates SK+ self-renewal
Notch2 mediates HSC/MPP repopulation 
after irradiation
Notch inhibition (γ-secretase inhibitor) 
(Anjos-Afonso et al., 2013) Human
Higher engraftment capacity (increased 
generation of CD34+CD38- from CD34-
HSCs)
dnMAML1-transduced HSCs 
(Benveniste et al., 2014) Human Reduction in HSC frequency but increase in number
Rbpjk loss of function (Rbpjkfl/fl/Vav-
Cre+ ; Rbpjkfl/fl/Mx1-Cre+) (Duarte et al.,
2018)
Mouse
Unperturbed haematopoiesis in steady 
state.
Rbpjκ-deficient BM cell capable of normal 
reconstitution
RBPJk, (Recombination signal binding protein for immunoglobulin kappa J region); 5-FU, fluorouracil; 
LSK, Lin-Sca-1+c-Kit+ HSCs; SK, Sca-1+c-Kit+ cells; dnMAML1, dominant negative form of Mastermind-
like1.
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Loss of Notch1 receptor or Jag1 ligand studies resulted with no apparent phenotype in HSCs 
function (Mancini et al., 2005), which has been attributed to the hypothetical compensation by 
other receptors and ligands. However, the deletion of Rbpjk, a key component of Notch 
signalling activation was also showed to have no role of Notch signalling in HSCs self-renewal 
(Maillard et al., 2008). Despite these early results, more recent reports have shown a role for 
Notch2 in regulating mouse short and long-term repopulating cells during transplantation 
(Varnum-Finney et al., 2011). Jag1 ligand has been recently shown to support self-renewal of 
HSCs in the adult bone marrow vascular niche (Poulos et al., 2013). Immortalised endothelial 
cells expressing Jag1, Jag2, Delta1 and Delta4 ligands were determined to support Notch-
mediated expansion of long-term HSCs and supported long-term reconstitution in lethally 
irradiated mice (Butler et al., 2010). Notably, knocking down different members of the Notch 
pathway has been correlated with the initiation of different types of leukaemias which is 
discussed in greater detail below.
In an interesting study, it was reported that the loss of Itch (an E3 ubiquitin ligase which 
negatively regulates Notch signalling by controlling Notch receptor degradation) led to 
sustained levels of Notch-1 receptor-mediated signalling (Rathinam et al., 2011). Mice 
transplanted with Itch-deficient Lin-Sca1+c-Kit+ (LSK) HSPCs had an expanded stem cell pool 
with enhanced haematopoietic contribution up to 24 weeks as compared to control LSK cells 
(Rathinam et al., 2011).  Early studies have established the Notch1/RBPJk/HES1 axis as a 
major regulator of T cell differentiation. However, disturbing this axis had no effect on myeloid 
and B cell lineage commitment (Radtke et al., 1999), (Han et al., 2002). Duncan and 
colleagues showed that LSK cells from a transgenic Notch reporter (TNR-GFP) mouse have 
high Notch activity as evidenced in bone marrow sections by co-localisation of c-kit+ and GFP+
cells and by flow cytometric analysis of primitive LSK cells showing GFP expression (Duncan 
et al., 2005). Interestingly, transplanting murine lineage negative (Lin-) cells transduced with 
dominant-negative suppressor of Xenopus Rbpj homologue (dnXSu(H)) resulted in the 
depletion of the HSC population after long-term reconstitution compared to control transduced 
cells (Duncan et al., 2005). Although Jag1 ligand is expressed in the osteoblastic niche, loss 
of Jag1 and Notch1 in the bone marrow does not affect HSC homeostasis (Mancini et al., 
2005). These studies do not rule out possible redundant effects from other Notch 
receptor/ligand pairs. In fact, Notch2 but not Notch1 receptor mediates LSK cell self-renewal 
and repopulation following transplantation and inhibits myeloid differentiation (Varnum-Finney 
et al., 2011). However, it was reported that neither the loss of Notch1 nor Notch2 receptor had 
any effect on the number of HSC in steady state conditions (Varnum-Finney et al., 2011). 
Perhaps more convincingly is a study undertaking a pan-inhibition of all canonical Notch 
signalling approach mediated by the overexpression of a dominant negative form of 
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mastermind-like 1 (dnMAML1), the authors reported no effect on LSK cell function (Maillard et 
al., 2008). They also proposed that under homeostatic conditions LSK cells are normally 
exposed to very low levels of Notch signalling in vivo (Maillard et al., 2008) which contrasts 
the observations by Duncan et al. In one of the few studies with human HSCs, Benveniste et 
al., directly compared the impact of canonical Notch signalling on human HSCs in vitro and in 
vivo by overexpressing dnMAML1 (Benveniste et al., 2014). Repopulation capacity was 
comparable in both Notch-inhibited and control HSCs. More recently, using pan-
haematopoietic (Vav-Cre) and inducible (Mx1-Cre) mouse models driving the deletion of Rbpj, 
Duarte and colleagues reported unperturbed haematopoiesis in steady state conditions upon 
Notch inhibition. Additionally, apart from the expected lack of T cell development, Rbpj-
deficient BM cells reconstituted recipients without any defects (Duarte et al., 2018). 
Outside the stem cell compartment however, Notch pathway appears to play a role in cell fate 
decisions at different nodes of the haematopoietic hierarchy. This has been best demonstrated 
in the murine system, where Notch1 and Notch2 receptors represent the two main regulators 
of early adult haematopoiesis (Oh et al., 2013). Notch1 drives lymphopoiesis through thymic 
epithelium-bound Delta4 (Hozumi et al., 2008). Alternatively, Notch2 receptor drives 
erythropoiesis at an early progenitor stage, presumably the pre-MkE. Also, it promotes 
marginal zone B-cell differentiation at the expense of follicular B cells (Tanigaki et al., 2002), 
(Saito et al., 2003). Most notably, Notch has been associated with the promotion of T cell 
development at the expense of B cell production. Specifically, Notch 1 receptor 
overexpression by retrovirally transduced haematopoietic progenitors was demonstrated to 
lead to the appearance of ectopic T cells in the BM (eventually leading to T-ALL) while 
inhibiting B cell formation (Pear et al., 1996). Conversely, blocking Notch 1 receptor in the 
bone marrow was confirmed to inhibit thymic T cell development while inducing ectopic 
appearance of B cells in the thymus (Wilson et al., 2001). This implies that one the roles for 
Notch signalling is to promote a bias towards T cell differentiation at the expense of B cell 
production. In addition, Notch 1 receptor has also been implicated in myelopoiesis (Schroeder 
et al., 2003) and megakaryopoiesis (Mercher et al., 2008). Using FDCP-mix cells – that contain 
haematopoietic progenitor cells derived from murine BM, Schroeder et al., indicated that 
Notch1 receptor signalling caused the decrease in self-renewal of FDCP cells while promoting 
differentiation towards the myeloid lineage with concomitant increase in Spi1 expression 
(Schroeder et al., 2003). The Notch1/Delta1 pathway mediates megakaryocyte development 
from HSCs in vivo (Mercher et al., 2008). This axis leads to induction of a megakaryocytic 
transcriptional programme that includes transcription factors GATA-1, GATA2 and FOG1 
which have been shown to play a role in megakaryopoiesis (Shivdasani et al., 1997), (Tsang 
et al., 1997), (Chang et al., 2002). Remarkably, Notch4 receptor only promotes megakaryocyte 
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development when is induced in MEPs, meaning there are different requirements for the Notch 
receptors at the various nodes of differentiation. 
As stated before, the BM tightly regulates HSPCs, partly through Notch signalling. Co-culture 
of HSPCs with bone marrow endothelial cells (BMECs) expressing Jag1 ligands leads to 
expansion of haematopoietic progenitors via Notch signalling. Interestingly, pro-inflammatory 
signals such as TNFα and LPS promote Jag2 ligand expression on ECs, which in turn activate 
Notch1/2-mediated signalling in haematopoietic progenitors in vivo (Fernandez et al., 2008). 
ECs were also shown to support long-term expansion of LSK cells through Notch signalling in 
another study (Butler et al., 2010). In an interesting study of signalling crosstalk, the secretion 
of vascular endothelial growth factor A (VEGF-A) by HSPCs was reported to stimulate cell 
surface expression of Jag2 ligand on ECs which in turn supported HSPCs expansion via 
Notch1/2 signalling (Butler et al., 2010). More evidences for EC-mediated support of HSPCs 
came from Poulos and colleagues’ work: although ECs-specific Jag2 deletion had no effect 
on HSPCs under homeostasis, Notch2 receptor signalling was shown to be essential for 
haematopoietic recovery under myelosuppressive conditions. Interestingly, Jag2 ligand-
mediated signalling enhanced Hey1 expression via Notch2 receptor, while suppressing Hes1
instead (Poulos et al., 2013). Other types of cells have been implicated in Notch-mediated 
regulation of HSPCs. High Jag1 ligand expressing CD146+ MSCs were determined to support 
long-term culture of HSPCs (Corselli et al., 2013). In contrast, osteoblast ablation was shown 
to reduce quiescence, long-term engraftment and overall self-renewal capacity of HSCs 
(Bowers et al., 2015). Interestingly, co-culture of osteoblasts expressing Jag1 ligand was 
described to reduce cell cycling and overall cell numbers of both leukaemic and normal HSCs 
(Bowers et al., 2015). In summary, these studies focusing on the haematopoietic niche provide 
strong evidence for the regulation of HSPCs by a variety of cell types involving crosstalk 
between Notch signalling and other pathways. 
1.4.6. A general view of Notch signalling in haematological malignancies
In contrast to the above results, suggesting the role for Notch is still not clearly understood in 
the human haematopoietic system, several mouse models where different members of the 
pathway have been deleted consistently show that defective Notch in the BM 
microenvironment is a major player in the development of different myeloproliferative disease 
(MPD) phenotypes (Table 1.6).
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Table 1.6 – Loss of Notch pathway members frequently results in myeloproliferative disease in 
mouse models
Mouse model Phenotype Effect on stem cells
Psen1+/-/Psen2+/- (Qyang et al., 2004) MPD (expanded granulocytes) Normal side population
MMTV-Cre/Mibf/f Mx1-Cre/Mibf/f  (Kim
et al., 2008)
MPD (expanded 
granulocytes) Expanded LSK
FX-/- (Zhou et al., 2008) MPD Normal LSK
Mx1-Cre/Pofutf/f (Yao et al., 2011) Increased neutrophils ND
Mx1-Cre/Adam10f/f (Yoda et al., 
2011)
MPD (increased 
neutrophils) Expanded LSK
Mx1-Cre/Ncstnf/f (Klinakis et al., 
2011) CMML-like disease Expanded LSK
Mx1-Cre/Rbpjf/f Tie2-Cre/Rbpjf/f
(Wang et al., 2014) MPD Expanded LSK
ND, Not determined; MPD, myeloproliferative disease; CMML, Chronic myelomonocytic leukaemia; 
LSK, Lin-Sca-1+c-Kit+
One of the earliest reports linking Notch signalling to MPD showed that presenlinin-1 haplo 
and presenilin-2-deficient (Psen1+/- Psen2-/-) mice had an expanded granulocytic compartment 
and the animals developed signs of MPD (Qyang et al., 2004). Also, FX-/- mice (FX mediates 
addition of N-acetylglucosamine residues to Notch receptors, which is essential for proper 
interaction with ligands) develop a myeloproliferative phenotype with expanded granulocytes 
and erythrocytes (Zhou et al., 2008). Similarly, Pofut-deficient marrow progenitors were 
revealed to have defective O-fucosylation of Notch receptors and no ability to bind to Delta-
like ligands (Yao et al., 2011). Thus, Pofut-deficient mice have increased numbers of 
neutrophils and reduced lymphocytes. In addition, loss of Mib1 - essential for ligand 
endocytosis, was shown to cause MPD originated from the LSK population (Kim et al., 2008). 
Especially, this report showed that defective Notch signalling between the cells that make up 
that microenvironment caused the MPD phenotype. Granulopoiesis can also develop 
following Adam10 deletion in the BM (Yoda et al., 2011). Loss of Adam10 further resulted 
in both cell-autonomous and non-cell-autonomous enlargement of the HSC pool and MPD 
(Yoda et al., 2011). 
In addition to this, Nicastrin-deficient HSCs were demonstrated to develop a human chronic 
myelomonocytic leukaemia-like (CMML) disease with expanded LSK compartment, with the 
Notch-suppressed cells showing a de-repressed myeloid transcriptional program (Klinakis et 
al., 2011). Finally, an elegant study from the Carlesso lab showed that mice that were 
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conditionally deleted of Rbpj using Mx1-Cre developed myeloproliferative disease (Wang et 
al., 2014). By performing reciprocal experiments, the authors showed that the mutant-LSK cell 
pool was significantly expanded but multiple progenitor subsets were unaffected thus, having 
no consequences in the WT recipient mice. However, when transplanting WT HSPCs into 
mutant mice, CMPs and GMPs in the BM and spleen were significantly increased, resulting in 
a lethal MPD (Wang et al., 2014). This study demonstrated that cell-autonomous loss of Notch 
activation was not sufficient to develop myeloid disease, but the loss of Notch signalling in the 
microenvironment induced lethal MPD in a non-cell autonomous manner. Mechanistically, the 
loss of Rbpj led to increased expression of mir-155 and consequently upregulated NFκB 
signalling by targeting one of its main regulators Kb-RAS1. This led to increased expression 
of G-CSF and TNFα, inducing a persistent inflammatory state in the BM (Wang et al., 2014). 
All these results suggest that a proper activation of Notch signalling must be maintained not 
only in HSPCs but also in the BM niche. It is rather remarkable that inhibition of Notch, through 
the loss of several different members of the pathway leads to the expansion of the most 
primitive HSCs impairing their repopulating capacity. This is probably due to the early 
differentiation induced by the loss of a quiescent state partly imposed by Notch signalling. 
Altogether these studies highlight the importance of maintaining a proper Notch signalling in 
the BM for a proper regulation of hematopoiesis. 
Activating NOTCH1 mutations are found in half of T-ALL cases (Weng et al., 
2004),(Chiaramonte et al., 2005) where they act as a well-known oncogene. These mutations 
result in ligand independent activation of the receptor and enhanced stability of the Notch1-
ICD by removing the destabilizing PEST domain (Weng et al., 2004). Similarly, Notch 
mutations have also been implicated in chronic lymphocytic leukaemia (CLL) (Puente et al., 
2011a),(Fabbri et al., 2011), whereby NOTCH1 mutations prevent FBW7 E3 ligase 
degradation of the Notch1 receptor. These events are associated with poor prognosis in this 
disease (Rossi et al., 2012). Contrastingly, Notch appears to be a tumour suppressor in B-cell 
leukaemias. Constitutive expression of truncated forms of all four Notch receptors or 
downstream effector HES1 prevented growth and induced apoptosis of various B-cell acute 
lymphoid leukaemia (B-ALL) cell lines including Hodgkin, myeloma and mixed-lineage 
leukaemia (Zweidler-McKay et al., 2005). Others have found that 8% of large B-cell 
lymphomas and 5% of marginal zone lymphomas possess activating Notch2 mutations (Lee 
et al., 2009). As mentioned earlier, deletion of Ncstn results in CMML-like disease in mice 
(Klinakis et al., 2011). The authors further identified additional mutations in Notch pathway 
components and have suggested a tumour suppressing role for Notch in this disease.
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1.4.7. The role of Notch in AML
As mentioned earlier, it is well established that Notch signalling acts as oncogene in T-ALL 
(Weng et al., 2004), (Chiaramonte et al., 2005), (Aster et al., 2008). However, it is still a 
matter of debate whether the Notch pathway plays an oncogenic or tumour suppressor in other 
haematological diseases (Nowell and Radtke, 2017). 
Early studies on the role of Notch in myeloid malignancies revealed that certain AML cell lines 
and primary AML samples express the Notch1 receptor (Tohda and Nara, 2001). The same 
group later demonstrated that stimulation of primary AML cells with immobilised Jag1 or Delta1 
ligand caused mixed outcomes on proliferation but Notch activation appeared to promote blast 
differentiation (Tohda et al., 2005). Conversely, activation of Notch1 receptor in the HL60 cell 
line impaired monocyte and granulocyte differentiation under pro-differentiative stimuli 
(Carlesso et al., 1999). A mechanism for this emerged later, when stimulation of Notch 
signalling by its cognate ligand Delta4 was shown to induce SKP2 up-regulation in HL60 cells 
and primitive haematopoietic cells, regulating the balance between proliferation and 
differentiation (Sarmento et al., 2005). Notch activation was also shown to cause inhibited cell 
cycle kinetics in erythroleukemic cell line TF1 (Chadwick et al., 2008) and in CML cell line 
K562 (Yin et al., 2009). Even though Notch components are rarely mutated in AML (for 
example, MAML1 is frequently deleted in 5q AMLs) (Jerez et al., 2012), NOTCH2 and FLT3
are the most frequently mis-spliced genes in AML (Adamia et al., 2014). The authors reported 
that as much as 73% of the AML samples analysed expressed a Notch2 splice variant named 
Notch2-Va. Expression of this variant was correlated with decreased Notch target gene 
expression and associated with poor outcome (Adamia et al., 2014). 
A few research groups have reported tumour suppressor roles for Notch signalling in myeloid 
leukaemias. As briefly mentioned, loss of Nicastrin led to enlargement of the GMP population 
and development of a CMML-like disease in a mouse model (Klinakis et al., 2011). This was 
thought to be mainly driven by the loss of Notch1 and Notch2. The authors believed that 
Nicastrin, through Notch, repressed a myeloid-specific programme which was de-repressed 
upon Nicastrin loss. Ectopic expression of Hes1 prevented granulocyte/monocyte lineage 
differentiation through repression of Cebpa and Spi1 (Klinakis et al., 2011). Notch1-IC knock-
in mice bred with Ncstn-/- mice supressed GMP enlargement and disease progression (Klinakis 
et al., 2011). Additionally, exon sequencing of CMML patient samples uncovered somatic 
heterozygous mutations in NCSTN, APH1, MAML1 and NOTCH2 (all members of the Notch 
pathway). In another study, AML cell lines were reported to have undetectable levels of active 
Notch receptors despite expressing Notch receptors on the cell surface (Kannan et al., 2013). 
Re-activation of Notch signalling by retrovirally transducing AML cell lines with ICN1-4 resulted 
in growth arrest and increase in HES1 expression. Interestingly, a similar effect was observed 
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when HES1 was overexpressed (Kannan et al., 2013). Notch reactivation caused caspase-
dependent apoptosis, along with a decrease in BCL2 expression and increase in p53/p21, 
although it was unclear whether HES1 had a direct involvement in these effects. 
Overexpression of N1-ICD or HES1 was also shown to reduce leukaemic burden in vivo, which 
on the other hand, seemed to be aggravated by using the Notch inhibitor dnMAML1. A Notch 
agonistic peptide (Jag1 DSL) was also used to demonstrate significant apoptotic induction in 
both primary and AML cell lines in vitro (Kannan et al., 2013). Similarly, another group showed 
that the Notch pathway was silenced in AML by performing microarray gene expression 
analysis of normal BM cells compared to AML cells (Lobry et al., 2013). The effect seen was 
in part due to hypermethylation of Notch target gene promoters such as HES1 and NRARP. 
The authors also complemented their studies by showing that an MLL-AF9 driven mouse 
model of AML also had silenced Notch signalling, with methylation of Notch target gene 
promoters Hes1, Nrarp and Gata3 (Lobry et al., 2013). Reactivation of Notch pathway by 
crossing the MLL-AF9-driven AML mouse to a model containing inducible N1-ICD expression, 
resulted in decreased leukaemic burden in vivo and overall increased survival (Lobry et al., 
2013). The reactivation of Notch induced in this experimental setting led to increased 
apoptosis and differentiation of AML LICs. Moreover, HES1-low cohorts of AML patients seem 
to have a worse outcome in terms of overall survival and relapse free survival than HES1-high 
groups, suggesting HES1 may serve as an independent prognostic factor in this disease (Tian 
et al., 2015). 
Surprisingly, Notch has also been shown to act as an oncogene. In a mouse model with an 
activating mutation in β-catenin, this caused increased Jag-1 ligand expression on osteoblasts 
that triggered Notch signalling in LSK cells, resulting in AML development (Kode et al., 2014). 
These mice were seen to have increased GMP and decreased MEP populations, with no 
apparent change in CMPs. Interestingly, transplanting BM cells from the Ctnnb1CAosb 
leukaemic mouse model into WT recipients generated AML. Conversely, when WT BM cells 
were transplanted into mutant mice, the recipient mice also generated AML. These results 
reinforce the notion that in some cases, AML may be induced by defective niche signals 
that are restricted to the BM cells such as osteoblasts (Kode et al., 2014). By deleting one 
Jag1 allele in osteoblasts, the authors of this work also demonstrated the rescued of anaemia 
previously seen and also prevented AML development (Kode et al., 2014). The authors of this 
work also found localisation of activated β-catenin in osteoblasts in 40% of human primary 
AML samples, while this was not observed in healthy BM controls (Kode et al., 2014). 
More recently however, a research group inter-crossed dnMAML1-GFP mice with Vav-Cre
animals to disrupt Notch in haematopoietic cells (Francis et al., 2017). Double heterozygous 
dnMAML1f/-Vav+/- mice displayed a reduction in the CMP compartment and an expanded GMP 
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fraction at 15-18 months. Despite GMP expansion, the authors did not report the emergence 
of a myeloid neoplasm thus, contrasting with the work from Klinakis and colleagues (Klinakis 
et al., 2011). Also, TRIB2 expression, encoding for Tribbles homolog 2 is modulated by Notch1 
and was shown to contribute to AML pathogenesis (Keeshan et al., 2006) even though Notch1 
activation does not cause AML in mice. The authors suggested that Notch1 regulation of Trib2 
may be context dependent and not operational in myeloid progenitors (Keeshan et al., 2006), 
(Puente et al., 2011). This reveals the complexity of Notch signalling modulation. In any case, 
re-activation of the Notch pathway has supported the notion of a tumour suppressor role for 
Notch signalling in this context.
1.5. Aims of the Thesis
Some studies mentioned here reveal that Notch signalling has been mainly exploited to 
expand HSPCs in vitro. However, the functions of this pathway in the regulation of human 
HSPCs and in AML have not been clearly elucidated yet. The objectives of this work are to:
- Characterise the expression and activity of Notch signalling in human HSPCs.
- Block Notch signalling (canonical only and pan-inhibition) via a γ-secretase inhibitor 
and shRNAs targeting NCSTN and RBPJ in human HSPCs.
- Gauge the effects of Notch inhibition on the maintenance and differentiation capacity 
of HSPCs in vitro.
- Gauge how inhibiting Notch impacts myelo-lymphoid engraftment and frequencies of 
HSPCs and mature blood cells in vivo.
- Characterise the expression and activity of Notch signalling in primary AML and AML 
cell lines.
- Activate Notch through membrane-bound ligands, small molecules and peptides in 
primary AML and AML cell lines and assess its effect on cell proliferation and 
apoptosis.
- Determine whether activation of distinct Notch receptors impacts AML cell proliferation 
and apoptosis differently. 
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Chapter 2 – Materials and Methods
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2.1 Materials and Methods
2.1.1 General laboratory equipment 
Suppliers of materials and reagents are provided below in the relevant methods sections. All 
plastic-ware and tissue culture vessels were purchased from Greiner Bio One, UK and VWR, 
USA. Centrifugation of cell suspensions were performed in a Beckman Allegra 6R (Beckman 
Coulter, USA). The centrifuges used for molecular biology work were a Heraeus™ Fresco™ 
21 Microcentrifuge (Thermo, USA) and a Heraeus™ Megafuge™ 40R (Thermo).
2.1.2 Buffers and stock solutions
See Appendix I.
2.2 Cell culture
All tissue culture was performed in a Safe 2020 Class II Biological Safety Cabinet (Thermo) 
and the cells were incubated in HeraCell 150 (Thermo) incubators at 37°C with 20% O2 and 
5% CO2.
2.2.1 Human cell lines
The adherent cell lines HeLa, Saos2 and HEK293TLTX (LentiXTM-293T) were maintained in 
Dulbecco’s Modified Eagle’s Medium – high glucose (DMEM; Merck, USA) supplemented with 
10% foetal bovine serum (FBS, LSP, UK), 1% Penicillin/Streptomycin (P/S) (Gibco, USA) and 
1X GlutaMAX (Gibco). This formulation is herein termed “complete DMEM”. Cells were 
passaged every 2 to 3 days when reached a 70-90% confluency. The leukaemia cell lines 
HL60, THP1, OCI-AML3, KG1, Kasumi, Molt4 and Raji were cultivated in RPMI 1640 (Merck) 
supplemented with 10% FBS and 1% P/S (formulation simply called “complete RPMI”). Cells 
were split every 3 to 4 days to a cell density of 3x105 cells/mL. All cell lines were originally 
acquired from the cell service of Cancer Research UK – London Research Institute. To 
passage adherent cells, growth media was removed, and cells were washed once with pre-
warmed PBS (Merck). Then, trypsin-ethylenediaminetetraacetic acid (EDTA) (0.05%), phenol 
red (Thermo) was added for 5 min at 37°C. Two volumes of complete growth media were then 
added to neutralise trypsin and cell suspension was harvested and centrifuged. Cell pellet was 
resuspended in complete growth media and re-plated at ratios between 1:4 and 1:6 every 3 
days until use.
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2.2.2 Murine cell lines
The MS5, S17, and S17-Delta4 murine stromal cell lines were a kind gift from Dr. Evelyn 
Lauret (University of Paris). Cells were maintained in alpha-MEM (Gibco) + 10% FBS + 1% 
P/S (termed “complete alpha-MEM”). Cells were passaged every 2 to 3 days when reached a 
70-90% confluency and passaged three times before were used in experiments. 
2.2.3 Thawing and Cryopreservation
Cells were thawed in a 37ºC water bath and transferred dropwise to a 15 mL tube with the 
respective culture medium. Cell suspensions were centrifuged at 300× g for 5 min, 
resuspended in the respective culture medium as described and plated at apropriate density. 
Cells were counted using a haemocytometer and trypan blue exclusion method. Adherent 
cells were plated on tissue culture-treated surfaces at densities around 1.5-2.5 × 104 cells/cm2
and split upon reaching 70-80% confluence as described. Suspension cells were plated on 
tissue culture-treated wells or flasks in vertical position at densities around 1-2×106 cells/mL 
and split after 2 days.
Human and murine cell lines were preserved in 90% of their respective growth media with 
10% of dimethyl sulfoxide (DMSO, Fisher Scientific, USA). Cells were resuspended in the 
appropriate freezing media and 1 mL of cell suspension was added per cryovial (Merck) and 
stored in Nalgene® Mr. Frosty freezing containers (Merck) at -80°C, allowing for gradual 
cooling process. Adherent cells were frozen at cell densities between 2-5×106 cells/mL and 
suspension cells at 8-10×106 cells/mL. The cells were then later transferred to a liquid nitrogen 
storage unit for long-term preservation. 
2.3 Molecular biology
2.3.1 Cloning of lentiviral constructs
The plasmids, primers and oligonucleotides used for the cloning of the various constructs are 
listed in Tables II.1-5 of Appendix II.
2.3.1.1 shRNA Design for miR-30-based and H1 promoter-driven shRNA lentiviral 
constructs
shRNA design was based on sequences commercially available (Table II.1 of Appendix II). 
and were mostly based on sequences available at Dharmacon™, USA.  The 19-mer 
oligonucleotides that presented the least complementarity to non-desired targets were chosen
(Table 2.1). 
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Table 2.1 – shRNA target sequence and location. Based on Nicastrin accession number 
NM_015331.3 and RBPJκ accession number NM_005349.3.
Clone Target sequence (5’ > 3’) Location
shNCSTN-1 ACTGTACAACATAAGTGGT 1701
shNCSTN-3 GAGTCAACATTCTCTAACT 1078
shRBPJ-2 TTTGGAGTGAAATTCTGTC 1360
shRBPJ-3 TGGAGTGAAATTCTGTCCT 1358
To adapt the 19-mer sequences to the miR-30 backbone few modifications were made: 1- by 
relying on the anti-sense sequence, the sense sequence was generated by complementarity; 
2- two nucleotides at position -1 and +20 were added based on their complementarity to the 
desired mRNA. As shown in Figure 2.1, that the anti-sense sequence aligns with 100% 
complementarity to the NCSTN (highlighted sequence). When reading the NCSTN mRNA, the 
nucleotide -1 is a C, while nucleotide +20 is an A. Therefore, the sense sequence becomes 5’ 
- CACCACTTATGTTGTACAGTA -3’; 3- the nucleotide at position -2 was used to generate a 
mismatch using nucleotides A or C with the nucleotide at position +21 when the RNA structure 
folds onto itself. Since, the nucleotide +21 in this case is a T, this means the nucleotide at 
position -2 will be a C. The sense sequence now becomes 5’-
CCACCACTTATGTTGTACAGTA-3’ and the anti-sense sequence is instead 5’-
TACTGTACAACATAAGTGGTGT-3’.
Figure 2.1 – Example of alignment of anti-sense sequence to target gene. Alignment of anti-sense 
sequence number 1 targeting the NCSTN gene using BLAST® tool (National Center for Biotechnology 
Information database)
A loop with the sequence TAGTGAAGCCACAGATGTA was introduced in between the sense 
and anti-sense sequences (based on the design of the pGIPZ™ construct (Dharmacon™)). 
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The forward and reverse oligos with the sequence below (with phosphate group on 5’ end) 
were purchased from Merck and were reconstituted to 1 mM in molecular grade water. Then, 
2 µL of each oligo were added to 48 µL of annealing buffer (see Appendix I). The mix was 
incubated for 4 min at 95°C, then 10 min at 70°C. The oligos were then allowed to cool slowly 
at room temperature (RT) for several hours. 
For the H1 promoter-driven shRNA lentiviral constructs, the shRNA sequences used were 
based on the 19-mer sequences that were validated with the miR-30-based system, with small
modifications (according to the recommendations from the Riken Institute, Japan): 1-the sense 
sequences starting with a C or a T were changed to an A or G (preferably A) by shifting the 
sequence in any direction for one or two nucleotides until this condition was reached;  2- a 
BglII-5’ overhang and a XbaI-3’ overhang were added; 3- a loop with the sequence 
TTCAAGAGA was introduced in between the sense and anti-sense sequences. 
Phosphorylated oligos were purchased from Merck.
2.3.1.2 Cloning of a miR-30-based lentiviral vector
The lentiviral vector for constitutive expression of miR30shRNA containing specific shRNA 
sequences along with a GFP reporter was generated based on the vector pLV.EF1α-
premiRNA30a-rPuro. First, the enhanced GFP (eGFP) gene was amplified by polymerase 
chain reaction (PCR) from the plasmid pSIN.Tet-HPGK-rtTA2-hDKK-Ires-GFP (available in 
the lab), using the primers to insert the XbaI and SalI restriction sites. Briefly, PCR 
amplification was performed using the HotStarTaq® (Qiagen, Germany) at 70°C. The PCR 
product was cleaned up by running the DNA in a 1% UltraPure Agarose (Thermo) gel, from 
which the band of interest was excised. The DNA was extracted from the gel using the 
PureLink™ Quick Gel extraction kit (Thermo), according to manufacturer’s instructions. Then, 
the DNA was then digested with the XbaI and SalI restriction enzymes (all restriction enzymes 
were purchased from New England Biolabs, USA). The pLV.EF1α-premiRNA30a-rPuro 
plasmid was also digested with XbaI and SalI and then dephosphorylated using the Shrimp 
Alkaline Phosphatase (rSAP) (New England Biolabs). The linearised vector was separated by 
gel electrophoresis and DNA extracted from the gel. The eGFP sequence was ligated to the 
linearised pLV.EF1α-premiRNA30a-rPuro vector at a molar ratio of 3:1, respectively, by using 
the Quick Ligation™ kit (New England Biolabs), according to manufacturer’s instructions. The 
ligation was transformed in NEB® Stable competent bacteria (New England Biolabs). Briefly, 
one vial of bacteria was thawed on ice for a few minutes. Then, 2 µL of ligation reaction was 
added to the bacteria and the mix was incubated on ice for 30 min. Then, heat-shock 
transformation was performed by placing the mix in a Thermo Mixer® (Eppendorf) at 42°C for 
30 seconds and then placing back on ice for 5 min. Then, 1 mL of pre-warmed S.O.C. medium 
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(Thermo) was then added to the mix which was incubated at 37°C while shaking at 225 rpm 
for 1 h. Lastly, 200 µL of the pre-growth was added to solidified Lennox broth (LB)-Agar 
(Thermo) plates with ampicillin and incubated at 30°C overnight. The next day, several 
bacterial colonies were picked and cultivated in LB medium (Merck) at 37°C while shaking at 
225 rpm for approximately 16 h. The next day, bacteria were harvested by centrifugation and 
plasmid DNA was extracted using the PureLinkTM miniprep kit (Thermo). Successful ligation 
was confirmed by sending the DNA to be sequenced at Eurofins Genomics (Ebersberg, 
Germany) with the primer “Seq GFP Fwd”. This generated the vector simply termed pLV. 
Then, the miR30 precursor sequence was replaced by a miR30shRNA sequence. The mir30 
backbone used for shRNA integration was obtained from the pGIPZ™ vector (Dharmacon™). 
Since XhoI and EcoRI sites are not single restriction sites within the pGIPZ™ vector, the 
fragment containing the mir30shRNA sequence from pGIPZ™ was first cloned into an 
intermediate vector (pECFP-C1; already available in the lab). Briefly, the miR30shRNA 
sequence was PCR amplified using the HotStarTaq®. The primers were modified to introduce 
BamHI and NheI recognition sites. The mir30shRNA was then transferred to pECFP-C1 via 
BamHI/NheI. Then, 1 µL of annealed oligos was then used for direct ligation with pECFP-C1-
mir30shRNA via XhoI/EcoRI. The ligation product was transformed in OneShot™ TOP10 
(Thermo) bacteria. The transformation protocol used was the same as the one used for NEB 
Stable competent bacteria, except for the selection plates being incubated at 37°C instead of 
30°C. To select positive clones, DNA from the various colonies were sent for DNA sequencing 
with the primer “Seq Fwd shmir30 pECFP”. Lastly, the mir30-shRNA backbone containing the 
shRNA of interest was transferred into the pLV vector via BamHI/NheI. The ligation product 
was transformed into NEB® Stable bacteria. Successful cloning was confirming by sequencing 
with the primer “Seq Rev shmir30 EF1”. Clones with the correct DNA sequences were then 
propagated in larger scale and DNA was extracted using the PureLinkTM Maxiprep or 
Megaprep kits (Thermo) according to manufacturer’s instructions.
2.3.1.3 Cloning of H1 promoter-driven shRNA lentiviral constructs (CS-shRNA)
The lentiviral vector CS-RfA-EG (RIKEN BRC DNA Bank, Japan) backbone was used to 
overexpress shRNA under the control of the H1 promoter. This construct contains a GFP 
reporter protein under the control of the EF1α promoter. The pENTR4-H1 (RIKEN BRC DNA 
Bank) plasmid was linearised via BglII/XbaI restriction enzymes, followed by 
dephosphorylation and gel purification. The annealed oligos were ligated into the linearised 
pENTR4-H1 plasmid and transformed in OneShot™ TOP10 bacteria. Successful cloning was 
confirmed by sequencing with the primer “pH1up2seq”. Finally, the H1-shRNA sequences 
from the pENTR4-H1-shRNA were transferred into the destination vector CS-RfA-EG through 
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Gateway® LR cloning. The reactions were incubated for 6 h and then transformed into 
OneShot™ TOP10 bacteria. Successful cloning was once more confirmed by sequencing with 
the primer “pH1up2seq”.
2.3.1.4 Cloning of a Notch reporter lentiviral vector
The mCherry sequence was amplified by PCR from the pmCherry plasmid (TakaraBio, Japan) 
and transferred via AgeI and HindIII into the pHes1-GFPd20 plasmid (Addgene; plasmid 
#14808), generating pHes1-mCherry. From the latter plasmid, the sequence spanning the 
Hes1 promoter and mCherry was amplified by PCR and transferred into an intermediate in-
house generated plasmid (plasmid A) which contained a cassette with the SFFV promoter 
driving another gene of interest, via XhoI and SalI restriction sites. This generated another 
intermediate plasmid (plasmid B). The truncated NGFR sequence was amplified by PCR from 
the pCCL-NGFR  plasmid (a gift from Prof. Luigi Naldini) via XhoI and NdeI, and cloned into 
plasmid B. Lastly, a third in-house generated plasmid (plasmid C, a modified version of the 
plasmid CSII-EF-MCS; Riken) containing the sequence for the EF1α promoter was digested 
with SanDI/XhoI restriction sites in order to transfer the fragment containing the sequence for 
EF1α into plasmid B therefore, generating the final Notch reporter lentiviral vector containing 
the EF1α promoter driving the expression of the truncated NGFR and further downstream, a 
Hes1 promoter driving the expression of the mCherry reporter protein. The construct was 
propagated in NEB® Stable competent bacteria as described before. Successful cloning was 
confirmed by using the primers “Fwd Seq NGFR”, “Rev Seq NGFR”, “Rev Seq Hes1”, “Fwd 
Seq cherry” and “Rev Seq cherry”.
2.3.2 Quantitative real-time PCR
RNA extraction was performed using the Direct-Zol RNA miniprep or microprep kits (Zymo 
Research, USA) depending on the starting number of cells, according to manufacturer’s 
instructions. cDNA was generated by performing reverse transcription of the mRNA using 
either the OmniScript or Sensiscript kits (Qiagen) depending on starting RNA quantity. Briefly, 
20 µL reactions containing 1 µL of reverse transcriptase enzyme, 2 µL of 2X reverse 
transcriptase buffer, 1 µL of Oligo-dT 14-mer (10 µM; Merck), 2 µL of dNTPs and varying 
amounts of mRNA, topped up with molecular grade water were incubated at 37°C for 1 h. The
reaction was stopped by incubating at 93°C for 5 min. The cDNA solution was then placed on 
ice for a few minutes. For quantitative real-time PCR, between 3-6 ng of the original equivalent 
mRNA were used per RT-PCR reaction (10 µL) using PowerSYBRTM (Thermo) according to 
manufacturer’s instructions. Primers were added at a final concentration of 600 nM (Primer 
list can be found in Table II.6 of Appendix II). The reactions were amplified using QuantStudio 
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7 Flex Real-Time PCR system (Thermo). The targets were amplified using the following 
protocol: Hold stage – 2 min at 50°C, then 10 min at 95°C; PCR stage (40 times) 15 sec at 
95°C then 1 min at 60°C; Melt curve stage – 15 sec at 95°C, 1 min at 60°C, 15 sec at 95°C.
The analysis was performed by using the ΔΔCt method (Livak and Schmittgen, 2001), 
(Schmittgen et al., 2000), (Winer et al., 1999). The ΔCt for a certain gene represents the 
difference in the cycle threshold (Ct) value for the gene of interest and the Ct value of the 
housekeeping gene and was calculated by using the formula ΔCt = Ct value (gene of interest) 
– Ct value (housekeeping gene). The ΔΔCt value represents the difference in Ct values 
between the gene of interest in two different conditions, normalised to the housekeeping gene 
within their respective conditions and was calculated according to the formula: ΔΔCt = ΔCt
(gene of interest in condition A) – ΔCt (gene of interest in condition B). Lastly, to quantify the 
fold-change in the expression of the gene of interest in relation to a control condition, the 
formula 2(-ΔΔCt). 
2.4 Western-Blot (WB)
2.4.1 Preparation of cell lysates
Adherent cells were harvested by trypsinisation and washed twice with PBS. Conversely, the 
appropriate number of suspension cells were harvested and washed twice with PBS. The 
pellet was then resuspended in the appropriate volume of RIPA buffer (Merck) containing 1% 
of Proteinase Inhibitor Cocktail (Merck). The cell lysate was incubated on ice for 30 min while 
mixing several times during the incubation period. The cell lysate was then cleared by 
centrifuging for 10 min at 4°C at 16,000x g and harvesting the supernatant. The protein was 
quantified using the DC Protein assay (Biorad, USA). Briefly, 5 µL of the protein suspension 
was added into a 96-well plate. Then, 25 µL of a mixture of Reagent S and Reagent A was 
added to the sample. Then, 200 µL of Reagent B was added to the sample and mixed. Known 
concentrations of stock BSA (bovine serum albumin; Merck) protein were used to generate a 
calibration curve. The samples were then incubated at room temperature (RT) for 10 min on 
a shaker, and after that, absorbance of each sample was measured using a CLARIOstar Plus 
microplate reader (BMG Labtech, Germany). The concentration of the samples was 
extrapolated using the calibration curve generated. 
2.4.2 Preparation of the gel
The desired quantity of protein was mixed with water and 6X Laemmli buffer (Merck) in 20 µL
solutions. The mix was incubated for 5 min at 95°C and then let cool down at RT for 10 min. 
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Before loading, the suspension was mixed and briefly centrifuged. Then, 20 µL of cell 
suspension was loaded per well of NuPAGETM 4-12% Bis-Tris Protein gels (Thermo). The gel 
was embedded in SDS Running buffer solution (Appendix I) and was run for 2.5 h at 100 
volts (V) using a PowerPac basic (Biorad).
2.4.3 Membrane transfer and immunoblotting
After the gel run, a piece of PDVF membrane (Maine Manufacturing LLC, USA) with the same 
size of the gel was cut and activated by incubating in methanol (Merck) for 3 min. After that, a 
sandwich composed of (in order): sponge, blotting paper, gel, PDVF membrane, blotting paper 
and sponge was put together. The sandwich was mounted on a cassette and transferred in 
Transfer buffer (Appendix I) for 1.5 h at 100 V at 4°C. The membrane was then blocked for 2 
h with blocking solution (Appendix I) at RT while shaking. After that, the membrane was 
incubated in primary antibody solution (diluted in blocking solution) overnight at 4°C while 
rotating. The next day, the membrane was washed five times with TBS-T solution (Appendix 
I) and incubated with an appropriate secondary antibody solution for 1 h at RT while rotating. 
The membrane was washed three times with TBS-T and then incubated with Immobilion HRP 
substrate (Millipore, USA) solution for 5 min. The proteins were detected using HyperfilmTM
ECLTM (Merck) developed in the ECOMAX X-ray processor (ClassicXRay, USA). Information 
on the antibodies used can be found in Table III.2 of Appendix III.
2.5 Flow cytometry (FCM) and immunostaining
2.5.1 General extracellular staining
Adherent cells were harvested by trypsinisation, whereas in the case of suspension cells, the 
desired number of cells were simply collected. Cells were centrifuged at 300x g for 5 min and 
resuspended in PBS + 2% FBS. Antibodies were added at x µL of antibody (see Appendix 
III) per 1x106 cells in 50 µL of staining solutions. The staining solutions were usually PBS + 
2% FBS + γ-Human globulins from Cohn fraction II, III (HAG, Merck, at 1:5 final dilution from 
a 20 mg/ml of stock), unless two or more Brilliant Violet (BV) fluorochrome-conjugated 
antibodies were used in the same master mix, in which case the staining solution was the BV 
staining buffer (BD Biosciences, USA). The list of antibodies used in this study are 
summarised in Table II.7 of Appendix III. Cells were incubated with the desired antibodies for 
30 min at 4°C in the dark. After staining, the cells were washed with PBS + 2% FBS, then 
resuspended in PBS + 2% FBS + 4′,6-diamidino-2-phenylindole (DAPI, Thermo, at 1:2000 
final dilution from a 2 mg/mL of stock) and were kept on ice until analysis. Samples were 
acquired on a BD LSRFortessaTM Flow cytometer (BD Biosciences) and analysis was 
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performed using the FlowJoV10 (software (FlowJo LLC, USA). Manual compensation was 
performed by using single-stained samples for each fluorochrome used in the experiment. 
Compensation was performed by adjusting the median fluorescence intensity (MFI) of each 
fluorochrome against that of all other fluorochromes used in the experiment. As seen on 
Figure 2.2, when analyzing a sample only stained with an antibody conjugated to the APC-
Cy7 fluorochrome, there was spillage of signal into the PE-Cy7 channel. Therefore, using the 
compensation matrix, this spectral overlap was discounted. This was performed for all 
fluorochromes until each is properly compensated against all others. For all analyses, at least
1x104 events were recorded. For immunophenotypic characterisation of stem/progenitor cell
populations 2.5x105-5x105 events were recorded.
Figure 2.2 – Compensation strategy. Dot plot and MFI values of an APC-Cy7-conjugated single-
stained sample plotted against PE-Cy7 (A) before and (B) after compensation. In (A), population P5 
has an MFI of 989 for PE-Cy7, compared to population P4 with an MFI of 27. After applying 
compensation (B), the MFI of P5 was reduced to similar MFI levels of P4 before compensation, to 
discount spill over. In this example, the spectral overlap was 9.2.
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2.5.2 Quantifying of apoptosis by Annexin-V staining
To quantify the degree of apoptosis, the cells were harvested and washed twice with PBS to 
remove traces of serum. These were then resuspended in 1X Annexin V binding buffer (BD 
Biosciences). Then, 5 µL of recombinant AnnexinV-APC (Biolegend, USA) was added per 
tube in 100 µL staining solutions and incubated for 15 min at RT in the dark. Then, 300 µL of 
1X binding buffer containing DAPI (1:2000) was added to each tube and analysed by FCM. 
To quantify apoptosis, cells were gated using FSC-A and SSC-A. Early and late apoptotic 
events were distinguished using Annexin-V and DAPI staining (Figure 2.3).
Figure 2.3 – Analysis of apoptosis by FCM. For analysis, the cells were gating using the forward 
scatter and side scatter parameters, and apoptosis was quantified by using DAPI and Annexin-V. Early 
apoptotic events are Annexin-V+DAPI- while late apoptotic events are Annexin-V+DAPI+.
2.5.3 Intracellular staining
The methods described in this section had already been optimised and performed by António 
de Soure, a former student in the lab. The whole procedure was performed in 15 mL tubes. 
When necessary, cells were stained for extracellular surface antigens first. Cells were then 
washed once in PBS and resuspended in 500 µL PBS at a density of 1x106 cells/ml. Then, 
500 µl of 4% methanol-free formaldehyde (PFA; TAAB Laboratories, UK) were added and 
cells were fixed at RT or at 37°C for 10 min and then washed with PBS and centrifuged at 
300x g for 10 min. Cells were resuspended in 250 µL PBS then 250 µL of 0.2% Triton X-100 
solution (Merck; made in PBS) were added. Then, cells were permeabilised at RT for 10 min 
and afterwards washed by filling up the tube with PBS and 1 mL of FBS and centrifuged at 
300x g for 10 min. Fixed/permeabilised cells were then resuspended in a desired volume of  
PBS + 2% FBS (50-100 µL) and each sample was divided into different tubes depending on 
the preferred number of testing conditions but each containing ~2.5x105 cells in 25 µL. Cells 
were incubated with primary intracellular antibodies (2 µL of each antibody) at 4ºC for 1 h, 
washed, then stained with appropriate secondary antibodies (0.25 µL) in the same staining 
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conditions. Following staining washes, cells were then resuspended in PBS + 2% FBS 
containing DAPI (1:200). For the quantification of the activated forms of Notch1 and Notch2, 
samples were acquired in an Amnis® ImageStream® (Luminex, Austin, TX, USA) image flow 
cytometer and analysed using the IDEAS® softwarea FCM and analysis was performed as 
described above in section 2.5.1. As for determining the percentage of cells with a nuclear-
translocated Notch4 receptor, the cell nucleus was stained with a DAPI solution (final 
concentration of 1.6 ng/mL), samples were acquired on an ImageStream® (Amnis®) and 
analysis performed using the IDEAS® software.
2.6 Fluorescence activated cell sorting (FACS)
All cell sorting was performed in a BD FACSAriaTM Fusion (BD Biosciences) and using the BD 
FACSDiva™ software (BD Biosciences). Cells were prepared in the same way as for FCM 
analysis. All cells were sorted into PBS + 2% FBS + 1% P/S. After sorting, cells were 
centrifuged and resuspended in their respective complete growth medium.
2.7 Generation of lentiviral particles and viral transductions
2.7.1 Production of lentiviral particles
Lentiviral particles were produced using the calcium phosphate transfection method. Briefly, 
107 HEK293LTX cells were seeded on 15 cm2 dishes in complete DMEM. The next day, the 
medium was replaced by Opti-MEM (Merck) + 2% FBS without antibiotics and 2 h later the 
cells were transfected. The transfecting particles were produced by mixing the pMD2G 
plasmid (envelope), pCMVdR8.74 plasmid (packaging) (a kind gift from Dr. Didier Trono; École 
Polytechnique Fédérale de Lausanne) and the transfer vector of interest at a 1:1:2 molar 
ration, respectively, in tissue culture-grade water. Then, 122 µL of CaCl2 (2.5M) were added 
to the mix dropwise followed by 1250 µL of 2x HEPES (Merck) dropwise topping up to 2500 
µL volume solutions, while mixing mildly. The mix was incubated for 10 min at RT and then 
added to the cells. After 8 h, the medium was replaced by Opti-MEM + 2% FBS + 1% P/S 
(Thermo) + HEPES (25 mM) (Merck). The viral supernatant was collected 48 h post-
transfection. 
2.7.2 Concentration of lentiviral particles
The lentiviral particles were concentrated by collecting the viral supernatant and centrifuging 
for 5 min at 300x g at 4°C to remove cells and debris. The supernatant was then filtered 
through Millex-HV syringe filter units (0.45 µm; Merck) and concentrated by ultracentrifugation 
for 2.5 h at 4°C at 90,000x g, in thin-wall polypropylene conical tubes (Beckman Coulter, USA) 
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using an Optima™ XPN-80 Ultracentrifuge (Beckman Coulter), with the SW32Ti rotor 
(Beckman Coulter). Following ultracentrifugation, the supernatant was discarded, and the 
pellet of viral particles was resuspended in the appropriate medium (same growth medium for 
the cells to be transduced). After a 2 h incubation period on ice, the suspension was then 
collected and aliquoted at -80°C until further use. 
2.7.3 Determination of virus titres
To determine viral titres, HeLa cells were seeded at 5x104 cells/cm2 on 24-well plates in 
complete DMEM. After 8 h, virus solutions were centrifuged for 3 min. Then, the cells were 
infected with various dilutions of the viral suspension. HeLa cells were incubated at 37°C and 
analysed 3 days post-transduction by FCM to quantify the percentage of transduced cells. The 
viral titre was calculated using the formula:
virus titre (TU/ml) = [%GFP] x [dilution factor (eg 1000)] x [no of cells (ie 5x104)]
100
2.7.4 Lentiviral transduction of cell lines
For transduction of adherent cell lines, cells were seeded at 2.5x104 cells/cm2. After 8 h, cells 
were infected at a multiplicity of infection (MOI) of 10. Cells were then incubated with virus 
overnight and the next day were washed with PBS + 2% FBS + 1% P/S to remove viral 
particles. Fresh complete media was then added. The AML cell lines used were diluted to a 
cell density of 3x105 cells/mL 1.5 days before transduction. Cells were recounted before 
lentiviral was added at a MOI of 10. Cells were then incubated with virus overnight and the 
next day were washed with PBS + 2% FBS + 1% P/S to remove viral particles. Suspension
cells were then resuspended in a 1:1 mix of fresh complete RPMI medium and conditioned 
RPMI (from growing cells) to help recovery. 
2.7.5 Generation of Notch reporter AML cell lines
Following the above the protocol, cells were then cultured for several days until enough 
numbers of cells were achieved for positive selection using FACS. For this, cells were washed 
with PBS + 2% FBS + 1% P/S and then stained with anti-CD271-AF647 antibody (5 µL of 
antibody/1x106 cells) for 30 min at 4°C in the dark. After this time, cells were washed and 
resuspended in PBS + 2% FBS + 1% P/S + DAPI (1:2000) and sorted for NGFR+ cells by 
FACS. After sorting, cells were resuspended in complete RPMI and cultured for several days, 
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until enough numbers were reached for freezing down. To generate Notch reporter AML cell 
lines with shLuc or shNOTCH1 or shNOTCH2, the various Notch reporter AML cell lines were 
transduced with the respective lentivirus as above (the latter two constructs were 
generated/validated by a colleague, Joana Carmelo in the lab). Cells were then cultured for 
several days until enough numbers of cells were achieved for GFP selection using FACS as 
described. After sorting, cells were resuspended in complete RPMI and cultured for several 
days, until enough numbers were reached for freezing down.
2.8 Human primary cells
2.8.1 Isolation and culture of CB-derived human HSPCs
Human CB/CB-MNCs were obtained from different sources (Anthony Nolan Cord Blood Bank, 
Stem Cell Technologies and The Royal London Hospitals) and were obtained after informed 
consent approved by their respective local ethical committees and the Declaration of Helsinki.  
HSPCs were isolated mostly from frozen cord blood mononuclear cells (CB-MNCs) and at 
some occasions from fresh CB. Briefly, CB-MNCs from fresh CB was obtained by transferring 
the blood to a T175 flask and diluting at 1:3 ratio with PBS. Then, 15 mL of Lymphoprep™ 
(Stem Cell Technologies, Canada) were added to a 50 mL Falcon™ tube. The diluted blood 
was then added carefully on top of the Lymphoprep™ at an angle. Two parts blood were 
added to one-part Lymphoprep™. The mix was centrifuged for 30 min at 20°C at 550x g with 
the brakes of the centrifuge on the “Off” position. After centrifugation, 3 distinct layers could 
be seen: a top layer of serum, a bottom layer of red blood cells and a thin middle layer 
containing the MNCs. The MNCs layer was carefully harvested by using a transfer pipette 
(Fisher). Collected MNCs were then diluted 1:2 with PBS and centrifuged at standard speed 
for 7 min at 5°C. The supernatant was discarded, and the pelleted cells were all pooled 
together into a new 50 mL falcon tube with PBS (enough to wash all tubes used). Next, 15 mL
ammonium chloride solution (NH4Cl) (Stem Cell Technologies) were added to the cell 
suspension (approximately 3 to 4 volumes of cell suspension). The mix was incubated at 4°C 
for 7 min to lyse red blood cells. Then, 2 mL of FBS were added balance osmolarity, and PBS 
was then added to top up the solution. Cells were centrifuged, resuspended in PBS + 2% FBS 
and counted. Cells were used right away or frozen in FBS containing 10% DMSO. 
Frozen CB MNCs were thawed at 37°C, washed once with PBS + 2% FBS, centrifuged at 
300x g and counted. CD34+ cells were selected using the EasySepTM Human CD34-positive 
selection kit (StemCellTM Technologies) according to manufacturer’s instructions. Briefly, cells 
were resuspended in 1 mL PBS + 2% FBS at 1-5x108 cells/mL, to which 100 µL of CD34+
selection reagent were added. The mix was incubated for 10 min at RT. Then, 50 µL of 
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magnetic particles were added and incubated for another 10 min. The tube was then placed 
into the EasySepTM magnet for 5 min and the supernatant was discarded while in the magnet. 
An additional 2.5 mL of PBS + 2% FBS were added and a total of 4 rounds of selection were 
performed.
2.8.2 Sorting of CD34+CD38- HSPCs
After CD34+ cell selection, cells were counted, resuspended in 50 µL of PBS + 2% FBS and 
stained with anti-CD34-APC and anti-CD38-PE-Cy7 antibodies (5 µL of antibody/1x106 cells) 
for 30 min at 4°C in the dark. After washing with PBS + 2% FBS and resuspension in PBS +
2% FBS + 1% P/S + DAPI (1:2000), cells were filtered and the CD34+CD38- cells were sorted 
as described in 2.6. 
 
2.8.3 Culture of CD34+CD38- HSPCs
After sorting, cells were pre-stimulated for approximately 16 h in a 96-well plate in StemSpanTM
(Stem Cell Technologies) containing SCF 100 ng/mL, Flt3L 100 ng/mL, G-CSF 25 ng/mL, IL-
3 10 ng/mL and IL-6 10 ng/mL (all from Peprotech, USA), 1% P/S and HEPES (10 mM) 
(Merck).  After this period, HSPCs were transduced at a MOI of 50 with the respective lentiviral 
particles for 10-12 h. Then, a few drops of FBS were added to the cells to inactivate the viral 
particles. Then, cells were washed three times with PBS to remove excess of viral particles 
and serum and resuspended in StemSpanTM containing SCF 300 ng/mL, Flt3L 300 ng/mL and 
TPO 20 ng/mL, 1% P/S and HEPES (10 mM) for an additional 4 days. After the 4-day 
expansion period, GFP+ HSPCs were sorted as described above. For expansion of primitive 
cells after lentiviral transduction, HSPCs were cultured with the latter condition and cultures 
were divided at 1:2 to 1:4 ratios every 3 days for 12 days.
2.8.4 Long-term culture initiating-cell (LTC-IC) assay
The MS5 stromal cell line was cultured in complete αMEM for three passages before use. 
T96-well plates were coated with collagen (StemCell Technologies) at 0.3 mg/mL for 1 min. 
Collagen solution was then removed from the wells, which were then left to dry for 1 h. Next, 
the wells were washed with PBS twice to neutralise the collagen pH before use. Then, MS5 
cells were seeded at a density of 3000 cells per well in Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Merck) supplemented with 10% FBS and 1% P/S (complete IMDM). Two days later, 
MS5 cells were irradiated at 6.8 Gys (Grays; using a 137Cs source). After irradiation, cells were 
incubated for at least 8 h at 37°C to allow for recovery, time after which the medium was 
replaced by MyeloCultTM H5100 medium (StemCell Technologies) + 1% P/S. Following 
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sorting, GFP+ HSPCs were resuspended in complete IMDM medium, and various cell 
quantities were dispensed on top of the MS5 feeder layer. On average 5 to 15 wells were used 
per cell dose in one independent experiment. Co-cultures were maintained in MyeloCultTM
H5100 medium + 1% P/S for a total of 5 weeks with weekly half-medium changes.  By the 
fourth week of the co-culture, CAFCs could be observed as exemplified in Figure 2.4. Only 
large colonies of >50 densely packed haematopoietic cells were counted in each condition. 
Figure 2.4– A cobblestone-area at week 4 of LTC-IC co-culture of human HSPCs and MS5 stromal 
cells. Highlighted in red, two large colonies of packed haematopoietic cells form cobblestone-
resembling patterns. 
2.8.5 Colony-forming unit (CFU) assay
At the end of the 5-week co-culture, both human HSPCs and murine MS5 stromal cells were 
harvested by trypsinisation. For this, the supernatant was also collected prior the harvest of 
the adherent fraction. Then, both non- and adherent fractions were mixed together. Depending 
on the number of wells per cell dose used in each experiment, the collected cells were 
resuspended in an equivalent volume of 100 µL complete IMDM/well. Then, 100 µL of this mix 
were added to 1 mL of MethoCult™ H4435 (StemCell Technologies) + 1% P/S. The mix was 
briefly vortexed to ensure proper distribution of the cells. Then, the mix was dispensed into 
two wells of a 12-well plate. Cultures were maintained for a total of 2 weeks, time after which 
the colonies were counted.
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2.8.6 Immunophenotypic characterisation of LTC-IC cells
The information of the antibodies used in this study can be found in Table III.1 of Appendix 
III. At the end of the 5-week co-culture period, cells were harvested as described above. After 
washing, cells were resuspended and a fraction of the cells was incubated with the HSPC 
panel of markers (CD34, CD38, CD90, CD45RA, CD135) and another fraction with the 
differentiated cell panel of markers (CD34, CD14, CD19, CD33, CD56 and CD11c). Another 
fraction of cells was incubated with Rabbit IgG isotype control-PE or Nicastrin-PE (dilution 1:4) 
antibodies to assess the knockdown levels of Nicastrin. In all the staining conditions, 5 µL of 
each crude or diluted antibody was used and stainings were performed as depicted in section 
2.4.1. 
2.8.7 Immunophenotypic characterisation of AML cells
Before immunophenotypic characterisation, samples were depleted of Annexin-V+ cells using 
the Annexin-V MicroBead kit (Miltenyi Biotec, Germany). For this, AML primary samples were 
thawed at 37°C, added to PBS + 2% FBS and centrifuged at 300x g for 10 min. After two 
additional washing steps with PBS, cells were then resuspended in 1X Annexin-V binding 
buffer at 80 µL/107 cells. Annexin-V beads were added at 20 µL/107 cells and the mix was 
incubated for 15 min at 4°C. After this step, 2.5 mL of 1X Annexin-V binding buffer were added 
and magnetic separation was carried out by placing the tube into the EasySep™ magnet for 
5 min at 4°C. The supernatant (containing live cells) was collected and the magnetic 
separation process was repeated for a total of 4 times. At the end, cells were washed and 
resuspended in PBS + 2% FBS. Next, 4x106 cells were stained with a panel of antibodies 
containing 20 µL of each anti- CD34, CD38, CD90, CD45RA and CD99 antibodies. Then, the 
whole mix was divided into 4 tubes to assess the expression of single Notch receptors. For 
this, different fractions of cells were stained separately with anti-Notch1-PE (5 µL/1x106 cells), 
Notch2-PE (5 µL/1x106 cells), Notch4-PE (2,5 µL/1x106 cells) or the mouse IgG isotype 
control-PE (10 µL/1x106 cells). The remaining staining protocol can be seen in section 2.4.1 
Detailed information on the antibodies used is listed in Table III.1 of Appendix III.
2.8.8 Activation of Notch signalling using ligand-overexpressing stroma
S17 and S17-Delta4 stromal cells were cultured in complete αMEM and passaged three times 
before use. For the co-culture assay, each stromal cell line was seeded at 2x104 cells/cm2 on 
24-well plates. All the AML cell lines used were resuspended in complete αMEM and added 
to stromal cells at 2.5x104 cells/well. 
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2.8.9 Testing small molecules interacting with Notch signalling
A collaboration with Professor Andrea Brancale at the School of Pharmacy of Cardiff 
University was setup, aiming to obtain candidate small molecule agonists of Notch signalling. 
The methods described in this section have been performed by the Master student Julija 
Jotautaite, who was a member of the Brancale’s research group. Briefly, virtual screening is a 
computational docking technique which screens libraries of small molecules to identify those 
with highest probability of binding to a given target. This can be done via structure-based 
virtual screening, which uses the 3D structure of the target to find cognate partners, whereas 
ligand-based virtual screening uses the 3D structure of the ligand to filter a library of small 
molecules. No three-dimensional information on Notch2-4 exist. Therefore, the crystallised 3D 
structures of Notch1 EGF11-13 region (code 2VJ3) were used along with that of Jag1 DSL 
and EGF1-3 region (code 2JV2) (obtained from RCSB protein data bank (www.rcsb.pdb.org)) 
to obtain a model of the Notch1/Jag1 complex, which the docking procedure could use to 
screen potential ligands. A total of 3,300,000 compounds available from libraries were virtually 
screened between the structure-based and ligand-based virtual screening techniques. A
series of molecular docking filters using different docking scoring functions were applied. The 
best scoring compounds were then visually inspected for their ability to interact and occupy 
with the selected binding site (i.e. number of hydrogen bond formations, hydrophobic 
interactions, etc.). Compliance with Lipinski’s rule of five (which determines the likeliness that
a chemical compound can be used as an orally active drug in humans) (Lipinski et al., 2001)
and absence of potential toxic groups, further reduced the number of compounds, generating 
a final selection of 177 molecules as potential binders of Notch. Of those, 19 compounds were 
purchased for biological evaluation, and 6 of those were evaluated in our lab (Table IV.1 of 
Appendix IV).
All the small molecules were reconstituted to either 50 mM or 25 mM, depending on their 
solubility in DMSO. Small molecules were added to the culture medium at a concentration of 
10 µM. In some testing conditions, the Notch inhibitor CompE (Merck) was added at a final 
concentration of 2 µM 2 h prior treatment with the drugs to ensure blocking of Notch receptor 
cleavage. 
2.8.10 Activation of Notch signalling with Jag1 based peptide
The CDDYYYGFGCNKFCRPR Jag1 peptide (Genscript, USA) was reconstituted to 5 mg/mL
in 1:1 water:DMSO and stored at -20°C. The Jag1 peptide was added to the culture at the final 
concentration mentioned in the text. In some testing conditions, the Notch inhibitor CompE 
was added at a final concentration of 2 µM 2 h prior treatment with the Jag1 peptide to ensure 
blocking of Notch receptor cleavage. Treated cells were analysed 48 h after Jag1 treatment.
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2.9 In vivo analysis of HSPCs
2.9.1 Xenotransplantation of HSPCs into NSG mice
Due to the lack of an appropriate animal facility at Cardiff University to breed the number of 
pathogen-free immunodeficient mice required for this project, both the animal adoptive 
transfer and the schedule-1 sacrifice procedures were performed by Dr. Fernando dos Anjos 
Afonso at The Francis Crick Institute in London. All the animal procedures were performed in 
accordance with the UK Home Office regulations after The Francis Crick Institute ethics 
committee approval. 
NSG mice aged 8-12 weeks were sub-lethally irradiated at 3.75 Gy (137Cs source) up to 24 h 
before tail vein injection of cells. For experiments of pan-Notch inhibition, 5000 FACS purified 
CD34+CD38- HSPCs were transplanted. Six to seven weeks post-transplant mice were 
randomly split into two groups: one group received 5 doses of α-secretase IX (DAPT; 12 
mg/Kg; Tocris Bioscience, UK), and another group received vehicle (DMSO), all dissolved in 
oil. Mice were intra-peritoneally injected every other day. Five and a half weeks later, the 
recipients were sacrificed, and their BMs analysed. To test the cell-autonomous Notch 
inhibition, 3800-5000 FACS purified GFP+ HSPCs were injected into the tail vein of sub-lethally 
irradiated NSG mice. After 12 weeks the recipients were sacrificed, and their BMs were 
harvested and analysed.
2.9.2 Immunophenotypic characterisation of engrafted cells
To analyse the bone marrow content of transplanted animals, three pairs of bones (tibiae, 
femurs and ileum) from NSG mice were flushed with 1 ml PBS + 2% FBS several times until 
the marrow had a white appearance, indicating successful removal of the marrow. Cell 
suspensions were submitted to red blood cell lysis by adding two times the initial volume of 
NH4Cl. The mix was incubated for 3 min at RT. Then, a few drops of FBS were added to 
balance the osmolarity, and the mix was centrifuged. Cells were resuspended in 200 µL of 
PBS + 2% FBS and their numbers were determined. In the experiments with DAPT, to quantify 
the level of human myelo-lymphoid engraftment, a fraction of the cell suspension (containing 
5x105 to 1x106 cells) was stained with anti-CD45, CD19 and CD33 antibodies. In the 
experiments injected with GFP+ HSPCs, cells were stained with the differentiation cell panel 
markers (anti- CD34, CD11c, CD19, CD33 and CD14 antibodies). Human engraftment was 
quantified as the proportion of live cells that were CD45+CD33+ and CD45+CD19+. For 
immunophenotypic characterisation of engrafted immature populations in mice, cells were 
also stained with a panel of antibodies to detect different HSPC fractions (anti- CD34, CD38, 
CD90, CD45RA, CD10, CD135, CD62L and Lineage). Staining conditions can be seen in the 
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section 2.5.1. Dead cells and debris were excluded from the analysis and the maximum 
number of lived effects were acquired.
2.10 Statistical analysis
All statistical analyses were performed using the Prism8 software (Graphpad, USA). Unpaired 
t-tests were used for the analyses. Statistical analysis of all engraftment data was performed 
by using the Mann-Whitney test, as the values within the groups being compared cannot be 
assumed to be normally distributed. The level of significance used was: *p<0.05, **p<0.005 
and ***p<0.0005. 
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Chapter 3 - Exploring the effects of pan-Notch 
inhibition in human HSPCs
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3.1 Brief introduction
Beyond the divergent data in mice discussed in Chapter 1, only recently some light has been 
shed on the role of Notch pathway in human HSCs in vivo. Similarly to Maillard et al., (Maillard 
et al., 2008), Benveniste and colleagues showed that human HSPCs have different 
requirements for Notch in vitro and in vivo (Benveniste et al., 2014). Specifically, stem cells 
seem to depend more on Notch signals in vitro, as it was shown by the blockade in T cell 
development and HSC maintenance/expansion in vitro, while only T cell lineage specification 
was impaired in transplanted Notch-inhibited HSCs in vivo (Benveniste et al., 2014). In 
contrast, Bhatia’s group showed that HSCs with superior regenerative and self-renewal 
capacity tend to localise to endosteal regions of the trabecular bone area (TBA) (Guezguez et 
al., 2013). These HSCs have distinct molecular activation enriched with Notch signalling 
signature compared to HSCs localising in the long bone area (LBA). Particularly within the 
TBA, phenotypic human HSCs and HPCs preferentially locate in the endosteal over vascular 
regions. The authors of this work also showed that osteoblasts from the TBA have increased 
expression of Notch ligands Jag1, Jag2, and Delta4 compared to osteoblasts from the LBA, 
consistent with the HSC activation profile (Guezguez et al., 2013). Of interest, a three-fold 
higher proportion of osteoblasts expressing Jag1 ligand was detected in the TBA compared 
to the LBA. Additionally, Jag1-binding HSPCs were found to have higher CFU capacity and 
repopulating capacity. Upon Notch inhibition with DAPT treatment in vivo, total human 
engraftment and HSPC numbers were not affected in the LBA, whereas there was a significant 
reduction in the TBA, suggesting that only this region is sensitive to Notch inhibition (Guezguez 
et al., 2013). These observations support a critical role of Notch signalling in human HSC 
regulation through interactions with specific bone marrow niche cells.
As still little is known on the importance of the Notch pathway in regulating human HSC and 
HPC functions, the aim of this chapter is to establish the role of Notch signalling by first 
employing pharmacological inhibition of the pathway using the well-known γ-secretase 
inhibitor DAPT and later by cell-autonomous shRNA-mediated knockdown of Nicastrin – a key 
member of the pathway and one of the few non-redundant members of the pathway
Additionally, targeting NCSTN has been well documented to inhibit the Notch pathway
(Klinakis et al., 2011).The use of shRNAs to silence genes of interest has been widely 
employed and has been greatly refined since its discovery (Hannon and Rossi, 2004), (Mohr 
and Perrimon, 2012). MicroRNA-30 can be excised from mRNA transcripts containing the 71 
nucleotide miR-30a precursor and when is introduced into an expression plasmid is able to 
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strongly silence target transcripts (Zeng et al., 2002). In this work, we first attempted to employ 
a tailored miR-30 backbone’s ability to be processed by the cells in order to silence genes of 
interest, along with the expression of fluorescent protein reporter genes (Fellmann et al., 
2013). Aiming at addressing the role of Notch signalling in human HSPC, we started by 
characterising Notch receptor expression and activity in the different stem and progenitor 
populations and by challenging Notch-deficient HSPCs under rigorous assays in vitro and in 
vivo. Importantly, no studies on the potential role of non-canonical Notch signalling have been 
performed so far. Blocking Nicastrin will prevent both non-canonical and canonical Notch 
signalling. On the other hand, silencing of RBPJ only affects canonical Notch signalling, which 
will be discussed in Chapter 4.
Aims of Chapter 3
- Measure the expression levels of Notch receptors and their active domains in human 
HSPCs.
- Determine the impact of Notch inhibition in human HSPCs in vivo by using γ-secretase 
inhibitor DAPT on myelo-lymphoid engraftment and frequencies of stem/progenitor 
cells.
- Block pan-Notch signalling in HSPCs by using shRNA lentiviral vectors that inhibit the 
expression of NCSTN – a member of the γ-secretase complex.
- Assess in vitro effects of Notch inhibition by measuring colony-forming and 
differentiation capacity under the LTC-IC assay.
- Assess in vivo effects of Notch inhibition by measuring myelo-lymphoid engraftment 
and frequencies of stem/progenitor and mature cells.
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3.2 Characterisation of the Notch signalling pathway in human HSPCs
As a first step, the Notch pathway activity in human HSPCs was characterised. To do this, the 
various sub-populations were defined through their immunophenotypic surface markers. As 
previously mentioned, the broad stem and progenitor cell compartment comprises a very 
heterogeneous population of cells. These can be divided into their respective self-renewal and 
differentiation potentials partially based on the expression of key surface markers. The 
immunophenotypic profile used was based on the work by Weissman’s group (Majeti et al., 
2007) and further adjusted by others (Notta et al., 2011) and is illustrated in Figure 3.1.
Figure 3.1 – Gating strategy for HSPCs. Within the CD34+CD38+ compartment, CD10- cells are 
selected, which can be separated into CMP, GMP or MEP based on CD45RA and CD135 expressions. 
Within the CD34+CD38- sub-population, HSCs and MPPs can be divided based on their CD90 and 
CD45RA expressions. The CD45RA+ cells can further be portioned into MLP or LMPPs based on CD10 
surface expression. FSC-A – Forward scatter-area; SSC-A – Side scatter-area.
By first selecting live cells and excluding cell debris, a subset of CD34+CD38+ cells can be 
subdivided into the CMP, GMP and MEP compartments based on their CD135 and CD45RA 
expressions. Conversely, within the CD34+CD38- fraction, HSC, MPP and MLP/LMPP 
populations can be found based on CD90 and CD45RA expressions. MLPs and LMPPs can 
be further fractionated based on CD10 expression. This is the gating strategy that will be 
followed throughout the entire thesis unless specifically stated otherwise. To begin with, the 
extracellular expression of each Notch receptor was determined in the various primitive 
haematopoietic stem and progenitor cell compartments using FCM (Figure 3.2).  
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Figure 3.2 – Human HSPCs highly express Notch1 and Notch2 receptors. FCM analysis of surface 
Notch receptors. The surface expression of (A) Notch1, (B) Notch2 and (C) Notch4 receptors was 
evaluated for each CB-derived HSPC sub-population by determining the MFI ratio of each receptor 
(anti-Notch/isotype controls). Results are presented as the mean ± standard error (SD) (n=4-5). 
All stem and progenitor cell populations were found to express Notch1 and Notch2 receptors 
but low/absent levels of Notch4 (Figure 3.2). The expression of the Notch3 receptor was not 
assessed, as previous studies have shown that this receptor is absent on human HSPCs
(Anjos-Afonso et al., 2013). The sub-populations with the highest Notch1 expression were the 
CD45RA+ sub-populations (LMPP, MLP and GMP), while the lowest was observed for HSC, 
MPP and MEP fractions. As for Notch2 receptor, its highest expression was observed in the 
CMP and MEP sub-populations. Altogether, this reveals the different HSPC sub-populations 
have distinct Notch expression profiles, indicating that different signalling responses to Notch 
ligands might occur within the various populations. This contrasts with the mouse 
haematopoietic system, in which HSPCs mainly express low levels of Notch2 while the Notch1 
receptor is almost absent (Oh et al., 2013). 
Yet, cell surface expression of Notch receptors alone does not imply activation of the pathway. 
To fully assess its degree of activation, the cleaved forms of the Notch receptors, which are 
indicative of Notch activity, were assessed by FCM. For this, antibodies that detect the Notch 
intracellular domain of Notch1 and Notch2 specifically following the S3 cleavage were used. 
Importantly, these antibodies do not recognize the full-length Notch receptors, but rather their 
cleaved form. To determine the optimal staining conditions, each antibody was titrated using 
different cell lines or primary cells as positive and negative controls for the expression of each 
of the Notch receptors (conditions had already been established in the lab). Regarding Notch4, 
no antibody that specifically detects the cleaved form of this receptor was commercially 
available at the time of the experiments. To devise that, an antibody that detects the C-
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terminus domain of Notch4 was used, and the percentage of translocation of N4-IC into the 
nucleus was measured using imaging flow cytometer ImageStream®X. N1-ICD, N2-ICD and 
nuclear Notch4 were present in all HSPC sub-populations (Figure 3.3), further supporting the 
notion that Notch is active in the broad CD34+ HSPC pool and may play an important role in 
controlling HSC biology.  
Figure 3.3 – Human HSPCs have Notch activity. The levels of activated (A) Notch1 (N1-ICD), (B) 
Notch2 (N2-ICD) and (C) the percentage of cells with nuclear-translocated of Notch4 receptor was also 
calculated (N4-IC) for each HSPC sub-population, (D) detection of intracellular Notch4. Scale bars 5µm. 
Results are presented as mean ± SD (n=4). Rh-Pha – Rhodamine Phalloidin. (Note: the nuclear-
translocation of Notch4 experiments were performed by a former lab member – António de Soure). 
Interestingly, all these populations appear to display a preferential level of Notch2 receptor 
activation. The reason for this has yet to be elucidated. However, some aspects of Notch 
regulation can be at play in this case. It is believed that different ligands have different affinities 
towards the different Notch receptors. For example, the Delta4 extracellular domain has an at 
least one order of magnitude higher affinity towards Notch1 than Delta1 does (Andrawes et 
al., 2013). Even though the nature of all possible interactions between the various 
ligand/receptor pairings has been the subject of much investigation, this remains a largely 
unclear aspect of Notch signalling biology. Nonetheless, it can be argued that this outcome 
can be explained if ligands with a higher propensity to interact with Notch2 are present in the 
niche. In addition to the well characterised activation of Notch through the trans-interaction of 
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ligands and receptors, cis-interaction leads to inhibition instead. Delta3 ligand appears to be 
unable to activate Notch in a trans fashion and instead, inhibits Notch when co-expressed on 
the same cell (Ladi et al., 2005). In addition, Notch ligands and receptors are susceptible to a 
great amount of post-translational modifications that modulate their responsiveness to one 
another (a great detailed review on the topic can be found on (Fortini, 2009)). The Fringe 
family of glycosyltransferases catalyses the elongation of O-fucose (a moiety added by Pofut-
1 in mammals) by adding N-acetylglucosamines at specific EGF-like repeats on the Notch 
extracellular domain. Although best characterised in Drosophila, these have been shown to 
impact Notch activity in mammalian cells as well. Lunatic-Fringe (one of the Fringe family 
members) appears to enhance Delta-induced Notch1 signalling over Jagged-induced Notch1 
signalling in C2C12 myoblasts and NIH3T3 cells. With these we can appreciate the additional 
layer of complexity that post-translational modifications impart in Notch signalling. To the best 
of our knowledge, no studies of the topic have been performed in human HSPCs, but it can 
be argued that these modifications probably occur in this system as well and might alter the 
responsiveness of the receptors to different DSL ligands. 
A higher level of N1-IC was observed in HSCs when compared to other sub-populations, 
suggesting that this receptor may be particularly important in regulating this population. As for 
the activation of Notch2, the broad CD34+CD38- HSPC fraction had higher N2-IC levels than 
the CD34+CD38+ HPC fraction, with a trend of higher expression in the most primitive HSCs 
(Figure 3.3). The Notch4 receptor was found to be minimally processed in CD34+ HSPCs 
(Figure 3.3). Of note, this contrasts again with the very rare primitive CD34- HSCs which show 
a unique Notch4 expression and cleavage pattern (Anjos-Afonso et al., 2013). In summary, 
this data consolidates the idea that human CD34+ HSPCs possess Notch activity, possibly 
relying on differential Notch receptor expression/activation for their regulation. Furthermore, 
at the technical level, it highlights the importance of assessing the extent of receptor cleavage 
in such sub-population, rather than solely relying on cell surface expression for a more 
complete appreciation of pathway activity. 
3.3 Pharmacological inhibition of Notch leads to depletion of haematopoietic 
stem and progenitor cell fractions in vivo
To test whether the Notch signalling pathway plays a role in HSPCs in vivo, sub-lethally 
irradiated NSG mice were transplanted with 5000 FACS purified human CD34+CD38- HSPCs. 
After six to seven weeks, DAPT or vehicle was administered to the animals five times every 
other day (Figure 3.4 A). The BMs of the recipients were analysed five and a half weeks post-
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DAPT treatment (for a total of 12 weeks post-transplantation) (Figure 3.4 B). Notch was not 
inhibited at least six weeks after transplantation to ensure the adequate regeneration of the 
vascular endothelial system which is disrupted following irradiation (Lee et al., 2012) and is 
dependent on Notch signalling for regeneration (Krebs et al., 2000), (Kim et al., 2015). 
 
Figure 3.4 – Pharmacological inhibition of Notch signalling leads to depletion of stem and 
progenitor cells in vivo. (A) Schematic representation of the experimental workflow: sub-lethally 
irradiated NSG mice were transplanted with CB HSPCs. Six to seven weeks later, the animals were 
treated five times with DAPT (12 mg/Kg) or vehicle (DMSO) every other day. Five and a half weeks 
later, the animals were sacrificed, and their bone marrows were analysed. (B) Percentage of myelo-
lymphoid engraftment at five and a half weeks post-transplantation. (C) Percentage of stem and 
progenitor cell compartments in the human cell fraction at five and a half weeks post-DAPT treatment. 
Each dot represents a mouse, and the bars the medians of the values. Median bars are shown (n=10).
DAPT - N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester. Mann-Whitney test. 
*p<0.05; **p<0.005; ***p<0.0005.
Following transplantation, human HSPCs home to the BM, where they self-renew and begin 
the differentiation process into mature blood cells. The percentage of myelo-lymphoid 
engraftment represents the percentage of cells with B lymphoid (CD19+) and myeloid (CD33+) 
lineage that were generated. A 2.5-fold reduction in myelo-lymphoid engraftment was 
observed in the animals treated with DAPT when compared to vehicle-treated recipients 
(Figure 3.4 B). This indicates that Notch inhibition impaired stem and progenitor cell 
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repopulating and/or differentiation capacity. When examining the BMs for the presence of 
human haematopoietic stem and progenitor cells, an overall reduction in the frequency of 
many subsets of cells was observed (Figure 3.4 C). The major reductions occurred in the 
HSC and the CMP compartments, with a 7- fold and a 20-fold decrease in their frequency 
compared to the control cohort, respectively. Still, in general, all progenitors downstream of 
HSCs were affected albeit to different degrees. Of note, phenotypically defined MLPs 
(CD34+CD38-CD45RA-CD10+) commonly found in CB were not detected after engraftment in 
NSG mice. Instead, phenotypic MLPs generated after transplantation adopted an 
immunophenotype similar to human BM MLPs (CD34+CD38+CD45RA-CD10-CD62L+) (Anjos-
Afonso, personal observations). Hence, this phenotype was used to define human MLPs in 
NSG mice. As mentioned earlier, a previous study has reported a reduction in the total 
engraftment in mice transplanted with human Lin- cells and treated with DAPT (Guezguez et 
al., 2013). Specifically, trabecular bone area (TBA)-HSCs in the BM which were particularly 
affected. CD34+CD38- HSPCs from the TBA had decreased frequencies when Notch was 
inhibited, while CD34+CD38+ progenitors were expanded, which the authors attributed to a 
likely induction of differentiation from stem to progenitor cells (Guezguez et al., 2013). In 
agreement with this, we have found a significant reduction in myelo-lymphoid engraftment and 
HSC pool in DAPT-treated animals. On the contrary, we did not find an expansion in 
CD34+CD38+ cells. This disparity may be related to the timings of the analyses. Guezguez 
and colleagues analysed the BM 5 days following initial treatment. Following Notch induction, 
enforced release of HSCs from quiescence induces a rapid expansion of progenitors. In our 
setup, we have analysed BMs almost 6 weeks following Notch inhibition, time by which this 
initial expansion may have ended, and instead both stem and progenitor cell compartments 
suffered exhaustion of their respective pools due to Notch inhibition. Although these results 
strongly suggest that maintenance of physiological levels of Notch signalling in the BM is 
fundamental for haematopoietic homeostasis, we cannot rule out the possibility that the effects 
seen may in part be non-cell autonomous. To address this question, Notch signalling needs 
to be inhibited exclusively in HSPCs.
3.4 shRNA-mediated silencing of NCSTN in human HSPCs
3.4.1 Testing a miR-30-based shRNA system in human HSPCs
To study the potential functions of Notch signalling in human HSPCs, and to assess whether 
the previously observed effects were cell-autonomous, lentiviral vectors overexpressing 
shRNAs targeting the NCSTN gene were generated. NCSTN, encoding for the Nicastrin 
protein - a member of the γ-secretase complex, is responsible for the S3 cleavage of Notch 
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receptors (Bray, 2006). Even though the dominant negative form of MAML1 (dnMAML1) has 
been used in a few reports (Maillard et al., 2008), (Maillard et al., 2008), (Duncan et al., 2005)
it only blocks canonical signalling. Furthermore, this protein has the potential to affect other 
non-Notch related pathways, as evidenced by its interaction and co-activator function of p53
(Zhao et al., 2007). On the other hand, a Nicastrin mutant that appears to act as a dominant 
negative protein has been reported (Klinakis et al., 2011). However, no other studies have 
validated the functionality of this mutant protein. Hence, a vector (pLV.EF1α-miRNA30-
shRNA-GFP) was developed to express premiRNA30-shRNA and GFP reporter protein under 
the EF1α promoter. Embedding the shRNA into the context of endogenous miRNAs has been 
used to overcome saturation of endogenous miRNA pathways and to increase Dicer 
processing accuracy by using natural substrates in the miRNA biogenesis pathways (Gu et 
al., 2012). These structures can trigger potent knockdown and their efficacy has been shown 
for various miRNA backbones, including miRNA30, yielding less off-target effects (Fellmann 
et al., 2013). miR-30 based systems have been shown to trigger potent cognate mRNA 
knockdown in mammalian cells (Zeng et al., 2002), (Stegmeier et al., 2005). A similar system 
has also been reported to efficiently transduce murine LSK cells (Holmfeldt et al., 2016). More 
recently, a study took advantage of a different miR-30 based system to transduce human 
CD34+ cells at high levels (Xiao et al., 2019). Cloning of the premiRNA30-shRNA sequence 
inside the EF1α intron allows it to be spliced out from the transcript. Following processing and 
stabilization, the reporter gene can be translated. The schematic representation of the 
construct used is depicted in Figure 3.5.
Figure 3.5 – Schematic representation of the pre-miR30 lentiviral construct. The EF1α promoter 
controls the expression of the shRNA embedded into the pre-mir30 intron and the GFP reporter protein.
In this system, the elongation factor alpha (EF1α) promoter drives the expression of the 
reporter GFP protein. Along with it, the shRNA embedded into the pre-miR30 backbone is 
generated through the processing of the pre-miR30 via the natural miRNA processing 
machinery found in the cells. To test this system, a shRNA sequence targeting the Luciferase 
gene (shLuc) was used as a control (the Luciferase gene is only found in the common firefly 
and therefore this sequence has no targets in mammalian cells) and sequences targeting 
NCSTN (shNCSTN) (listed in Appendix II) were cloned into the intermediate vector 
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(pECFPc1) using XhoI/EcoRI restriction sites. Then, those sequences, now flanked by the 
mirRNA30 backbone were then transferred into pLV.EF1α-miR30shRNA-GFP using 
BamHI/NheI restriction sites. The correct cloning of the different sequences was confirmed by 
plasmid sequencing. Lentiviral particles for the various constructs were produced as described 
in the Chapter 2. Next, HEK293T cells were transduced with the different pLV.EF1α -miR30-
shRNA-GFP clones. After 8 days in culture, the cells were analysed by FCM to assess GFP 
expression, and afterwards, both protein and RNA were extracted. GFP expression was found 
in more than ~94% of the cells analysed after transduction (Figure 3.6). 
 
Figure 3.6 – HEK293T cells transduced with CS-shRNA constructs. HEK293T cells were analysed 
for their GFP expression 8 days post-transduction with CS-shRNA constructs. 
Measurement of knockdown efficiency was carried out by assessing the decrease in the 
Nicastrin protein levels by Western-blotting (WB) and at the mRNA level by quantitative real-
time PCR (qRT-PCR). A total of 7 shRNAs were tested for their ability to silence the NCSTN
gene. The constructs termed shNCSTN-1 and shNCSTN-3 were found to be the most 
effective. For this reason, these two constructs were used for the remaining work. shNCSTN-
1 and shNCSTN-3 resulted in a decrease of 58% and 57% of the Nicastrin protein, respectively 
(Figure 3.7 A and B) and 52% and 72% at the mRNA level, respectively (Figure 3.7 C). 
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Figure 3.7 – shRNA-mediated knockdown of Nicastrin in HEK293T cells. (A) Representative WB 
of shRNA-mediated knockdown of the Nicastrin protein. Quantification of (B) protein and (C) mRNA 
knockdown of NCSTN. Results are the mean ± SD (n=4). Unpaired t-test. *p<0.05; **p<0.005; 
***p<0.0005.
Following validation of silencing efficiency from these constructs in the HEK293T cell line, the 
clones were tested for their efficiency to silence their targets in human HSPCs. Firstly, HSPCs 
were isolated from CB MNCs. An initial round of CD34+ cell selection was performed. CD34+
cells were incubated with magnetic beads that possess affinity to the CD34 antigen. In this 
manner, the CD34-expressing cells were magnetically separated from the bulk of the 
population. Following this initial enrichment step, the cell suspension was stained with anti-
CD34 and anti-CD38 antibodies conjugated to fluorochromes. The CD34+CD38- fraction was 
then sorted by FACS. The sorted cells were pre-stimulated in serum-free StemSpan culture 
medium containing cytokines (SCF, FLT3L, G-CSF, IL-3 and IL-6) (Haylock et al., 1997), 
(Conneally et al., 1997). The cells were then transduced with the lentiviral constructs at a 
multiplicity of infection (MOI) of 50. The next day, the cells were washed to remove excess 
viral particles and were cultured for an additional four days in StemSpan containing a 
combination of high concentration of cytokines (SCF, FLT3L and TPO) that was demonstrated 
to maintain stemness (Arrighi et al., 1999), (Vanheusden et al., 2007). After the four-day 
expansion period, the HSPCs were sorted based on their GFP reporter protein expression by 
FACS. However, despite many attempts only maximum of ~9% of transduction efficiency was 
achieved (Figure 3.8). 
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Figure 3.8 – miR-30 based shRNA lentiviral vector has low infectivity potential of human HSPCs. 
Representative dot plot of human CB CD34+CD38- cells transduced with the miR-30 lentiviral vector at 
MOI 50. At day 4 post-transduction, the cells were analysed for their GFP expression. 
Hence, even though miR-30 based strategies have been employed to transduce murine LSK 
cells (Wang et al., 2012), (Holmfeldt et al., 2016) and more recently human haematopoietic 
progenitor cells (Xiao et al., 2019) at high efficiencies, this reveals that this specific construct 
is not a good option for human HSPCs or may need further optimisation. Importantly, this miR-
30 based system also inefficiently transduced HSPCs when shRNA sequences targeting 
different genes were used (data not shown), indicating that this is not exclusive to Nicastrin 
knockdown. At this point, a different shRNA-mediated silencing method was sought out to 
carry out the remaining work. 
3.4.2 Silencing of NCSTN using an H1 promoter-driven shRNA system
To circumvent the previous issue, a system using the well-established H1 promoter-driven 
shRNA expression was utilised (Hannon and Rossi, 2004). The H1 promoter drives the 
expression of the shRNA sequence of interest while GFP is controlled by the EF1α promoter 
(Figure 3.9). The same sequences tested in the pre-miR30 system were used. The shRNA 
sequences were cloned into the pENTR4 plasmid. Afterwards, the pENTR4-H1 constructs 
now carrying the shRNAs, were recombined with the destination vector CS-RfA-EG by 
gateway cloning, generating the final products. HEK293T cells were once more used to assess 
knockdown potential. 
Figure 3.9 – Schematic representation of the CS-shRNA lentiviral construct. The H1 promoter 
drives the expression of the shRNA. The EF1α promoter controls the expression of the GFP reporter 
protein.
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After transducing HEK293T cells with the various constructs, these were cultured for 8 days. 
At this point, the cells were analysed by FCM to measure GFP expression, and in parallel, 
both protein and RNA were extracted. GFP expression was found in more than 90% of cells 
analysed (data not shown) after transduction. A greater than 90% decrease in the protein 
(Figure 3.10 A and B) and mRNA (Figure 3.10 C) levels were observed for both shNCSTN-
1 and shNCSTN-3. Following validation in the HEK293T cell line, HSPCs were transduced 
with the lentiviral constructs at a MOI of 50. In contrast to the low infectivity potential from 
miR30-based viral particles, the transduction efficiency using the CS-shRNA system was 
significantly higher (Figure 3.11) and was used for the remaining work. 
Figure 3.10 – The CS-shRNA lentiviral construct yields potent Nicastrin knockdown in HEK293T 
cells. (A) Representative western blot of shRNA-mediated knockdown of the Nicastrin protein. 
Quantification of (B) protein and (C) mRNA knockdown of Nicastrin. Results shown are the mean ± SD 
(n=4). Unpaired t-test. ***p<0.0005.
Figure 3.11 – The CS-shRNA lentiviral vector yields high transduction efficiency in human 
HSPCs. CD34+ HSPCs were enriched from MNCs which were then FACS sorted based on CD34 and 
CD38 expression. After transduction, GFP+ HSPCs were FACS sorted 4 days post-transduction.  
98
3.5 Pan-Notch inhibition leads to HSC pool depletion and perturbed 
myeloid/lymphoid balance in vitro
Following GFP+ HSPCs selection (transduction efficiencies obtained were up to ~50%) a 
fraction of the cells was co-cultured along with murine stromal MS5 cells to initiate the LTC-IC 
assay to address the role of Notch in human HSPCs ex vivo (Figure 3.12). 
Figure 3.12 – Schematic representation of workflow. HSPCs were isolated from mononuclear cells 
by sorting CD34+CD38- cells which were then transduced with lentivirus at MOI 50. GFP+ HSPCs (as 
exemplified in Figure 3.10) were sorted 4 days following transduction and co-cultured with MS5 stromal 
cells for 5 weeks, following by methylcellulose sub-culturing for a further 2 weeks to measure the colony 
output of the LTC-IC assay.
The remaining cells were cultured for an additional 8 days in StemSpan containing SCF, 
FLT3L and TPO. At the end of this period, the number of cells in each condition was monitored 
throughout the culture. The Nicastrin-knockdown (Nicastrin-KD) HSPCs divided at a similar 
rate to the control cells, indicating that the constructs had no apparent toxic effects to the cells 
(Figure 3.13). 
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Figure 3.13 – Nicastrin-KD HSPCs proliferate at a similar rate to control cells. The number of cell 
doublings from day 4 to day 12 of HSPCs expansion was evaluated. Each dot represents an 
independent experiment and the bars are the mean of the values.  
In addition, knockdown efficiencies were determined at day 12 of the culture at the mRNA and 
protein levels. While the shNCTSN-1 construct yielded a knockdown of ~50%, shNCSTN-3 
consistently resulted in almost 100% knockdown, as determined by FCM analysis (Figure 
3.14 A and B). Also, a reduction of approximately 55% and 65% of the NCSTN gene was 
achieved with shNCSTN-1 and shNCSTN-3, respectively (Figure 3.14 C). 
Figure 3.14 – The CS-shRNA lentiviral vector imparts potent Nicastrin knockdown in human 
HSPCs. (A) Representative histogram demonstrating Nicastrin knockdown. Quantification of Nicastrin 
(B) protein knockdown by FCM and (C) mRNA levels. Results shown are the mean ± SD (n=4-5).
Unpaired t-test. ***p<0.0005.
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A portion of the sorted GFP+ HSPCs were tested under the LTC-IC assay. The cultures were 
maintained for a total of 5 weeks. It is well established that during this assay, HSPCs migrate 
underneath the stromal feeder layer which supports HSPCs survival and maintenance. 
Primitive cells present in the mix are then able to divide and generate cobblestone-resembling 
colonies. First, both HSPCs and murine MS5 cells were harvested and analysed for the 
expression of GFP. We observed a trend suggesting a reduction in the frequency of human 
cells generated in the Nicastrin-KD conditions at the end of assay, which is suggestive of a 
diminished capacity to maintain primitive cells when Notch pathways was inhibited (Figure 
3.15).
Figure 3.15 – Silencing of NCSTN reduces total human haematopoietic cell output in LTC-IC 
assay. Frequencies of GFP+ cells in the total number of cells present at the end of the LTC-IC assay. 
The data represents the combination of preliminary optimisation and subsequent validated experiments 
(n=5).  
An impaired increase in the number of CAFCs was detected at the various cell dosages, with 
significant reduction in the shNCSTN-3 condition (Figure 3.16). 
Figure 3.16 – Nicastrin-KD HSPCs have defective CAFC capacity. (A) Total number of CAFCs 
generated at 4 weeks after HSPCs seeding and (B) number of CAFCs generated at various cell doses
at 4 weeks after seeding. The results are the mean ± SD (n=3). Unpaired t-test. *p<0.05; **p<0.005.
101
This data also suggests a dose dependent effect of the Notch inhibition and demonstrates that 
Notch is essential for the long-term maintenance of cells with primitive features in vitro. 
However, this data does not prove impaired differentiation potential. Hence, at the end of the 
five-week co-culture period, the cells were harvested and re-plated onto methylcellulose for 
an additional two weeks to measure the number of differentiated progenies generated from 
LTC-ICs that remained in culture (Figure 3.17). At the end of the LTC-IC assay, progenitors 
present in the initial suspension had differentiated and died off.  
Figure 3.17 – Nicastrin-KD HSPCs have defective LTC-IC derived CFU capacity. (A) The total 
number of CFUs generated two weeks after re-plating in methylcellulose (B) and the number of CFUs 
generated at the corresponding cell dose. The results are the mean ± SD (n=3-4). Unpaired t-test.
*p<0.05; **p<0.005.
Therefore, this measures the capacity of more primitive cells that were retained in the five-
week culture period to generate differentiated progenies. We observed an almost 2-fold 
reduction in the total number of colonies in both conditions (Figure 3.17 A) compared to the 
control – an effect which was especially evidenced at the higher cell dose (Figure 3.17 B). 
Indeed, a decrease of approximately 50% and 65% was observed in the number of colonies 
generated in the shNCSTN-1 and shNCSTN-3 conditions compared to the control, 
respectively (Figure 3.17 B).
To complement this functional assay, the remaining cells were characterised 
immunophenotypically at the end of the LTC-IC assay. A fraction of the cell suspension was 
stained with a panel of antibodies aimed at the detection of primitive populations and analysed 
by FCM (Figure 3.18).
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Figure 3.18 – Cell-autonomous Notch inhibition leads to reduced HSC compartment in vitro. (A) 
Representative dot plot of stem and progenitor cell frequencies. The cells were gated on the 
GFP+CD34+CD38- compartment. (B) Quantification of stem and progenitor cell frequency in control and 
Nicastrin-KD HSPCs. The results are the mean ± SD (n=3). Unpaired t-test. *p<0.05.
Hence, by gating on GFP+CD34+CD38- cells, the frequencies of the three most primitive cells 
compartments were analysed. In support of the effects observed, we detected a greater than 
4-fold and 5-fold decrease in the frequency of phenotypic HSCs in shNCSTN-1 and shNCSTN-
3 conditions compared to shLuc, respectively (Figure 3.18 A and B). The reduction of HSCs 
appeared to have left the balance of downstream progenitors unaffected.  Nonetheless, a 
trending increase in the MLP/LMPP compartment was observed in Nicastrin-KD HSPCs. Due 
to the large variation in the frequencies of CD38+ progenitors (including CMPs, GMPs and 
MEPs) among the three independent experiments that would prevent a more rigorous 
analysis, these subpopulations were grouped in the larger collective CD38+ population which 
revealed to be at comparable frequency to the control group. Nevertheless, the significant 
reduction in CAFCs and LTC-IC-derived CFUs observed could be mostly accounted for by the 
reduced HSCs frequencies (and total numbers, given the reduction in the total human GFP+
cells generated - Figure 3.15) when Notch signalling was reduced. In addition to this, another 
fraction of cells was stained with a panel of antibodies that allowed the detection of 
differentiated cells. The LTC-IC assay has been modified over the years, initially confined to 
the support of granulocyte and macrophage differentiation (Dexter et al., 1977) and it was later 
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modified to support broad myeloid and B cell differentiation (Berardi et al., 1997). T-cell 
differentiation requires a different co-culture system (La Motte-Mohs et al., 2005) and therefore 
was not analysed. By excluding primitive CD34+ cells from the analysis, more mature progeny 
could be detected based on various markers. CD19 is an early B cell marker. Monocytes can 
be detected in the CD19-CD33+CD14+ fraction. Within the CD33+CD14-CD11c+ compartment 
we can find DC-like cells. NK cells are the CD56+ cells within the CD14-CD11c- fraction (Figure 
3.19 A). 
Figure 3.19. Nicastrin-KD HSPCs are skewed toward lymphoid development in vitro. (A) 
Representative dot plot of the differentiated fractions. Top row: CD19+ B-cells and CD19- cells could be 
found in the CD34- compartment. The CD19- can be divided into DC-like cells, monocytes or other cells. 
CD14-CD11c- cells can be NKs based on CD56 expression, or other myeloid precursors based on CD33 
expression. Bottom three rows: representative dot plots for the conditions examined. (B) Quantification 
of myeloid versus lymphoid potential in the various conditions. (C) Quantification of non-CD19+ cells 
present in the CD34- population. Results are the mean ± SD (n=3). Unpaired t-test. *p<0.05; **p<0.005; 
***p<0.0005.
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Notably, the balance between myeloid and lymphoid cells was perturbed by NCSTN silencing 
(Figure 3.19 B). Both Nicastrin-KD conditions had an increase in the lymphoid (CD19+ B cell) 
compartment with concomitant reduction of the CD33+ myeloid cells (Figure 3.19). Within non-
CD19+ compartment, a small reduction in the frequency of CD56+ cells was observed in the 
shNCSTN-1 condition.
3.6 Pan-Notch inhibition leads to a depleted HSC pool in a cell-autonomous 
manner in vivo
Lastly, to address whether the effects of pan-Notch inhibition in vivo were cell-autonomous, 
HSPCs were transduced with the shLuc or the shNCSTN-3 constructs. The latter was chosen 
over shNCSTN-1 given its stronger silencing efficiency. Following expansion and selection of 
HSPCs, 3800 to 5000 of FACS sorted GFP+ HSPCs were injected intravenously into sub-
lethally irradiated NSG mice. Twelve weeks after the transplantation, the recipients were 
sacrificed, and the bone marrows from three pairs of bones (tibiae, femurs and ileum) were 
analysed (Figure 3.20). 
Figure 3.20 – Schematic representation of workflow. Human HSPCs isolated from CB MNCs were 
transduced with shRNA-carrying lentivirus constructs. Following selection and expansion of GFP+
HSPCs, sub-lethally irradiated NSG mice were transplanted with the cells. Twelve weeks post-
transplantation, the animals were sacrificed, and their BMs were analysed.
The flushed bone marrows were depleted of red blood cells. After that, the whole suspensions 
were stained with the HSPCs or differentiation antibody panels, and the outcomes were 
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analysed by FCM. Engraftment after xenotransplantation assays is usually done by the 
detection of human CD45+CD33+ and CD45+CD19+ which represents myelo-lymphoid 
engraftment. In this project, the transplanted HSPCs express the GFP reporter protein 
constitutively, and the measurement of GFP+CD33+ and GFP+CD19+ was used as an 
indication of the engraftment in the recipient animals. The shNCSTN-3 cohort had a 3-fold 
reduction in the myelo-lymphoid engraftment compared to that of the control, although this did 
not reach statistical significance due to the variability obtained (Figure 3.21).  
Figure 3.21 – Nicastrin-KD HSPCs have a reduced human myelo-lymphoid engraftment capacity. 
(A) Representative example of FCM analysis of Nicastrin-KD HSPCs. Live cells were gated on the 
GFP+ population. (B) The sum of the frequencies of CD19+ (Lymphoid) and CD33+ (Myeloid) cells in 
GFP+ cells are shown. Each dot represents a mouse and the bar is the median of the values (n=7 for 
the shLuc cohort; n=9 for the shNCSTN-3 cohort). Mann-Whitney test.
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Next, the frequencies of stem and progenitor cells in each cohort were measured. 
Representative dot plots showing the gating strategy can be found in Figure 3.22. A significant 
5-fold reduction in the HSC fraction was found, while all other progenitor compartments 
remained largely unchanged (Figure 3.22 B). 
Figure 3.22 – NSG mice transplanted with Nicastrin-KD HSPCs have a reduced HSC 
compartment. (A) Representative dot plot of gating strategy for stem and progenitor cells with 
representative dot plots of shLuc and shNCTSN-3-transplanted NSG mice. (B) Quantification of stem 
and progenitor cells in the various conditions. Each dot represents a mouse. The bar is the median of 
the values (n=5 in the shLuc cohort; n=7 in the shNCSTN-3 cohort). Mann-Whitney test. **p<0.005
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The reduction of HSCs observed was consistent with the previous observations when 
pharmacological inhibition of Notch was employed in vivo (Figure 3.4 C) or shRNA mediated 
NCSTN silencing in vitro (Figure 3.18). This reinforces the notion that Notch is necessary for 
the maintenance of haematopoietic homeostasis and that its inhibition strongly affects the 
most primitive stem cell compartment. Interestingly, the effects seen are less striking than 
those previously observed with pharmacological inhibition of Notch. Even though we should 
be cautious with the direct comparison of the two approaches given their technical differences, 
this may be due to the nature of the experiments. DAPT, while being administered to the whole 
animal has the potential to affect all cells in the niche. On the other hand, cell autonomous 
inhibition of Nicastrin ensures Notch inhibition confined to the stem and progenitor cell 
compartment. Additionally, even though we observed a decrease in the total myelo-lymphoid 
engraftment from Nicastrin-KD cells, this did not translate into deregulated myeloid versus 
lymphoid balance, nor did it affect the frequencies of myeloid cells in vivo (Figure 3.23 B and 
C).
108
Figure 3.23 - NSG mice transplanted with Nicastrin-KD HSPCs have normally differentiated 
progenies. (A) Representative dot plot of gating strategy for stem and progenitor cells with 
representative dot plots of shLuc and shNCTSN-3-transplanted NSG mice. (B) Quantification of mature 
cells in the various conditions. Each dot represents a mouse (n=7 in the shLuc cohort; n=9 in shNCSTN-
3 cohort). Mann-Whitney test. The bar is the median of the values.
3.7 Discussion
Firstly, Notch signalling was shown to be highly expressed and active in various human 
haematopoietic stem and progenitor cell fractions. This agrees with early studies that first 
demonstrated Notch expression in human CD34+Lin- cells (Milner et al., 1994) which were 
later confirmed by others in both CD34- and CD34+ HSCs (Anjos-Afonso et al., 2013). Since 
then, Notch has been postulated as a regulator of human HSPCs self-renewal and 
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differentiation (Lauret et al., 2004), (Delaney et al., 2005). While canonical Notch signalling in 
murine BM cells appears to be dispensable in vivo (Maillard et al., 2008), whether Notch plays 
a role in human HSPCs in vivo remains unanswered. Benveniste et al., have suggested 
human HSPCs require Notch signalling in vitro but not in vivo (Benveniste et al., 2014). 
However, a close inspection of the authors’ results could infer a different interpretation. First, 
the percentage of the dnMAML1-HSC population within the human graft was half of that of the 
control. Second, the total number of dnMAML1 engrafted cells was more than double 
compared to controls. Given this, the authors concluded that the total number of engrafted 
dnMAML1 HSCs was unchanged relative to control HSCs in vivo (Benveniste et al., 2014). 
However, it can be interpreted that it did, as the frequency of dnMAML1 HSCs was reduced 
with a concomitant increase in total differentiated human cells. Here, employing a pan-Notch 
inhibition approach by using DAPT resulted in a significant reduction of various stem and 
progenitor cell compartments, including the HSC fraction. Pharmacological inhibition of Notch 
using DAPT non-selectively blocks the processing of all Notch receptors, as well as other γ-
secretase substrates (CD44, ErbB4 among many others (Jurisch-Yaksi et al., 2013)). Non-
haematopoietic cells in the bone marrow niche have been shown to express Notch ligands
(Calvi et al., 2003), (Guezguez et al., 2013) and through them, regulate haematopoietic cells 
in the microenvironment. To address whether these outcomes were cell-autonomous, we 
challenged HSPCs with knockdown of the NCSTN gene (Nicastrin-KD HSPCs) under various 
assays in vitro. A miR-30 based shRNA-mediated silencing lentiviral construct was briefly 
tested for its capacity to block Notch processing. However, this system yielded very poor 
transduction efficiency in primitive human haematopoietic cells. To circumvent this issue, an 
H1 promoter-driven system was used instead which yielded very strong transduction and 
silencing efficiency. 
The LTC-IC assay is the in vitro surrogate for xenotransplantation studies and challenges stem 
cells. The significant reduction (~60%) in the total number of CAFCs generated in vitro
indicates the importance of Notch signalling in the maintenance of primitive cells. When re-
plated onto differentiation-inducing conditions we noticed once more a significant reduction in 
the total number of colonies generated reinforcing the notion that physiological levels of Notch 
are fundamental for primitive cells with differentiation capacity ex vivo. Next, we carried out 
immunophenotypic analysis of the cells generated at the end of the LTC-IC assay. 
Interestingly, when assessing the frequency of HSPCs and differentiated cells at the end of 
the assay, a reduction in the HSC pool was found. A trending increase in the frequency of 
MLP/LMPP cells may be suggestive of the idea that there is differentiation of HSCs towards 
more committed progenitors. A fraction of those HSCs could also have undergone cell death 
as a result of Notch inhibition, although this was not observed (Anjos-Afonso et al, 2013) and 
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(Anjos-Afonso, personal observations). Additionally, a lower frequency of CD33+ cells was also 
observed in Nicastrin-inhibited conditions in vitro. Of note, to formally test the various 
subpopulations detected under this assay, the cells should be harvested, sorted and rigorously 
tested for their true potential. Importantly, most of what is known about the role of Notch on 
HSPCs derives from gain-of-function studies, whereby Notch ligand stimulation or 
overexpression of NICD are employed. To the best of our knowledge, this is the first report 
showing the requirement for Notch signalling in human HSPCs in vitro by using a loss-of-
function approach.
Lastly, to complement the in vitro functional characterisation of Notch-KD cells, shLuc or 
shNCSTN-3-transduced HSPCs were transplanted into NSG mice to gauge their potential in 
vivo. At 12 weeks post-transplantation, the HSC compartment was markedly reduced in NSG 
mice transplanted with Nicastrin-KD HSPCs (5-fold decrease compared to the control). We 
have previously shown that all stem and progenitor cell fractions expressed Notch receptors 
and possessed an active pathway. Pharmacological inhibition of Notch signalling most likely 
affected all those fractions to different extents which resulted in larger impact in many cell 
compartments. On the other hand, by inhibiting Notch in CD34+CD38- the effects are initially 
confined to a smaller fraction of cells which are potentially extended to their immediate 
progeny later. Indeed, the 5-fold reduction in the frequency of HSCs in the Nicastrin-KD 
condition (that was equal to 15-fold in the total HSC pool) resulted in a total 3-fold reduction 
in total human engraftment, affecting equally all the lineages. Regarding the role of Notch 
signalling in the differentiation of haematopoietic cells, in vitro studies have yielded conflicting 
results. While some have argued that Notch signalling promotes myeloid differentiation (Tan-
Pertel et al., 2000), (Schroeder et al., 2003), other studies have reported opposite effects, 
where Notch signalling indeed decreases myeloid potential (Milner et al., 1996), (de Pooter et 
al., 2006). It should be noted that most of these studies employed cell lines, which may not 
faithfully represent the behaviour of primary cells. On the other hand, in vivo studies have 
clearly established the role for Notch1 in T cell development (Radtke et al., 1999). More 
recently, it was shown to induce megakaryocyte development in vitro and in vivo (Mercher et 
al., 2008). In our study, even though we observed a lower frequency of CD33+ cells in vitro, 
this effect was not evident in vivo. This could be due to the myeloid-bias nature of the LTC-IC 
which is better to reveal myeloid output variations as compared to the in vivo assay, which is 
biased toward lymphoid development. Still, the reduction of HSC frequency in all the assays 
performed indicates the requirement for Notch signalling in the maintenance of phenotypically 
defined HSCs both in vitro and in vivo. Yet. to confirm true impairment on stem cell activity, 
secondary transplantation into new recipients should be performed. Additionally, assuming 
Notch signalling maintains a quiescent and immature cell state, the cell cycle regulation of 
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cells recovered from these mice could be analysed. This would inform on the percentage of 
cells that exited the G0 phase of the cell cycle. Importantly, we observed differential Notch 
receptor activation in various HSPC compartments. To understand which receptor is 
responsible for the outcomes observed, knockdown of the individual receptors could be 
performed (which is an ongoing project in the lab). Collectively, these data indicate Notch 
signalling is active in haematopoietic stem and progenitor cells. Its inhibition by 
pharmacological or shRNA-mediated silencing of key Notch components results in 
destabilised primitive haematopoietic cell compartments, with exceptional effect on HSCs both 
in vitro and in vivo. The NICD has been shown to interact with molecules from many of the 
major signalling pathways. Hence, the effects described could partially be the result of 
impaired non-canonical Notch signalling. To address this subject, the Notch transcriptional co-
activator RBPJκ molecule was silenced causing disruption of canonical Notch signalling 
exclusively. This is described in Chapter 4.
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Chapter 4 - Exploring the roles of canonical 
Notch signalling in human HSPCs
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4.1 Brief introduction
Canonical Notch signalling requires cell-cell interactions to be activated in a ligand- and 
RBPjκ-dependent manner. Non-canonical Notch signalling can be independent from RBPjκ 
and/or ligand-mediated activation. Notch receptors can interact with components of the major 
signalling pathways such as PI3K, AKT, mTORC2, Wnt, NFκβ, YY1 and HIF1α (Bigas and 
Espinosa, 2016), (Colombo et al., 2019). Although the functions of non-canonical Notch 
signalling have not been properly elucidated, some believe it may comprise a more efficient 
way to carry out cell-specific functions by activating specific transcription factors (Sanalkumar 
et al., 2010). As an example, Delta1 ligand was shown to activate STAT3 in CD34+ cells and 
cause the loss of membrane bound IL-6 receptor through not yet defined mechanisms. The 
loss of IL-6 cis-signalling skewed the cells away from myeloid differentiation (Csaszar et al., 
2014). Additionally, in the murine haematopoietic system, Notch signalling specifies T- or B
cell commitment at the CLP stage (Wilson et al., 2001). RBPJκ/NICD-mediated signalling is 
required for T cell maintenance and differentiation (MacDonald et al., 2001), (De Smedt et al., 
2002), (Han et al., 2002). On the other hand, a RBPjκ-independent Deltex-mediated 
mechanism inhibits expression of the E47 transcription factor that is required for B cell 
development (Bain et al., 1997), (Ordentlich et al., 1998), (Han et al., 2002). As explained in 
Chapter 1, RBPjκ interacts with NICD, MAML1 and other co-activators to initiate canonical 
Notch signalling. Disruption of the canonical Notch pathway has been achieved by deleting 
Rbpj in mouse models (Maillard et al., 2008), (Duarte et al., 2018), or by expressing a dominant 
negative form of Xenopus suppressor of hairless (dnXSu(H) – the xenopus homolog of CBF-
1) (Duncan et al., 2005), or by expressing a dominant negative form of MAML1 (dnMAML1)
(Maillard et al., 2008), (Benveniste et al., 2014). The outcomes of these studies were varied. 
Whereas some have reported no role for the canonical Notch signalling in murine BM cells in 
vivo (Maillard et al., 2008) , (Duarte et al., 2018) others have shown a depletion of LT-HSCs
(Duncan et al., 2005). In the human haematopoietic system, Benveniste and colleagues 
suggested a differential need for Notch in vitro and in vivo (Benveniste et al., 2014). 
Conversely, Anjos-Afonso et al., have reported Notch activity in very primitive CD34- HSCs 
which produce more CD34+CD38- progeny upon Notch inhibition (Anjos-Afonso et al., 2013). 
As described in Chapter 3, disruption of pan-Notch signalling through pharmacological or 
shRNA-mediated methods resulted in deregulation of stem and progenitor cells 
compartments, with a particularly drastic reduction in HSC numbers and impairment of HSC 
repopulating capacity. Here, we focus on addressing the specific role of canonical Notch 
signalling by silencing the RBPJ gene which encodes for the essential Notch co-activator 
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RBPjκ. Importantly, the differential roles of the canonical and non-canonical Notch signalling 
pathway in human HSPCs have not been addressed.
Aims of Chapter 4
- Block canonical Notch signalling in HSPCs by using shRNA lentiviral vectors that 
inhibit the expression of RBPJ – an essential canonical Notch co-activator.
- Assess in vitro effects of canonical Notch inhibition by measuring colony-forming and 
differentiation capacity under the LTC-IC assay.
- Assess in vivo effects of canonical Notch inhibition by measuring myelo-lymphoid 
engraftment and frequencies of stem/progenitor and mature cells.
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4.2 shRNA-mediated silencing of RBPJ in human HSPCs
4.2.1 Testing a miR-30-based shRNA system in human HSPCs
The miR30-based system previously cloned and tested in HSPCs was also investigated for its 
ability to silence the RBPJ in the HEK293T cell line. This was performed concurrently when 
this system was tested for NCSTN silencing. Despite achieving very efficient silencing of RBPJ
in HEK293T cells (Figure 4.1), this construct was again unable to efficiently transduce human 
HSPCs (Figure 4.2).
Figure 4.1 – shRNA-mediated knockdown of RBPjκ in HEK293T cells. (A) Representative WB of 
shRNA mediated knockdown of the RBPjκ protein. Quantification of (B) protein and (C) mRNA 
knockdown of RBPJ. Results are the mean ± SD (n=4). Unpaired t-test. **p<0.005; ***p<0.0005. 
Figure 4.2 – miR-30 based shRNA lentiviral vector has low infectivity potential in human HSPCs.
Representative dot plot of human CB CD34+CD38- cells transduced at MOI 50 with the miR-30 lentiviral 
vector carrying a shRNA sequence targeting RBPJ. At day 4 post-transduction, the cells were analysed 
for GFP expression. 
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This indicates that the poor transduction efficiencies obtained were likely to be due to an 
intrinsically low ability of this specific construct to transduce primary primitive haematopoietic 
cells.
4.2.2 shRNA-mediated silencing of RBPJ using an H1 promoter-driven shRNA 
system
Given the poor efficiency of the miR-30 based system to transduce human HSPCs, the H1 
promoter-driven shRNA system was again used for the remaining work. HEK293T cells were 
successfully transduced with the various constructs and showed a larger than 97% GFP 
expression 8 days post-transduction (Figure 4.3). 
Figure 4.3 – HEK293T cells transduced with CS-shRNA constructs. HEK293T cells were analysed 
for their GFP expression 8 days post-transduction with CS-shRNA constructs. 
Out of three sequences tested, the constructs termed shRBPJ-2 and shRBPJ-3 resulted in
approximately 95% reduction of protein levels from both constructs as assessed by WB 
(Figure 4.4 A and B), and 80% and 90% reduction of RBPJ mRNA levels, respectively (Figure 
4.4 C).
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Figure 4.4 – The CS-shRNA lentiviral constructs induce potent RBPjκ knockdown in HEK293T 
cells. (A) Representative western blot of shRNA-mediated knockdown of the RBPjκ protein. 
Quantification of (B) protein and (C) mRNA knockdown of RBPJ. Results shown are the mean ± SD 
(n=4). Unpaired t-test. **p<0.005; ***p<0.0005.
4.3 Silencing of RBPJ results in reduced HSC compartment and perturbed B 
cell output in vitro
After validation of the constructs in the HEK293T cells, human HSPCs were transduced with 
the various lentiviral vectors at a MOI of 50. In contrast to the miR30-based system, the CS-
shRNA constructs yielded high transduction efficiencies in human HSPCs (Figure 4.5).
Figure 4.5 – The CS-shRNA lentiviral vector efficiently transduces human HSPCs. SSC-A – Side 
Scatter-Area; GFP – Green Fluorescent Protein. 
A reduction of 63% and 80% of RBPJ mRNA levels was achieved by using shRBPJ-2 and 
shRBPJ-3, respectively (Figure 4.6). 
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Figure 4.6 – The CS-shRNA lentiviral vector imparts potent RBPJ knockdown in human HSPCs.
Quantification of RBPJ mRNA by qRT-PCR. Results shown are the mean ± SD (n=3). Unpaired t-test.
***p<0.0005.
Importantly, RBPJκ-knocked down (RBPJ-KD) cells proliferated largely at comparable rate 
without significant difference to control cells (Figure 4.7). 
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Figure 4.7 – RBPJ-KD HSPCs proliferate at a similar rate to control cells. The number of cell 
doublings from day 4 to day 12 of HSPCs expansion was plotted. Each dot represents an independent 
experiment and the bars are the mean of the values.  
Then, at four days post-transduction GFP+ HSPCs were sorted by FACS and challenged 
under the LTC-IC assay. At the fourth week of the assay, we observed a greater than 5-fold 
and 8-fold reduction in the total number of CAFCs generated in the shRBPJ-2 and shRBPJ-3 
conditions, respectively as well as in the number of colonies generated at different cell doses 
(Figure 4.8). This was the same outcome that was observed in Nicastrin-KD HPSCs which 
suggests that Nicastrin acts via RBPjκ to maintain primitive cells in vitro. 
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Figure 4.8 – RBPJ-KD HSPCs have defective CAFC capacity. (A) Total number of CAFCs generated 
at 4 weeks after HSPCs seeding and (B) number of CAFCs generated at various cell doses at 4 weeks 
after seeding. Both shRBPJ-2 and shRBPJ-3: p<0.0005. The results are the mean ± SD (n=4). Unpaired 
t-test. ***p<0.0005.
Accordingly, we also observed a strong 10-fold and 20-fold reduction in the number of LTC-
IC-derived CFUs generated in shRBPJ-2 and shRBPJ-3 HSPCs, respectively (Figure 4.9).
Figure 4.9 – RBPJ-KD HSPCs have defective LTC-IC derived CFU capacity. (A) The total number 
of CFUs generated two weeks after re-plating in methylcellulose (B) and the number of CFUs generated 
at the corresponding cell dose. Both shRBPJ-2 and shRBPJ-3: p<0.0005. The results are the mean ± 
SD (n=4). Unpaired t-test. ***p<0.0005.
A linear increase in the number of LTC-IC derived colonies can be seen in the control condition 
with increased number of cells seeded, which is almost completely abolished in the RBPJ-KD 
conditions (Figure 4.9 B) suggesting an almost complete loss of cells with primitive features 
in these cases. These data indicate that the reduction in LTC-IC activity observed among 
Nicastrin-KD HSPCs was at least in part due to impaired canonical Notch signalling. 
To address the effects of RBPJ silencing in HSPCs in vitro, the cells were harvested at the 
end of the LTC-IC assay and analysed by FCM. We observed a significant 2.8-fold and 2.4-
fold reduction in the number of human cells generated in the shRBPJ-2 and shRBPJ-3 
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conditions at the end of assay, respectively (Figure 4.10). This indicates the cells were 
depleted during the assay when canonical Notch signalling was compromised.
Figure 4.10 – Silencing of RBPJ reduces total human haematopoietic cell output in LTC-IC assay. 
Frequencies of GFP+ cells in the total number of cells present at the end of the LTC-IC assay. Each dot 
or triangle represents one experiment. The bar is the mean ± SD (n=5). Unpaired t-test. *p<0.05; 
**p<0.005.
Additionally, a 6-fold and 3-fold decrease in the HSC frequency was observed in shRBPJ-2 
and shRBPJ-3 transduced cells, respectively (Figure 4.11). This was accompanied by an 
increase in the frequency of subsequent progenies (e.g. increase in MPPs in shRBPJ-3 or in 
MLP/MLPPs in shRBPJ-2 transduced cells - see Figure 4.11 B), which again is suggestive of 
enforced differentiation from HSCs.
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Figure 4.11 – RBPJ inhibition leads to reduced HSC compartment in vitro. (A) Representative dot 
plot of stem and progenitor cell frequencies. The cells were gated on the GFP+CD34+CD38-
compartment. (B) Quantification of stem and progenitor cell frequency in control and RBPJ-KD HSPCs. 
Results are presented as mean ± SD (n=3). Unpaired t-test. *p<0.05.
Another fraction of cells was analysed for the expression of differentiation markers instead. 
Interestingly, a shift towards myeloid cell development was observed in RBPJ-KD cells, 
whereby an almost complete suppression of B cell development was observed (Figure 4.12
B). A deeper look into the non-CD19+ compartment revealed deregulation of other mature cell 
types such as DCs and NKs (Figure 4.12 C). These perturbations were different than the ones 
observed upon NCSTN silencing, perhaps hinting at RBPJκ-independent mechanisms being 
also at play.
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Figure 4.12. RBPJ-KD HSPCs have impaired B cell development in vitro. (A) Representative dot 
plot of the differentiated fractions. Top row: CD19+ B-cells and CD19- cells could be found in the CD34-
compartment. The CD19- can be divided into DC-like cells, monocytes or other cells. CD14-CD11c- cells 
can be NKs based on CD56 expression, or other myeloid precursors based on CD33 expression. 
Bottom row: representative dot plots for the control condition. (B) Quantification of lymphoid and myeloid 
cell compartments present in the CD34- population. (C) Quantification of non-CD19+ cells present in the 
CD34- population. Results are presented as mean ± SD (n=3). Unpaired t-test. *p<0.05; **p<0.005; 
***p<0.0005. 
4.4 Silencing of RBPJ results in reduced HSCs and reduced B cell output in 
vivo
At last, to address the effects of canonical Notch inhibition in vivo, shLuc or shRBPJ-3-
transduced HSPCs were injected into NSG mice. Mouse bone marrows were harvested at 12 
weeks post-transplant. shRBPJ-3 was favoured over shRBPJ-2 due to its stronger silencing 
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efficiency.  A 68-fold decrease in the percentage of myelo-lymphoid engraftment was observed 
in RBPJ-KD cell recipients (Figure 4.13), demonstrating the significant deficiency on 
repopulating capacity that impaired canonical Notch signalling imparts. 
Figure 4.13 – NSG mice transplanted with RBPJ-KD HSPCs have reduced human (GFP+) myelo-
lymphoid engraftment. (A) Representative example of FCM analysis of engraftment. Live cells were 
gated on the GFP+ population then verified for the presence of CD33+ and CD19+ cells in both 
conditions. (B) The sum of the frequencies of CD19+ (Lymphoid) and CD33+ (Myeloid) cells in GFP+
cells are shown. Each dot represents a mouse and the bar is the median of the values (n=7 for the 
shLuc cohort; n=10 for the shRBPJ-3 cohort). Mann-Whitney test. **p<0.005.
Of note, due to the very low engraftment obtained in mice transplanted with RBPJ-KD HSPCs,
this hampered a proper phenotypic analysis of the engrafted primitive sub-populations. 
Nevertheless, from the few mice that we were able to acquire enough events, we observed,
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so far, a 2-fold reduction of the HSC population frequency at 12 weeks post-transplantation 
(Figure 4.14). 
Figure 4.14 – NSG mice transplanted with RBPJ-KD HSPCs have a reduced HSC compartment. 
(A) Representative dot plot of gating strategy for stem and progenitor cells with representative dot plots 
of shLuc and shRBPJ-3-transplanted NSG mice. (B) Quantification of stem and progenitor cells in the 
various conditions. Each dot represents a mouse (n=5 for the shLuc cohort; n=3 for the shRBPJ-3 
cohort). Mann-Whitney test. The bar is the median of the values. 
When assessing the effects on differentiation, we observed a drastic deficiency in B cell 
development from RBPJ-KD cells (Figure 4.15 B). In addition to this, a significant increase in 
the frequencies of CD14+ monocytes and CD11+ DCs was also be observed (Figure 4.15 C).
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Figure 4.15 - NSG mice transplanted with RBPJ-KD HSPCs have impaired B cell development in 
vivo. (A) Representative dot plot of gating strategy for stem and progenitor cells with representative dot 
plots of shLuc and shNCTSN-3-transplanted NSG mice. (B) Quantification of mature cells in the various 
conditions within GFP+CD45+ cells. Each dot represents a mouse (n=8 for the shLuc cohort; n=7 for the 
shRBPJ-3 cohort). The bar is the median of the values. Mann-Whitney test. *p<0.05.
4.5 Discussion
A miR30-based lentiviral system was tested for its ability to silence target gene expression in 
human HSPCs. However, this system yielded poor transduction efficiencies in this cell type 
irrespective of the shRNA sequences used. The CS-shRNA lentiviral vector was used instead 
which efficiently transduced human HSPCs and elicited potent knockdown of Notch target 
genes. 
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Blocking Notch signalling by expressing dnMAML1 or by conditional deletion of Rbpj had no
impact on the preservation of mouse HSC function following transplantation into irradiated 
recipients (Maillard et al., 2008), (Duarte et al., 2018). Additionally, Varnum-Finney and 
colleagues have not reported a role for Notch1 or Notch2 in murine haematopoiesis during 
homeostasis (Varnum-Finney et al., 2011). On one of the few studies carried out in the human 
haematopoietic system, Benveniste and colleagues have reported blocked in expansion of 
HSCs in vitro when dnMAML1 was employed but argued that blocking of Notch signalling has 
no impact in HSC repopulation capacity in vivo (Benveniste et al., 2014), although we have 
previously discussed how a different interpretation could be made. In contrast, Notch2 has 
been shown to modulate BM recovery under stress conditions (Varnum-Finney et al., 2011). 
Here, we showed that canonical Notch signalling inhibition severely impacted the maintenance 
of CAFCs and phenotypically defined HSCs in vitro. In addition, although both myeloid and 
lymphoid outputs were affected, the latter was even more affected. In fact, activating Notch 
mutations have been found in B cell leukaemias (Di Ianni et al., 2009), (Puente et al., 2011b)
implicating this pathway in B cell development. Accordingly, RBPJ silencing reduced 
engraftment and deregulated HSC frequency. However, due to the severe impact that the 
RBPJ-KD had on engraftment, the number of mice with sufficient engraftment was limited, 
preventing proper analysis of the stem/progenitor cell compartment. Nonetheless, the 
reduction in HSCs observed agrees with our previous observations when DAPT was 
employed, as well as with the in vitro studies. Further experiments where higher number of 
transplanted cells are required to fully appreciate the impact of RBPJ silencing in HSCs. 
Altogether this indicates that canonical Notch signalling is essential for the repopulation of 
human HSPCs is vivo.
As depicted above, most mouse studies revealed little impact on HSCs upon Notch signalling 
blockage. With the exception of the study performed by Duncan and colleagues in which the 
authors reported that transplanting dnXSu(H)-transduced c-Kit+Thy1.1+Linneg/loSca-1+ cells 
into lethally irradiated mice resulted in a significant decrease in HSC numbers when compared 
to recipients receiving control cells (Duncan et al., 2005). The authors also showed
accelerated differentiation from dnXSu(H)- or dnMAML1-transduced haematopoietic 
stem/progenitor cells. In agreement with their latter observation, several studies have reported 
the expansion of myeloid cells upon Notch signalling disruption. A Ncstn-/- mouse model was 
shown to develop a CMML-like disease with expansion of GMPs (Klinakis et al., 2011). 
Furthermore, expression of Notch target gene Hes1 appeared to supress the expression of 
granulocyte/monocyte-related genes such as Cebpa and Spi1 (Klinakis et al., 2011). Also, 
Francis and colleagues have reported that a double heterozygous mouse model dnMAML1f/-
Vav-Cre+/- possessed an increased GMP compartment, at the expense of CMPs. The results 
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obtained in this project with human HSPCs differ greatly from most mouse studies. Indeed, 
our data support that Notch is important in the maintenance of HSPCs’ regenerative capacity 
and in the development of B cells, with no apparent role in regulating the GMP compartment.
Interestingly, the different in vivo xenotransplantation strategies employed here resulted in a 
varied degree of outcomes. Pharmacological inhibition of Notch resulted in a reduction of the 
HSC pool as well as most progenitors. Whole-animal administration of DAPT likely disrupted 
Notch signalling in all those cell compartments possessing Notch activity leading to major 
destabilisation of homoeostasis. Furthermore, disturbing Notch signalling in the non-
haematopoietic niche also likely further disrupted haematopoietic cell maintenance. In contrast 
to this, cell-autonomous disruption of Notch signalling via shRNA-mediated knockdown of 
Notch key components caused mainly a reduction in the HSC compartment. By targeting the 
restricted CD34+CD38- subset, the effects of Notch inhibition are only initially confined to this 
fraction. We can argue that sustained Notch signalling inhibition may have released HSCs
from quiescence and/or enforced differentiation towards committed progenitors. Whether 
these observations would result in reduced self-renewal capacity could only be confirmed by 
secondary transplantation of Notch-inhibited cells. Still, the reduction of HSCs appears to be 
at least in part due to the impaired cell-autonomous of canonical Notch signalling. 
Importantly, to better compare the experiments undertaking pharmacological or cell-
autonomous Notch inhibition, an inducible shRNA expression system would be necessary. 
With this, shNCSTN-3 or shRBPJ-3-transduced HSPCs could be transplanted into irradiated 
NSG mice and at 6-7 weeks post-transplantation, shRNA expression would be induced, 
triggering Notch silencing. Then, the BM of the recipients would be analysed 5-6 weeks later. 
All in all, we suggest that canonical Notch modulates human HSC maintenance and cell fate 
in vitro and in vivo.
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Chapter 5 - Exploring the roles of Notch 
signalling in Acute Myeloid Leukaemia
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5.1 Brief introduction
AML is a type of blood cancer characterised by the proliferation of abnormally differentiated 
haematopoietic cells. The role of Notch signalling in the broad group of leukaemia diseases 
has been best characterised by the oncogenic role of Notch1 in T-ALL (Weng et al., 2004),  
(Aster et al., 2008). In addition, Notch mutations have also been identified in B cell leukaemias 
and lymphomas (Di Ianni et al., 2009), (Puente et al., 2011b), (Trøen et al., 2008). Conversely, 
the role of Notch signalling in AML has not been as well elucidated, although notable efforts 
in the past 20 years have mitigated this. Notch1 and Jag1 proteins were detected in AML 
(Tohda and Nara, 2001). However, the Notch1 intracellular fragment was determined to be 
absent in most primary AML samples tested (Tohda and Nara, 2001). Later, Chiaramonte and 
colleagues also reported Notch receptor expression in AML cells, but Notch target gene HES1
was expressed at low levels (Chiaramonte et al., 2005). Reactivation of Notch signalling has 
since then emerged as a conceivable therapeutic approach. Tohda and Nara reported that 
Notch activation through immobilised ligands had a wide range of outcomes depending on the 
sample analysed (Tohda et al., 2005). Since, Notch activation was shown to inhibit 
proliferation of TF-1 AML cells (Chadwick et al., 2008) and CML cell line K562 (Yin et al., 
2009). More recently and in agreement with these early studies, it was revealed that Notch 
signalling was silenced in most primary AML cells tested (Lobry et al., 2013), (Kannan et al., 
2013). Lobry and colleagues have further reported Notch silencing in an MLL-AF9-driven 
mouse model of AML. Reactivation of the pathway prevented disease progression in vivo, 
which was correlated with the induction of apoptosis and differentiation (Lobry et al., 2013). 
Accordingly, Notch signalling reactivation was shown to induce apoptosis with downregulation 
of BCL2 (Kannan et al., 2013). Interestingly, even though any of the four Notch intracellular 
domains was used to prevent proliferation of an AML cell line, different effects were observed 
(Kannan et al., 2013), reinforcing the notion that the various Notch-ICDs are not totally 
redundant. Indeed, several studies have indicated that maintenance of adequate Notch 
signalling in the BM microenvironment is essential to prevent myeloproliferative disorders in 
mouse models were introduced in Chapter 1 (Table 1.5). Despite this strong evidence pointing 
toward a tumour suppressor role for Notch in this context, activating β-catenin mutations in 
osteoblasts led to upregulated Jag1 ligand expression which subsequently activated Notch 
signalling in HSCs resulting in AML (Kode et al., 2014). In fact, the role of Notch in the crosstalk 
between the niche and AML cells have further supported stimulation of proliferation (Takam 
Kamga et al., 2016). Here, we proposed to characterise the Notch pathway in primary and 
AML cell lines, to explore the effects of Notch signalling reactivation and attempted to 
discriminate between the differential roles of Notch1 and Notch2 receptors in AML.
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Aims of Chapter 5
- Measure the expression levels of Notch receptors and their active domains in primary 
and AML cell lines.
- Assess the effects of Notch activation on primary and AML cell lines on cell frequencies 
and apoptosis levels when co-cultured with stromal cells and by using Notch agonists 
such as peptides and small molecules.
- Evaluate the capacity of potential small molecule Notch agonists uncovered by virtual 
screenings to induce apoptosis in primary and AML cell lines.
- Determine the differential roles of Notch receptor activation on apoptosis of primary 
and AML cell lines.
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5.2 Characterisation of the Notch pathway in primary and AML cell lines
We began by characterising Notch signalling in primary and AML cell lines. Cells and samples 
representing various cytogenetic background and risk profiles were used in order to have a 
general overview of the pathway in the several cases. The characteristics of the cells used in 
this study are summarised in Table 5.1.
Table 5.1 – Characteristics of AML cells used. 
Denomination Name Karyotype/Cytogenetics Risk profile
AML cell lines HL-60
THP-1 
OCI-AML3
KG-1 
Kasumi-1 
Patient samples AML1 49,xy,+5,+18,+19(5) / 46,xy(13) Adverse
AML2
47-
48,XX,del(2)(p12),del(5)(p12),?t(6;7)(q21;q32),t(9;?)(q
34;?);-11,del(12)(p11),+19,+4 markers[cp9]/46,XX[3]
Adverse
AML3 (46,XX,+8, FLT3) Adverse
AML4 normal FLT3-ITD Intermediate
AML5 normal FLT3-ITD, NPM1a Intermediate
AML6 NPM1 mutated; Flt3 mutated Intermediate
AML7 normal Intermediate
AML8 normal Intermediate
AML9 NPM1 mutated Favourable
AML10 inv16 Favourable
AML11 NPM1 mutated Favourable
AML12 inv16 Favourable
AML13 t(8;21) Favourable
Normal – normal karyotype, 46XX or 46XY
The expression of Notch receptors was measured by FCM. For primary AML samples, 
immunophenotyping was performed. CD99 is nowadays a well-recognised antigen for AML 
cells (Chung et al., 2017). Indeed, we found that all AML samples expressed high levels of 
CD99 antigen, and as such, after excluding low FSC and SCC cells such as lymphocytes,
gating on CD99hi cells was then performed. Within the CD34+CD38+ compartment, GMP-like 
cells (CD90-CD45RA+) were found, while MLP-like cells (also CD90-CD45RA+) were present 
in the CD34+CD38- fraction as described in (Goardon et al., 2011) (Figure 5.1).
136
Figure 5.1 - Gating strategy for primary AML samples. Representative example of gating strategy 
for (A) CD34+ AMLs (AML3), CD99hi cells contain the CD34+CD38+ compartment which can be further 
separated into GMP-like cells (CD45RA+CD90-). Instead, in the CD34+CD38-, MLP-like cells can be 
found (CD45RA+CD90-). (B) In CD34- AMLs (AML8), the CD99hi compartment contains the population 
with less than 10% expression of the CD34 antigen. SSC-A – Side scatter-area.
Notch expression was analysed in the main population, which we considered as the whole 
fraction of CD34+ cells in the case of CD34+ AMLs (presenting at least 10% of CD34 
expression) or the whole fraction of CD34- cells for CD34- cases (less than 10% CD34 
expression). No significant differences were found in the expression levels of Notch receptors 
in the whole population when compared to the main population. Hence, only the expression 
for the whole population is shown (Figure 5.2). For AML cell lines, Notch receptors expression 
was simply measured on the unfractionated population (Figure 5.2). 
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Figure 5.2 – Primary and AML cell lines express Notch1 and Notch2 receptors. FCM analysis of 
surface Notch receptors. The surface expression of (A) Notch1, (B) Notch2 and (C) Notch4 receptors 
were evaluated for each AML cell line and primary cell sample. On the bottom representative histograms 
are shown for AML cell lines (HL60) and primary cells (AML3). The MFI ratio of each receptor (anti-
Notch/isotype controls) is shown. The bar is the median. Each dot represents a different sample or cell 
line.
We found both primary and AML cell lines to express Notch1 and Notch2 receptors. Notch4 
receptor could not be detected in any of the samples analysed. In general, AML cell lines 
possessed greater expression of Notch1 and 2 receptors when compared to primary AML 
cells. Yet, several studies have reported silencing of the pathway despite expression of 
surface receptors (Chiaramonte et al., 2005), (Lobry et al., 2013), (Kannan et al., 2013). 
Hence, to complement this approach, cleaved Notch1 and Notch2 expressions were 
measured by WB. In agreement with the literature on the topic, we did not detect expression 
of active Notch components in both primary and AML cell lines for most cases (Figure 5.3).
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Figure 5.3 – Notch signalling is mostly silenced in primary and AML cell lines. Primary samples 
(in blue) and AML cell lines (in black) were probed for the expression of cleaved Notch1 or cleaved 
Notch2 antibodies. Raji cells treated with EDTA and Molt4 cells were used as positive controls for the 
expression of cleaved Notch2 and cleaved Notch1 receptors, respectively. 
Still, we found that some primary AML cells express active Notch2 (AML3 and 5), albeit at low 
levels. Also, some AML cell lines expressed cleaved Notch1 (HL60) or Notch2 (KG1 and 
Kasumi-1), suggesting some Notch activity might be retained in some instances. Overall 
however, the pathway appears to be inactive especially in primary AML samples. Even though 
evidence can be found in support of both a tumour suppressor and an oncogenic role for Notch 
in AML, this likely depends on the presence of additional genetic lesions. In any case, given 
our observation that Notch signalling appears to be silenced in the samples analysed, we next 
tested the hypothesis that Notch reactivation may be of therapeutic value.
5.3 Notch activation in AML via Delta4-expressing stromal cells
To begin to investigate the potential roles that Notch signalling may have in AML, various AML 
cell lines were cultured in the presence of a feeder stromal cells layer expressing the Notch 
ligand Delta4 (S17-Delta4) or with parental S17 cells. The frequency of AML cells was 
measured four days after seeding. For this, AML cells and murine stromal cells were harvested 
and stained with human CD45 to distinguish human AML cells from the murine S17 cells. We 
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observed a significant reduction in the number of AML cells present at the end of culture with 
S17-Delta4 when compared to the culture on wild type S17s (Figure 5.4)
Figure 5.4 – Reduced frequency of AML cell lines when co-cultured in S17-Delta4. AML cell lines 
were co-cultured on wild type S17 or S17-Delta4 stromal cells. Four days after AML cell seeding, the 
frequency of human CD45 was analysed by FCM (n=3-5). Unpaired t-test. *p<0.05; **p<0.005 
***p<0.0005.
Simultaneously, apoptosis was quantified by Annexin-V staining at the end of the co-culture. 
We found a significant increase in total apoptosis (the sum of early and late apoptotic events) 
in cell lines HL60, OCI-AML3 and KG1 cells and a trending increase in apoptosis in Kasumi-
1 cells cultured with S17-Delta4 when compared to the controls (Figure 5.5). Still, the THP1 
cell line had comparable numbers of apoptotic events in both conditions. This may indicate 
that the reduction in cell numbers observed earlier may be the result of decreased proliferation 
and/or changes in the cell cycle. 
Figure 5.5 – Co-culturing AML cell lines on S17-Delta4 induces apoptosis. AML cell lines were co-
cultured on wild type S17 or S17-Delta4 stromal cells. Four days after AML cell seeding, the percentage 
of Annexin-V+ cells were measured by FCM. (n=3-5) Unpaired t-test. *p<0.05; **p<0.005.
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5.4 Notch activation in AML via a Jag1 ligand peptide
These results agree with reports in which membrane-bound ligands were shown to produce a 
similar effect (Tohda et al., 2005), (Kannan et al., 2013), (Klinakis et al., 2011) and conveyed 
that Notch signalling reactivation may be of therapeutic value. Nonetheless, a potential 
therapeutic approach with immobilised or membrane-bound ligands is not practical. For this 
reason, we tested the ability of a 17-aminoacid peptide based on the DSL domain of Jag1 
ligand (herein termed Jag1 peptide) to induce apoptosis when supplemented in the growth 
media. Various AML cell lines were exposed to increasing concentrations of Jag1 peptide. 
Two days after treatment, the percentage of live cells was measured (Figure 5.6). The HL60 
and Kasumi-1 cell lines had a significant response to the Jag1 peptide while OCI-AML3, THP1 
and KG1 cells were affected by the DMSO in the vehicle solution. This peptide was 
reconstituted to the recommended concentration in a mix of DMSO and water (1:1). Serial 
dilutions were made in water and as such, for higher Jag1 concentrations a higher quantity of 
DMSO was used, which revealed to be toxic in the THP1 and OCI-AML3 cells above the 60 
µM concentration threshold and above 20 µM for KG1 cells. Still, within the non-toxic window, 
no differences were found between the vehicle and Jag1 peptide conditions in these cell lines. 
Figure 5.6 – Jag1 titration in AML cell lines. AML cells were treated with increasing concentrations 
of Jag1 peptide or vehicle and apoptosis was measured by FCM two days after treatment.
A Notch reporter lentiviral construct was generated as described on Chapter 2 aiming to 
monitor Notch activity in a quicker and more practical manner (Figure 5.7). The vector 
contains a truncated nerve growth factor receptor (NGFR) sequence under the control of the 
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EF1α promoter allowing for positive selection by FACS using an anti-NGFR antibody. The 
mCherry fluorescent protein is controlled by Notch target gene Hes1 allowing the 
monitorisation of Notch activity under various assays.
Figure 5.7 – Schematic representation of the Notch reporter lentiviral construct. The EF1α 
promoter controls the expression of the NGFR selection marker. mCherry expression is controlled by 
Notch target gene Hes1.
The HL60 cell line was transduced with the Notch reporter lentiviral construct at a MOI of 10 
and then selected for NGFR expression by FACS. Attempting to distinguish conceivable 
diverse roles for Notch1 and Notch2 receptors in the regulation of AML cells, the Notch 
reporter HL60 cell line was then transduced with lentiviral constructs expressing shRNA 
sequences targeting the NOTCH1 or NOTCH2 genes (shLuc was used as a control) 
previously validated and used in the lab for other projects. The cells were selected for GFP
expression by FACS. As seen on Figure 5.8, the shRNA sequences were specific to the 
respective genes and did not affect the expression of the other Notch receptor. 
Figure 5.8 – Potent and specific knockdown of NOTCH1 and NOTCH2 in HL60 cells. Histograms 
of Notch1 (in blue) and Notch2 (in red) (isotype control in grey) expression in Notch reporter HL60 
transduced with shLuc, shNOTCH1 or shNOTCH2 lentiviral constructs. 
Next, the Notch Reporter HL60 cell line with Notch1 or Notch2 knockdown (here termed NRep-
HL60 shLuc, NRep-HL60 shNOTCH1, NRep-HL60 shNOTCH2) were exposed to Jag1 
peptide. The concentration chosen (20 µM) was the approximate dose needed to induce 50% 
cell death (IC50). Two days after the treatment, apoptosis was quantified (Figure 5.9). 
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Interestingly, the Jag1 peptide induced apoptosis in the NRep-HL60 shLuc condition. 
However, this effect was greatly reduced when either of the Notch receptors was silenced
(Figure 5.9 A and B). Although not pointing toward preferential activation through Notch1 or 
Notch2 receptors, these results may instead suggest that both receptors are required perhaps 
in a synergistic way, or that the levels of Notch activation are important in this setting. 
Additionally, upregulation of mCherry protein expression was detected upon Jag1 peptide 
treatment indicating Notch activation through HES1 – an effect that was abolished when either 
Notch1 or Notch2 receptor was absent (Figure 5.9 C). 
Figure 5.9 – Jag1 peptide induces apoptosis in the HL60 cell line via Notch activation. Jag1 
peptide (20µM) was added to HL60 cells. After two days, Annexin-V+ cells were quantified.  (A) 
Representative example of increased apoptosis in NRep HL60 cells upon Jag1 treatment, (B) 
quantification of apoptosis, (C) induction of mCherry expression upon Jag1 treatment. Bars are the 
mean ± SD (n=3). Unpaired t-test. *p<0.05; **p<0.005.
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5.5 Notch activation in AML via small molecules
Next, we explored the use of small molecules with Notch agonistic properties to circumvent 
the limited bioavailability issues of peptide-based therapies (Craik et al., 2013). Thus, a
collaboration with Professor Andrea Brancale from the School of Pharmacy at Cardiff 
University was established. The aim was to uncover small molecules with general Notch 
agonistic properties and/or agonists of specific receptors. By using a 3D generated model of 
the Notch1-Jag1 interaction (Figure 5.10 A), over three million compounds were virtually 
screened for their likeliness to interact with Notch receptors. Structure-based virtual screening 
uses the 3D structure of the target to find cognate partners, whereas ligand-based virtual 
screening uses the 3D structure of the ligand to filter a library of small molecules. After a series 
of filtering steps, a short list of 117 compounds was generated. Filtering steps included visual 
inspection for the ability of candidate molecules to interact and occupy with selected binding 
site. Molecules should also comply with Lipinski’s rule of five (Lipinski et al., 2001). Briefly, this 
analysis shows that poor absorption of permeation of a compound is more likely when there 
are more than five hydrogen-bond donors; molecular mass is greater than 500 Da; high 
lipophilicity and the sum of nitrogen and oxygen atoms is more than 10 (Lipinski et al., 2001). 
These guidelines determine the likeliness that a chemical compound can be used as an orally 
active drug in humans. In Figure 5.10 A, a predicted model for the Notch/Jag1 interaction is 
shown (Notch1 receptor in purple, Jag1 ligand in orange). Importantly, the natural structure of 
this interaction would be uncovered by protein crystallography. However, no data on this has 
been generated yet. In Figure 5.10 B and C, candidate molecules uncovered by ligand- or 
structure-based are depicted in green and red as docked on the Notch1 receptor binding 
domain (in purple), respectively. Aromatic rings can be observed in the same location that the
Jag1 ligand (in orange) at Phe199 interacts with Notch1 receptor. This in addition with 
hydrogen interactions along the length of the compound may indicate a potential agonistic 
capacity from this and structurally similar compounds, mimicking the interaction between Jag1 
ligand and Notch1 receptor. Of note, the drug screening and analysis of candidate molecules 
was performed by Professor Andrea Brancale lab members. To first assess whether the 
computational evaluation translated into biological activity, only 19 compounds were selected 
due to being commercially available at a trusted company. Of those, the top six scoring 
molecules were tested for this study. 
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Figure 5.10 – Small molecule interaction with Notch1. After (A) 3D modelling of the Notch1/Jag1 
interaction, ligand based (B) or structure based (C) screening uncovered molecules that theoretically 
interact with Notch1 receptor at the same positions as natural ligand Jag1. Notch1 receptor in purple, 
Jag1 ligand in orange, compound “X” in green and compound number 21 used in this study in red.
(Adapted from the models generated by Julija Jotautaite at the School of Pharmacy from Cardiff 
University).
The five AML cell lines were exposed to the various compounds and apoptosis was measured 
the next day. Varied outcomes were observed, but compounds 24 and 31 induced the most 
apoptosis in various cell lines (Figure 5.11). As such, these compounds were selected for the 
remaining experiments. 
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Figure 5.11 – Drug screening in AML cell lines. (A) Representative dot plot of an AML cell line 
(Kasumi) treated with the various drugs at a final concentration of 10 µM. The cells were analysed for 
the presence of Annexin-V 24 h after treatment. (B) Quantification of apoptosis induced by various 
compounds in the indicated AML cell lines.
In order to address whether any potential toxicity caused by these small molecule treatments
is due to a reactivation of Notch pathway, AML cells were pre-treated with a γ-secretase 
inhibitor (compoundE, herein abbreviated to compE) or DMSO for 2 h prior drug treatment. 
After that, the compounds were added at a final concentration of 10 µM. The next day, 
apoptosis levels were measured by FCM (Figure 5.12). We noticed a generalised induction 
of apoptosis by both drugs in several cell lines. Unfortunately, this revealed to be independent 
of Notch activation. Therefore, future testing on these small molecules will address whether 
the cytotoxic effects are confined to AML cells. If so, dissection of the Notch-independent 
mechanisms by which these compounds induce apoptosis may be of therapeutic value. 
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Figure 5.12 – Drugs 24 and 31 induce apoptosis in AML cell lines in a Notch-independent 
manner. Representative dot plots of AML cell lines treated with (A) drug number 24 and (B) drug 
number 31. The cells were analysed for the presence of Annexin-V 24 h after treatment (n=2). 
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5.6 Discussion
The results presented in this study support other published findings that despite Notch 
receptor expression on AML cells (especially on cell lines), the cleaved fractions of the 
receptors could not be detected in most samples analysed. Culturing AML cell lines on S17-
Delta4 stroma resulted in decreased AML cell frequency in all cell lines tested and induced 
apoptosis in some. Still, in some cases, a reduced number of AML cells was detected without 
apparent changes in apoptotic levels. This may instead indicate altered cell cycle kinetics and 
proliferation as a result of Notch activation – an effect that has been reported before (Carlesso 
et al., 1999), (Sarmento et al., 2005). Even so, THP1 cells have been reported to undergo 
apoptosis following ligand stimulation (Lobry et al., 2013), (Kannan et al., 2013). Lobry and 
colleagues reported apoptosis induction 48 h following stimulation with immobilised plate 
bound Delta4 ligand (Lobry et al., 2013), while others presented induction of apoptosis 24 h 
after co-culturing THP1 cells on HS5 stromal cells expressing Delta1 (Kannan et al., 2013). 
Here, we determined that measuring apoptosis at the fourth day of the co-culture yielded 
higher percentages of apoptosis (personal observations). Therefore, this timepoint was used 
to better reveal putative differences between the conditions tested. Yet, future work will involve 
determining the kinetics of apoptosis for all cell lines tested as different timepoints may be 
required. 
Following the observation that Notch reactivation through membrane bound ligand induces 
apoptosis and perhaps cell growth arrest in AML cell lines, we then used a Jag1 peptide in 
solution which would more closely resemble a possible therapy approach. This peptide was 
shown to possess cytotoxic activity in both primary and AML cell lines (Kannan et al., 2013). 
In our study, we observed a dose-dependent decrease in viability in HL60 and Kasumi-1 cells. 
To better measure Notch activity, HL60 cells were transduced with a Notch reporter and 
subsequently with shRNA sequences targeting the NOTCH1 or NOTCH2 genes. So far, only 
HL60 cells were tested given their response to membrane bound Delta4 and to soluble Jag1 
peptide. Following validation of the Notch reporter and specificity of shRNA sequences, we 
observed an increase in the number of apoptotic cells in NRep-HL60 shLuc treated with the 
Jag1 peptide when compared to vehicle treated. This effect was abolished in the HL60 cell 
line when either NOTCH1 or NOTCH2 were silenced, perhaps suggestive of the importance 
of signalling levels. Importantly, a Notch reporter construct indicated that apoptosis was 
mediated via Notch signalling activation. Still, cell lines representing other AML subtypes 
should be tested. While remaining a serious condition, the HL60 cell line represents the acute 
promyelocytic leukaemia subtype which owing to advances in diagnostics and treatments is 
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nowadays considered the most curable of adult acute myeloid leukaemias, with complete 
remission rates as high as 90% (Coombs et al., 2015). 
Future confirmation of Notch reactivation should be done by detecting the cleaved forms of 
Notch receptors by WB with simultaneous use of Notch signalling inhibitors. Importantly, 
improvements on the Jag1 peptide experiments should be considered. The peptide was 
diluted in a mix of water and DMSO (1:1) at the recommended stock solution concentration. 
However, we observed high toxicity in OCI-AML3, THP1 and KG1 cell lines with vehicle only
preventing its use in these cell lines. Therefore, requesting to synthesise larger amounts of 
the peptide in order to have a significantly lower DMSO/Jag1 peptide ratio to overcome the
toxicity issues caused by DMSO in these cell lines would allow to uncover concentrations at 
which the peptide may have a potential effect in these cell lines. Additionally, the remaining 
AML cell lines used in this study should be transduced with the Notch reporter construct as 
well as the various Notch receptor silencing lentiviral vectors, providing valuable tools for the 
study of Notch signalling in AML with different genetic backgrounds.
The HL60 cell line with NOTCH1 or NOTCH2 KD generated during this study provided a tool 
for studying the role of Notch in AML. However, due to time constraints, limited testing was 
performed with these cell lines. In addition to stroma expressing Delta4, it would be interesting 
to assess whether different membrane bound ligands result in a different outcome. As 
mentioned earlier, mice constitutively expressing active β-catenin is osteoblasts exhibit 
upregulation of Jag1 ligand which promotes AML development (Kode et al., 2014) further 
showcasing the role of the niche in this context. It would be interesting to address the effect of 
membrane bound Jag1 ligand in AML cells. In combination with the several AML cell lines with 
NOTCH1 or NOTCH2 KD, these experiments could establish what are the consequences of 
each ligand/receptor pairing regarding cell growth, differentiation and apoptosis providing 
valuable insight into AML biology. In fact, mice with haematopoietic cells expressing the 
Notch1-ICD have been reported to develop aggressive T-ALL (Pear et al., 1996), (Lobry et al., 
2013). On the contrary, expressing Notch2-ICD supressed MLL-AF9 driven AML development 
in vivo and did not result in T-ALL (Lobry et al., 2013). Therefore, the design of Notch2 specific 
agonists emerges as an attractive option. Still, given the different genetic background in the 
various AML subtypes, it would be relevant to address which specific cases might benefit from 
this approach. With the advent of molecular biology and recombinant protein tools, a new class 
of protein-based drugs have been explored since then. Within this class, antibodies have seen 
a tremendous success in their use for a variety of diseases (reviewed in (Craik et al., 2013). 
High potency and selectivity with potentially lower toxicity than small molecules turn peptide-
based therapeutics into an attractive option. Still, disadvantages including poor metabolic 
stability and membrane permeability, limited oral bioavailability and rapid clearance limit their 
150
usefulness (Craik et al., 2013). Improving peptide screening and new delivery formulations 
may circumvent some of these issues allowing for their more widespread use in clinical 
settings. Therefore, in addition to the Jag1 peptide, we attempted to uncover potential small 
molecule agonists of Notch signalling. Six small molecules were tested for their ability to 
induce apoptosis in AML cells. Despite two of the six molecules tested exhibited cytotoxicity 
effects, this was shown to be independent of Notch reactivation. Nonetheless, if cytotoxicity is 
proven to be specific to AML cells while sparing normal haematopoietic cells, these 
compounds should warrant further investigation. A vast array of small molecules has been 
tested for their antagonistic capacities toward Notch – particularly relevant in T-ALL cases 
(reviewed in (De Kloe and De Strooper, 2014). Conversely, with the growing body of evidence 
demonstrating a potential tumour suppressor role for Notch in AML, small molecules with 
Notch agonistic properties have instead emerged as promising potential therapies for AML. In 
one example, N-methylhemeanthidine chloride (NMHC), a compound derived from the plant 
Zephyranthes candida has shown promising and specific cytotoxicity toward AML cells, while 
sparing B-ALL, T-ALL and CML cells (Ye et al., 2016a). Remarkably, NMHC administration 
significantly reduced tumour development in a human AML xenograft model (Ye et al., 2016a). 
Finally, due to time constraints, the various Notch signalling reactivation approaches could not 
be tested on primary AML cells. Future work will involve investigating whether the effects 
observed on AML cell lines are valid on primary AML cells which should provide further insight 
into the clinically relevant aspects of Notch in this disease. In summary, Notch appears to be 
silenced in human AML cells and reactivation of this pathway through different means 
indicated suppression of proliferation and induction of apoptosis. Pursuing the development 
of Notch receptor specific agonists should be a valuable strategy toward the development of 
more specific AML treatments.
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Chapter 6 – Conclusions
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The Notch pathway has a well characterised role in the emergence of HSCs during 
development (Kumano et al., 2003). Further to this, several studies showed a positive role for 
Notch regulation in HSPCs (Chapter 1, Table 1.3). This was achieved by various methods 
such as direct exposure of stem and progenitor cells to Notch ligands in vitro, expressing 
Notch intracellular domains or downstream targets. These gain-of-function studies have 
consistently demonstrated that activation of this pathway is implicated in increased in HSC 
self-renewal (Varnum-Finney et al. (1998), (Carlesso et al., 1999), (Karanu et al., 2001), 
(Ohishi et al., 2002), (Kunisato et al., 2003), (Calvi et al., 2003), (Varnum-Finney et al., 2003), 
(Lauret et al., 2004). Consequently, Notch signalling has been exploited as a strategy for the 
ex vivo expansion of HSCs for clinical purposes (Delaney et al., 2010). On the other hand, 
loss-of-function studies have generated a variety of outcomes including depletion or no effect 
on HSCs (Duncan et al., 2005), (Maillard et al., 2008). The employment of varied mouse 
models, the loss of function approach undertaken (loss of specific Notch receptors, ligands, 
or Notch coactivators (RBPJκ) or overexpression of dominant negative molecules) all 
contributed to the variety of outcomes reported. In addition, researchers disagree on the levels 
of Notch signalling present in mouse HSCs. Maillard and colleagues have proposed that stem 
cells have low levels of Notch signalling in vivo under homeostatic conditions (Maillard et al., 
2008). On the contrary, using transgenic Notch reporter mice, Duncan and colleagues have 
suggested that cells with primitive phenotype showed high Notch signalling activity in vivo and 
was downregulated when HSCs differentiated (Duncan et al., 2005). Despite all these 
controversies, little has been described on role of this signalling pathway in human HSPC
regulation and this was one of the emphasis of this project. Thus, the work reported in this 
thesis set out to explore the role of Notch signalling in the regulation of human HSPCs and 
AML cells. 
Firstly, we showed that Notch1 and 2 receptors were highly expressed in all stem and primitive 
progenitor cell compartments analysed. However, we observed slightly higher Notch1 and 2 
receptor activation in HSCs despite that these cells did not harbour the highest cell surface 
expression as compared to other primitive populations. By employing DAPT as a pan-Notch 
inhibitor, we observed a significant reduction in myelo-lymphoid engraftment along with a 
decline in most stem/progenitor cell compartments, whereby the HSC frequency within the 
human graft was reduced by 7-fold when compared to the vehicle treated cohort. Cell-
autonomous suppression of Nicastrin or RBPJκ expression led to reduced LTC-IC capacity 
with reduction of HSC fraction and deregulated mature progenies. Agreeing with these 
observations, cell-autonomous silencing of NCSTN or RBPJ resulted in decreased myelo-
lymphoid engraftment in NSG mice, especially when RBPJ was silenced. The HSC fraction 
was significantly reduced by the silencing of either NCSTN or RBPJ and consequently reduced 
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numbers of mature cells were found as well. Overall, the results presented here contrast with 
most mouse studies and support the notion that the Notch pathway is important in the 
maintenance of HSPCs during regeneration. Nonetheless, secondary transplantation of 
Nicastrin-KD and RBPJ-KD HSPCs should be performed to reveal the roles of Notch signalling 
in HSC self-renewal.
Regarding the role of Notch pathway in the differentiation of haematopoietic cells, several 
studies have also reported varied results. Approximately 12% of B cell chronic lymphocytic 
leukaemia patient samples harbour Notch activation mutations suggesting a role for Notch 
signalling in B cell differentiation (Puente et al., 2011). In fact, deletion of Rbpj or Notch2 in B 
cell progenitors impaired marginal zone B cells while enhancing follicular B cell development 
(Tanigaki et al., 2002), (Saito et al., 2003). Loss of Notch1 receptor or RBPJκ in adult BM cells 
prevents T cell development with concomitant ectopic appearance of B cells in the thymus 
(Han et al., 2002), (Radtke et al., 1999), (Wilson et al., 2001). Moreover, through lineage 
tracing experiments in mice, Oh et al proposed that Notch signalling acts at different nodes of 
differentiation in special localised niches, whereby Notch1 receptor has been implicated in 
commitment towards the lymphoid lineage while Notch2 receptor initiates erythroid 
differentiation (Oh et al., 2013). Conversely, the idea that Notch signalling imposes repression 
on myeloid transcription factor programme has been suggested (Klinakis et al., 2011). 
Approximately 12% of CMML patient samples possess Nicastrin loss of function mutations. 
Additionally, HES1 was suggested to supress GMP-associated genes Cebpa and Spi1, and 
when Nicastrin was lost, de-repression of a myeloid specific programme was observed 
(Klinakis et al., 2011). The authors further complemented this by showing that culturing CB 
CD34+CD38- HSPCs with Notch ligands had supressed differentiation towards granulocyte 
and monocyte lineages (Klinakis et al., 2011). Even though we did not detect expansion of 
any specific cell lineage given the significant reduction of all cells analysed, B cell development 
was more affected than myeloid differentiation in the RBPJ-KD condition. As such, our 
observations of in vitro and in vivo B cell development impairment from RBPJ-KD cells indicate 
RBPJk to be required for proper B cell development.  While it is difficult to pinpoint the reasons 
for these results, most likely non-canonical Notch-independent RBPJκ roles may be involved. 
This has been described in other systems, whereby for instance the pancreas specific RBPJκ
loss phenotype is drastically different from the pancreas specific Notch1/2-deficient mice 
(Nakhai et al., 2008). Whereas RBPJκ loss in pancreatic progenitor cells led to premature 
differentiation and decrease in endocrine progenitor cells, the loss of Notch1 and Notch2 
receptors only caused a moderate reduction in proliferation of pancreatic epithelial cells 
(Nakhai et al., 2008). Elucidation of Notch-independent RBPJκ functions revealed the 
interaction of RBPJκ with Ptf1a/p48 – a transcription factor indispensable for pancreas 
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development (Obata et al., 2001). The domain of RBPJκ interacting with Ptf1a is the same as 
the Notch receptor RAM binding domain and appears to be mutually exclusive. Therefore, 
competition for the RBPJκ binding site occurs between Ptf1a and the NICD (Beres et al., 
2006).  Still, mutations resulting in dominant negative effect of Nicastrin, but not the loss of 
RBPJκ, results in CMML-like disease in mice (Klinakis et al., 2011), (Han et al., 2002) thus, a 
similar mechanism may operate in this context as well. Adding to the complexity of the system, 
RBPJκ was initially considered a transcriptional repressor (Dou et al.,1994), (Hsieh et al., 
1995). And in fact, it is believed that in some instances, in the absence of NICD, RBPJκ recruits 
co-repressors to supress target gene expression (reviewed in (Bray, 2016)). Recently, Duarte 
et al reported upregulation of Hes1 and Hes5 in the absence of Rbpj in megakaryocyte and 
erythrocyte progenitors, suggesting a repressive role for RBPJκ in the absence of Notch 
signalling (Duarte et al., 2018). Analysing the transcriptome of Nicastrin-KD and RBPJ-KD 
HSPCs by RNA sequencing should elucidate on the possible downstream mechanisms 
involved in the regulation of these cells. Additionally, chromatin immunoprecipitation assay 
(ChIP) sequencing may expose the DNA binding sites for the RBPJκ coactivator/corepressor 
complex.
Beyond the deletion of pathway members including Ncstn (Klinakis et al., 2011), Rbpj (Wang 
et al., 2014) and Adam10 (Yoda et al., 2011), regulators of Notch receptor post-translational 
modifications such as Presenilins (Qyang et al., 2004), FX (Zhou et al., 2008) and Pofut (Yao 
et al., 2011) have been implicated in the generation of myeloproliferative diseases in mouse 
models (see Table 1.5), demonstrating the requirement for adequate levels of signalling in 
preventing malignant transformation. But determining the role of Notch pathway in myeloid 
malignancies has proved to be a complex task owing to the genetic diversity of the diseases, 
the pleiotropic roles of this pathway and the experimental differences in reported studies 
(mouse models, immortalised cell lines or primary cells, in vitro or in vivo). In chronic myeloid 
leukaemia (CML) mouse models - a myeloproliferative disease driven the BCR-ABL1 fusion 
gene, HES1 appears to cooperate with BCR-ABL1 to promote CML blast crisis (Nakahara et 
al., 2010). On the other hand, HES1 downregulation was associated with blast crisis in human 
samples (Sengupta et al., 2007) and Notch signalling reactivation supressed cell growth 
suggesting a tumour suppressor role in this case (Yang et al., 2013), (Yin et al., 2009). 
Therefore, mouse and human studies show conflicting results and as such, additional research 
might clarify these disagreements. 
Whether Notch signalling has an oncogenic or tumour suppressor role in AML may depend 
on the presence of additional genetic lesions. For example, in a rare subset of acute 
megakaryocytic leukaemia, the OTT-MAL fusion protein activates RBPJ (Mercher et al., 
2009). Also, indirect evidence of Notch signalling involvement in AML was shown by Notch 
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target Trib2 which enhanced proliferation of myeloid progenitors and promoted AML through 
degradation of C/EBPα (Keeshan et al., 2006). In acute promyelocytic leukaemia, an 
enhanced Notch expression signature was found in both human primary APL cells and in pre-
leukemic cells derived from Ctsg-PML-RARA mice (Grieselhuber et al., 2013). The authors 
reported that the PML-RARA fusion protein caused Notch signalling activation, which 
promoted self-renewal in myeloid progenitors without affecting downstream commitment. 
However, other evidences support a tumour suppressor role for Notch signalling in myeloid 
leukaemias instead (Klinakis et al.,  2011), (Lobry et al., 2013), (Kannan et al.,  2013),  
(Chadwick et al.,  2008), (Sengupta et al., 2007). In support of this, deletion of Rbpj accelerated 
MLL-AF9 driven AML. Mechanistically, the authors proposed that HES1 supresses MLL-AF9 
driven AML likely through repression of Flt3 (Kato et al., 2015). Additionally, Notch loss of 
function cooperates with Tet2 loss of function to induce AML in vivo (Lobry et al., 2013).
In our study, we showed that Notch pathway is silenced in most of the AML samples analysed. 
Possible mechanisms for Notch silencing in this context have been proposed (Lobry et al., 
2014): (1) the possible absence of ligands in the AML niche – however, this has still yet to be 
demonstrated; (2) gene mutations; Mastermind-like 1 (MAML1) is a Notch coactivator 
frequently lost in 5q- AML (a type of AML lacking the long arm of chromosome 5). In cases 
where Mastermind like-1 is not lost (in 5q- AMLs), point mutations have been found in the 
MAML1 (Jerez et al., 2012); (3) epigenetic modifications have also been implicated, as 
hypermethylation of Notch member genes LFNG, MAML3 and HES5 have been uncovered in 
IDH1- or IDH2-mutated AML (Sasaki et al., 2012) and (4) alternative splicing, whereby 
NOTCH2, along with FLT3 were found to be commonly mis-spliced in AML. In fact, up to 79% 
of AML patient samples analysed in that study expressed a NOTCH2-Va variant (Adamia et 
al., 2014). The authors correlated the expression of this variant with poor clinical outcome in 
the intermediate cytogenetic risk group. Moreover, NOTCH2-Va was associated with 
downregulation of Notch target genes HES1, HEY1 and DTX1 compared with AML cells 
expressing full length NOTCH2 (Adamia et al., 2014). 
Given the apparent Notch signalling downregulation observed in AML cells analysed in our 
work, reactivation of this pathway was hypothesised as holding promising therapeutic value. 
Indeed, co-culturing AML cells on Delta4-expressing stroma or stimulating with soluble Jag1 
ligand-based peptide induced apoptosis in some instances. A Notch reporter construct 
indicated the effects might be mediated through the reactivation of Notch signalling due to 
increased Hes1-controled mCherry expression, although future confirmation by qRT-PCR and 
WB is warranted. Future work will also involve generating more Notch reporter AML cell lines 
with NOTCH1 or NOTCH2 knockdown. This should allow the determination of the roles of 
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specific receptors in various contexts and be a valuable tool in the study of Notch signalling in 
AML.
Given its prominent oncogenic role in T-ALL and other haematological malignancies, a vast
array of Notch antagonists such as γ -secretase inhibitors have been tested in pre-clinical and 
clinical trials (Hernandez Tejada et al., 2014). In addition, monoclonal antibodies targeting
either Notch1 or Notch2 receptor were shown to possess anti-tumour and anti-angiogenic 
properties (Wu et al., 2010). An antibody targeting the γ-secretase complex has also shown 
promising results against T-ALL (Hayashi et al., 2012). Conversely, agonistic strategies have 
been developed aiming to treat diseases where Notch signalling appears to act as a tumour 
suppressor. Several ligand-mimicking proteins and peptides have been used as Notch 
agonists (reviewed in (Hernandez Tejada et al., 2014)). We have used a Jag1 ligand peptide 
previously shown to possess in vitro effectiveness against AML (Kannan et al., 2013). 
Modifications to peptides that enhance their bioavailability while preserving their activity and 
improving on their delivery and transport strategies are key technical issues that should be 
addressed in order to facilitate the use of molecules that show in vitro efficiency. Of note, an 
anti-Notch2 agonist antibody has been useful in a mouse model of nephrosis (Tanaka et al., 
2014) and could perhaps be of value in certain haematological malignancies. Even though re-
activation of Notch pathway through immobilised ligands (Tohda et al., 2005), (Lobry et al., 
2013) or overexpression of NICDs or downstream targets (Carlesso et al., 1999), (Kannan et 
al., 2013), (Lobry et al., 2013) has proven efficient in targeting myeloid leukaemic cells, this is 
not a practical strategy in vivo. We and others have reported peptide-based approaches to 
cause apoptosis in AML cells (Kannan et al., 2013). Still, these molecules have limited 
applications in AML due to peptide instability and low bioavailability (Craik et al., 2013). Other 
types of compounds have proven effective against AML cells in vitro. N-methylhemeanthidine 
chloride (NMHC) which can be found in the plant Zephyranthes candida proved to be toxic to 
several AML cell lines in vitro, by inducing cell cycle arrest, downregulation of cyclin B1 and 
upregulation of cell cycle regulator p21 (Ye et al., 2016b). This compound was also 
demonstrated to cause caspase-mediated apoptosis. The effects of NHMC are believed to be 
due to increased processing of Notch1 receptor as assessed by upregulation of N1-ICD, and 
Notch target genes HES1 and HEY1. Notably, NHMC was shown to significantly reduce 
tumour burden in nude mice injected with HL60 cells. In another example, Resveratrol -
commonly found in grapes, has been shown to synergise with HDAC inhibitors to induce 
apoptosis in leukaemia cells (Yaseen et al., 2012). Here, we attempted to find and test small 
molecule agonists of Notch signalling. Unfortunately, the compounds uncovered proved to 
cause cytotoxicity independent of Notch reactivation. Still, future investigation should address 
the specificity of the cytotoxic effects towards AML cells and the mechanisms behind it.
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All in all, reactivation of Notch in some AML cases may hold a beneficial therapeutic potential.
Therefore, the ever-increasing knowledge on the genetic background of this group of disease 
should allow for the development and use of more specific drugs targeting signalling pathways 
critical to AML cell regulation, of which Notch may be a useful candidate.
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Appendix I 
Solutions
Annealing buffer
100 mM C2H3KO2 (Merck) 
30 mM HEPES pH7.4 (Merck)
2 mM Mg(CH3COO)2 (Merck)
This should be stored at -20 °C and is ok to freeze-thaw.
SDS Running buffer
50 ml 20X NuPAGETM MOPS SDS Running buffer solution (Thermo) 
950 ml distilled miliQ water
Transfer buffer
50 ml 20X NuPAGETM Transfer Buffer (Thermo)
100 ml 100% methanol (Merck)
850 ml distilled miliQ water
Blocking solution
5 g of non-fat milk powder
100 ml TBS-T 
 
20X TBS
60.57 g Tris base (Fisher)
88 g NaCl (Merck)
Dissolve in 400 ml miliQ water
Adjust to pH 7.6 with HCl
Make up to 500 ml with miliQ water
TBS-T 
250 ml 2X TBS
249.5 ml miliQ water
0.5 ml Tween 20 (Merck)
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Appendix II
Table II.1 - Oligos used to generate the miR30-based lentiviral constructs
sense; loop; anti-sense
Gene Clone Oligo sequences (5' to 3') Reference
Fwd 5' pho - TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCTACGCTGAGTACTTCGAAATGTAGTGAAGCCACAGATGTACATTTCGAAGTACTCAGCGTAATGCCTACTGCCTCGG 
Rev 5' pho - AATTCCGAGGCAGTAGGCATTACGCTGAGTACTTCGAAATGTACATCTGTGGCTTCACTACATTTCGAAGTACTCAGCGTAGCGCTCACTGTCAACAGCAATATACCTTC
Fwd 5’pho-TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCACCACTTATGTTGTACAGTATAGTGAAGCCACAGATGTATACTGTACAACATAAGTGGTG TTGCCTACTGCCTCGG
Rev  5’pho-AATTCCGAGGCAGTAGGCAACACCACTTATGTTGTACAGTATACATCTGTGGCTTCACTATACTGTACAACATAAGTGGTGGCGCTCACTGTCAACAGCAATATACCTTC
Fwd  5’pho-TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCGTGCGTTCTACTGCACGATTATAGTGAAGCCACAGATGTATAATCGTGCAGTAGAACGCACATGCCTACTGCCTCGG
Rev 5’pho-AATTCCGAGGCAGTAGGCATGTGCGTTCTACTGCACGATTATACATCTGTGGCTTCACTATAATCGTGCAGTAGAACGCACGCGCTCACTGTCAACAGCAATATACCTTC
Fwd  5’pho-TCGAGAAGGTATATTGCTGTTGACAGTGAGCGACAGTTAGAGAATGTTGACTCATAGTGAAGCCACAGATGTATGAGTCAACATTCTCTAACTGCTGCCTACTGCCTCGG
Rev 5’pho-AATTCCGAGGCAGTAGGCAGCAGTTAGAGAATGTTGACTCATACATCTGTGGCTTCACTATGAGTCAACATTCTCTAACTGTCGCTCACTGTCAACAGCAATATACCTTC
Fwd  5’pho-TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCTCAGTGGAGAGGAAGATATATAGTGAAGCCACAGATGTATATATCTTCCTCTCCACTGAGTTGCCTACTGCCTCGG
Rev 5’pho - AATTCCGAGGCAGTAGGCAACTCAGTGGAGAGGAAGATATATACATCTGTGGCTTCACTATATATCTTCCTCTCCACTGAGGCGCTCACTGTCAACAGCAATATACCTTC
Fwd 5’pho - TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCGGTGCCTTCCATAACAAATATTAGTGAAGCCACAGATGTAATATTTGTTATGGAAGGCACCATGCCTACTGCCTCGG 
Rev 5’pho - AATTCCGAGGCAGTAGGCATGGTGCCTTCCATAACAAATATTACATCTGTGGCTTCACTAATATTTGTTATGGAAGGCACCGCGCTCACTGTCAACAGCAATATACCTTC 
Fwd 5’pho - TCGAGAAGGTATATTGCTGTTGACAGTGAGCGAATCTTCAAGAAGAAAGATGGGTAGTGAAGCCACAGATGTACCCATCTTTCTTCTTGAAGATGTGCCTACTGCCTCGG
Rev 5’pho - AATTCCGAGGCAGTAGGCACATCTTCAAGAAGAAAGATGGGTACATCTGTGGCTTCACTACCCATCTTTCTTCTTGAAGATTCGCTCACTGTCAACAGCAATATACCTTC 
Fwd 5’pho - CGAGAAGGTATATTGCTGTTGACAGTGAGCGCATGTAGAGTATTCAGTAGAGCTAGTGAAGCCACAGATGTAGCTCTACTGAATACTCTACATTTGCCTACTGCCTCGG
Rev 5’pho - AATTCCGAGGCAGTAGGCAAATGTAGAGTATTCAGTAGAGCTACATCTGTGGCTTCACTAGCTCTACTGAATACTCTACATGCGCTCACTGTCAACAGCAATATACCTTC 
Fwd 5’pho - TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCGGGAAGCTATGCGAAATTATTTAGTGAAGCCACAGATGTAAATAATTTCGCATAGCTTCCCTTGCCTACTGCCTCGG
Rev 5’pho - AATTCCGAGGCAGTAGGCAAGGGAAGCTATGCGAAATTATTTACATCTGTGGCTTCACTAAATAATTTCGCATAGCTTCCCGCGCTCACTGTCAACAGCAATATACCTTC
Fwd 5’pho - TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCGGACAGAATTTCACTCCAAATTAGTGAAGCCACAGATGTAATTTGGAGTGAAATTCTGTCCTTGCCTACTGCCTCGG
Rev 5’pho - AATTCCGAGGCAGTAGGCAAGGACAGAATTTCACTCCAAATTACATCTGTGGCTTCACTAATTTGGAGTGAAATTCTGTCCGCGCTCACTGTCAACAGCAATATACCTTC
Fwd 5’pho - TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCAGGACAGAATTTCACTCCAATAGTGAAGCCACAGATGTATTGGAGTGAAATTCTGTCCTGTTGCCTACTGCCTCGG
Rev 5’pho - AATTCCGAGGCAGTAGGCAACAGGACAGAATTTCACTCCAATACATCTGTGGCTTCACTATTGGAGTGAAATTCTGTCCTGGCGCTCACTGTCAACAGCAATATACCTTC
Dharmacon (V2LHS_263385)
Dharmacon (V2LHS_1148633)
Dharmacon (V3LHS_342058)
Dharmacon  (V3LHS_300634)    
Dharmacon  (V3LHS_300632)
Dharmacon (V2LHS_255892)
Dong et al  2010
Dong et al  2010
shRBPJ-3
shNCSTN-7
shRBPJ-1
NCSTN
NCSTN
RBPJ
NCSTN
shRBPJ-2
shNCSTN-5
shNCSTN-6
shNCSTN-3
shNCSTN-4
RBPJ
RBPJ
NCSTN
NCSTN
NCSTN
NCSTN
Luc shLuc
shNCSTN-1
shNCSTN-2
Dharmacon (V3LHS_300630)
Sigma (TRCN0000308211)
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Table II.2 - Oligos used to generate H1 promoter-driven shRNA constructs (CS-shRNA)
sense; loop; anti-sense
Gene Clone Oligo sequences (5' to 3')
Luc shLuc
Fwd 5' pho - GATCCCCACGCTGAGTACTTCGAAATGTTTCAAGAGAACATTTCGAAGTACTCAGCGTTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAACGCTGAGTACTTCGAAATGTTCTCTTGAAACATTTCGAAGTACTCAGCGTGGG
NCSTN shNCSTN-1 
Fwd 5' pho - GATCCCCACCACTTATGTTGTACAGTATTTCAAGAGAATACTGTACAACATAAGTGGTTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAACCACTTATGTTGTACAGTATTCTCTTGAAATACTGTACAACATAAGTGGTGGG
NCSTN shNCSTN-3 
Fwd 5' pho - GATCCCCAGTTAGAGAATGTTGACTCATTTCAAGAGAATGAGTCAACATTCTCTAACTTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAAGTTAGAGAATGTTGACTCATTCTCTTGAAATGAGTCAACATTCTCTAACTGGG
RBPJ shRBPJ-2 
Fwd 5' pho - GATCCCCGGACAGAATTTCACTCCAAATTTCAAGAGAATTTGGAGTGAAATTCTGTCCTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAGGACAGAATTTCACTCCAAATTCTCTTGAAATTTGGAGTGAAATTCTGTCCGGG
RBPJ shRBPJ-3 
Fwd 5' pho - GATCCCCAGGACAGAATTTCACTCCAAATTCAAGAGATTTGGAGTGAAATTCTGTCCTTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAAGGACAGAATTTCACTCCAAATCTCTTGAATTTGGAGTGAAATTCTGTCCTGGG
NOTCH1 shNOTCH1
Fwd 5' pho - GATCCCCAGGTGCAGCCACAAAACTTACTTCAAGAGAGTAAGTTTTGTGGCTGCACCTTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAAGGTGCAGCCACAAAACTTACTCTCTTGAAGTAAGTTTTGTGGCTGCACCTGGG
NOTCH2 shNOTCH2
Fwd 5' pho - GATCCCCACCACATCCTCTCCAATGATTTTCAAGAGAAATCATTGGAGAGGATGTGGTTTTTTGGAAAT
Rev 5' pho - CTAGATTTCCAAAAAACCACATCCTCTCCAATGATTTCTCTTGAAAATCATTGGAGAGGATGTGGTGGG
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Table II.3 – Starting plasmids used for the generation of lentiviral constructs
Plasmid name Source
pLV.EF1α-premiRNA30-RFP Biossettia Inc. (USA)
pSIN.Tet-HPGK-rtTA2-hDKK-Ires-
GFP Generated in-house
pGIPZ™ Dharmacon – Horizon Discovery Group plc (UK)
pmCherry Clontech (Takara Bio, Japan)
pECFP-C1 Clontech (Takara Bio, Japan)
pEntr4-H1 Riken (Japan)
CS-RfA-EG Riken (Japan)
pCCL-NGFR a gift from Prof. Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy)
CSII-EF-MCS Riken (Japan)
pHes1-GFPd20 plasmid Addgene (plasmid #14808)
Table II.4 – Primers used for molecular cloning
Primer name Sequence (5' to 3')
Fwd cherry for reporter ACTGACACCGGTCGCCACCATGG
Rev cherry for reporter GCTAAGCTTCTTGTACAGCTCGTCCATGCC
Fwd Hes1 GFP ACTGACCTCGAGACTGACTGCCTCTAGGCATATGACACGCACGCACACACAC
Rev Hes1 GFP ACTGACGTCGACCTACACATTGATCCTAGCAGAAGCAC
Fwd NGFR ACTGACCTCGAGCGCCACCATGGGGGCAGG   
Rev NGFR ACTGACCATATGACTGACGCGTCTAGAGGATCCCCCTGTTCCACC     
Fwd GFP TACCCCTCTAGAGTCGAGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAGG
Rev GFP TTGGAACCTAAGTCGACACGCGTTTACTTGTACAGCTCGTCCATGCC
Fwd miR30shrna TCTCGAGGATCCACAGAATCGTTGCCTGCAC
Rev miR30shrna GCTCGAGCTAGCTTCAGCTTTGTAAAAATGTATCAAAG
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Table II.5 – Primers used in DNA sequencing
Primer name Sequence (5' to 3')
Fwd Seq NGFR GTTCTCCGACGTGGTGAGC
Rev Seq NGFR CTCATCCTGGTAGTAGCC
Rev Seq Hes1 CTAATGTCTTCCGGAATTCC
Fwd Seq cherry AAGCTGAAGGTGACCAAG
Rev Seq cherry TTCACGTAGGCCTTGGAG
Seq rev SHMIR30 EF1 TTACATCAAGTGCCAAGCTG
Seq Fwd SHMIR30 pECFP CCAAAATGTCGTAACAACTCC
pH1up2seq CAGGAAGATGGCTGTGAGG
Seq Fwd GFP CCTCTAGAGTCGAGCTACC
Table II.6 – Primers used in qRT-PCR.
Gene Primers (5' to 3') Melting temperature (°C)
NCSTN
Fwd GCAATGGTTTGGCTTATGAAG 63.2
Rev ATGCATGTGTGAAAAGAGCTG 62.9
RBPJ
Fwd AGAGTCTCAACCGTGTGCATT 63.7
Rev GTGCTTTCGCTTGTCTGAGTC 64
GAPDH
Fwd GGGAAGGTGAAGGTCGGAGT 66.6
Rev GGGTCATTGATGGCAACAATA 64.4
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Appendix III 
 
Table III.1 – Antibodies used in FCM/FACS
Antigen Reactivity Fluorochrome Clone Dilution Company
CD10 Human APC CB-CALLA 1:10 eBiosciences, USA
CD11c Human PE B-ly6 1:10 BD Biosciences, USA
CD11c Human APC MJ4-27G12 1:10 Miltenyi Biotec, Germany
CD14 Human PE-Cy7 61D3 1:10 eBiosciences
CD19 Human AF780 HIB19 1:10 ebiosciences
CD33 Human APC P67.6 1:10 BD Biosciences
CD33 Human BV711 WM53 1:10 BD Biosciences
CD34 Human APC 581 1:10 BD Biosciences
CD34 Human PerCP 8G12 1:10 BD Biosciences
CD38 Human APC-eFluor 780 HIT2 1:10 eBiosciences
CD38 Human PE-Cy7 HB7 1:10 eBiosciences
CD45RA Human PE-Cy7 HI100 1:10 eBiosciences
CD45RA Human APC Fire 750 HI100 1:10 Biolegend
CD56 Human BV605 5.1H11 1:10 Biolegend
CD62L Human PE DREG-56 1:10 Biolegend
CD90 Human BV605 5E10 1:10 BD Biosciences
CD90 Human PE eBio5E10 (5E10) 1:10 eBiosciences
CD135 Human BV711 4G8 1:10 BD Biosciences
CD271 Human AF647 C40-1457 1:10 BD Biosciences
NOTCH1 Human PE MHN1-519 1:10 BD Biosciences
NOTCH2 Human PE MHN2-25 1:10 BD Biosciences
NOTCH4 Human PE MHN4-2 1:20 BD Biosciences
Lineage Human eFluor 450
RPA-2.10, 
OKT3, 61D3, 
CB16, HIB19, 
TULY56, HIR2
1:10 eBiosciences
Nicastrin Human PE polyclonal 1:40 Sino biological, China
Rabbit IgG 
isotype control PE polyclonal 1:10
BIOSS antibodies, 
USA
Mouse IgG1, k 
isotype control PE MOPC-21 1:5 BD Biosciences
Mouse IgG1 
negative control AF647 MOPC-21 1:10 BD Biosciences
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Table III.2 – Antibodies used in WB.
Antigen Reactivity Conjugate Clone Dilution Company
Notch1 Human unconjugated D1E11 1/750 Cell Signaling Technology, USA
Notch2 Human unconjugated D76A6 1/500 Cell Signaling Technology, USA
Notch4 Human unconjugated L5C5 1/1000 Cell Signaling Technology, USA
Cleaved Val1744
Notch1 Human unconjugated
Rabbit 
monoclonal
D3BA
1/500 Cell Signaling Technology, USA
Cleaved Ala1734 
Notch2 Human unconjugated polyclonal 1/300 Thermo
Nicastrin Human unconjugated polyclonal 1/1500 Abcam, UK
RBP-Jκ Human unconjugated E-7 1/25 
Santa Cruz 
Biotechnology, 
USA
β-actin Human unconjugated AC-15 1/10000 Merck
Goat anti-mouse 
Immunoglobulins Mouse HRP polyclonal 1/5000 DAKO, USA
Goat anti-rabbit 
Immunoglobulins Rabbit HRP polyclonal 1/5000 DAKO, USA
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Appendix IV
Table IV.1 – Characteristics of small molecules.
Compound number Structure Molecular Weight
21 549.55
22 371.44
24 407.91
26 471.55
31 648.53
36 467.54
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